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Cys/C – cysteine  
DDD - Deciphering Developmental Disorders 
DDR – DNA damage response 
DNA – deoxyribonucleic acid  
dNTPs - deoxyribonucleotides 
DSB – double strand break 
DSE - double-strand end 
DSIF - DRB sensitivity-inducing factor  
E – embryonic stage 
EPPF – Edinburgh Protein Production Facility  
eRNA – enhancer RNA 
ET – extraterminal 
FA – Fanconi Anaemia  
FISH – fluorescent in situ hybridisation  
FPKM - Fragments per kilobase mapped 
GAR -glycine and arginine rich 
GC – gene conversion 
GFP – green fluorescent protein 
Gln – glutamine 
GO – gene ontology 
gRNA – guide ribonucleic acid 
HAT - histone acetyltransferase 
HDR - homology directed repair 
His/H - histidine 
HJ – holliday junction  
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HR – homologous recombination  
HRD – HR deficient  
hpf - hour postfertilisation 
HU – hydroxyurea 
IF – immunofluorescence  
Ile/I – isoleucine 
Ig - immunoglobulin 
IGMM – Institute of Genetics and Molecular Medicine  
IP – immunoprecipitation/immunoprecipitates 
IR – ionising radiation 
IRIF - irradiation induced foci 
Kb - kilobase  
LCL - lymphoblastoid cell line 
Leu/L – leucine  
LiDS - DNA ligase IV deficiency syndrome  
LIF - leukemia inhibitory factor  
LFQ – label free quantification 
LOF – loss of function 
Lys/K - lysine 
M – molar 
MACS - Model-based Analysis of ChIP-Seq data 
Mb – megabase  
Me – methylation 
MEF – mouse embryonic fibroblast 
mESC – mouse embryonic stem cell  
MNase - Micrococcal Nuclease 
MO - morpholino 
mRNA - messenger RNA 
MS – mass spectrometry  
NCBRS - Nicolaides–Baraitser syndrome 
NCS – neocarzinostatin 
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NELF – negative elongation factor 
NHEJ – non-homologous end joining 
NIPBL – Nipped-B-like  
NLS - nuclear localisation sequence 
nM – nanomolar  
NMC - NUT midline carcinoma 
NMR – nuclear magnetic resonance  
OD - oligomerisation domain 
OE1 – 1st oxygen atom of the carbonyl group  
OH – hydroxyl  
OPT - OCT1/PTF/transcription 
-P - phosphorylation 
PAM - protospacer adjacent motif 
PCS – premature chromatid separation  
PDB – Protein Data Bank 
Phe/F - phenylalanine 
PIC – pre-initiation complex 
PIKKs - phosphoinositide-3-kinase-related protein kinases 
PSF - point spread function 
P-TEFb - positive transcription elongation factor B 
PTM - post-translational modifications 
Q - glutamine 
qPCR – quantitative polymerase chain reaction 
RBS - Roberts Syndrome 
RIPA - radioimmunoprecipitation assay  
RNA - ribonucleic acid 
RNAPII – RNA polymerase II 
RP10M – reads per 10 million 
RPKM – reads per kilobase per million mapped reads  
RS-SCID - radiosensitive severe combined immunodeficiency 
RT – room temperature  
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RT-qPCR – reverse transcription-qPCR 
SDSA - synthesis dependent strand annealing 
SE- super enhancer 
Ser – serine/S 
SEM – standard error of the mean 
SSA - single strand annealing  
SMC - structural maintenance of chromosomes  
snRNA – small nuclear ribonucleic acid  
snRNP – small nuclear ribonucleoprotein 
SS – Seckel Syndrome  
SSB – single strand break 
ssDNA – single stranded DNA 
TAD - topologically associated domains 
TAM – tamoxifen 
TBS(-T) – tris-buffered saline(-tween) 
TE – typical enhancer 
Thr – threonine/T 
TOP – topoisomerase 
TPR - tetratricopeptide repeat 
Trp - triptolide 
TSS – transcription start site 
Tyr/Y - tyrosine 
UCSC - University of California Santa Cruz 
UDR - ubiquitylation-dependent recruitment 
UV – ultra-violet 
Val/V - valine 
WDSTS - Wiedemann-Steiner syndrome 
μg – microgram 
μl – microliter 
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Lay summary of thesis  
Cornelia de Lange Syndrome (CdLS) is a rare developmental genetic disorder. It causes a 
wide range of symptoms, including limb abnormalities, delayed growth, and intellectual 
disability. 
The majority of CdLS patients have a mutation in one of a group of proteins that form a 
protein complex called cohesin. Cohesin is important during cell division and also has roles 
in the organisation of chromosomes and the repair of damaged DNA. However, cohesin 
mutations only make up about 70% of CdLS cases, leaving a significant number of patients 
for whom the underlying mutation is unknown.  
In this thesis I describe the identification and characterisation of a mutation in a protein 
called BRD4, which is unrelated to the cohesin complex, in a patient with a CdLS-like 
syndrome. I recreated this mutation in mouse embryonic stem cells, allowing me to study its 
effects on cell behaviour. Surprisingly, I found that this mutation, although affecting the 
ability of BRD4 to bind correctly to genomic regions that regulate the expression of genes, 
does not alter gene regulation. Instead I found an increase in DNA damage and a slower cell 







































   
 
Abstract 
Acetylation of lysine residues is a histone modification associated with active chromatin. The 
modified residues provide docking sites for the epigenetic reader BRD4, which binds to the 
acetylated lysines via its two bromodomains. BRD4 is known to be involved in RNA 
polymerase II activation, maintaining the pluripotency of embryonic stem cells and in DNA 
damage response signalling.  
In this thesis, I describe a newly identified missense mutation (Y430C) in BRD4 in a patient 
with a Cornelia de Lange syndrome (CdLS)-like phenotype. CdLS is a neurodevelopmental 
disorder that can cause a range of symptoms including upper limb malformations, 
craniofacial abnormalities and intellectual disability and is usually associated with mutations 
in components of the cohesin complex and the cohesin loader NIPBL. How these mutations 
may cause CdLS is currently unknown, but the assumption has been that they cause altered 
gene regulation during development.  
Using a mouse embryonic stem cell (mESC) line, engineered through CRISPR-Cas9 
technology to be homozygous for the patient mutation in BRD4, I show that the mutation 
decreases the affinity of BRD4 for acetylated lysines. This causes a loss of BRD4 binding in 
the genome, most noticeable at cis-regulatory elements. However, surprisingly I found no 
evidence for altered gene expression in the cells with the Brd4 mutation. Instead I identify 
increased G2/M checkpoint activation in the Y430C mESCs compared to wild-type cells, 


























































































   
 
1.1 Cornelia de Lange Syndrome  
1.1.1 Clinical phenotype and inheritance  
Cornelia de Lange Syndrome (CdLS) is a rare neurodevelopmental disorder, estimated to 
affect 1:10,000-1:50,000 new-borns (Beck and Fenger, 1985; Liu and Baynam, 2010). CdLS 
is characterised by a range of symptoms, that vary vastly in severity between patients 
(Newkirk et al., 2017). The most diagnostic symptom is the distinctive facial dysmorphism 
(Figure Ch1-1A-D); patients often present with microbrachycephaly, synophrys, long 
philtrum, thin lips, crescent shaped mouth, depressed nasal bridge with anteverted nares and 
cleft palate (Rohatgi et al., 2010). Other symptoms include growth retardation, intellectual 
and psychomotor delay, upper limb malformations (Figure Ch1-1E-J), hirsutism, and cardiac 
and gastrointestinal issues (Liu and Baynam, 2010; Noshir Mehta and Bhatia, 2013). A large 
percentage of patients die before the age of 2, due to pneumonia or cardiac, respiratory and 
gastrointestinal complications (Beck and Fenger, 1985) however, in the absence of these 
problems, patients often survive to adulthood (Badoe, 2006).  
Figure Ch1-1. CdLS is a genetically heterogeneous syndrome that causes a 
spectrum of phenotypes. Characteristic facial phenotype in two patients with 
NIPBL mutations (A&B) and two patients with SMC1A mutations (C&D).  
Spectrum of upper limb involvement is shown with decreasing severity (E-J). Taken 
from Dorsett and Krantz, 2009.  
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Most cases of CdLS are caused by de novo mutations. The low probability of an affected 
individual to reproduce may limit the level of familial inheritance, although some cases have 
been reported and point towards an autosomal dominant mode of inheritance. (Russell et al., 
2001). There have been rare cases of phenotypically unaffected parents having multiple 
children with CdLS, suggesting that germline mosaicism may occur (Gillis et al., 2004).  
1.1.2 De novo gene mutations causing CdLS 
1.1.2.1 NIPBL 
In 1933 Cornelia de Lange first described CdLS as a distinct syndrome (Badoe, 2006), but it 
wasn’t until 2004 that the first causal gene for CdLS was reported in back-to-back 
publications. The breakpoints of a de novo balanced translocation, found in a patient with 
CdLS, were mapped to 5p13.1 and 13q12.1. This identified a new gene - named Nipped-
B-like (NIPBL) -, found to also carry point mutations in a number of CdLS patients. In 
parallel to this, genome wide linkage exclusion analysis in 12 families with CdLS identified 
mutations in NIPBL in 6 of the patients studied (Krantz et al., 2004). 
NIPBL mutations are not identified in all CdLS patients – only about half of all CdLS cases 
are caused by NIPBL loss of function (LOF) mutations (Zuin et al., 2014), although the total 
percentage may be higher due to the presence of somatic mosaicism for NIPBL mutations 
in around 23% of mutation negative individuals (Huisman et al., 2013; Ansari et al., 2014). 
This, combined with the variability of the CdLS phenotype, suggests genetic heterogeneity 
(Revenkova et al., 2009).  
1.1.2.2 Cohesin subunits  
NIPBL is the ortholog of Scc2-type sister chromatid cohesion proteins in yeast and 
Nipped-B in D. melanogaster (Tonkin et al., 2004). Scc2 regulates the loading and unloading 
of the cohesin and condensin complex (Deardorff et al., 2007). This led others to look for 
mutations in other members of the cohesin complex.  
Mutations (largely missense) in the cohesin components SMC1A (Musio et al., 2006), SMC3 
(Deardorff et al., 2007) and the kleisin subunit RAD21 (Deardorff, Wilde, et al., 2012), and 
the cohesin regulator HDAC8 (Deardorff, Bando, et al., 2012) were also found to cause 




   
 
1.1.2.3 Transcriptional regulators  
Recently, a number of patients have been reported that have CdLS-like phenotypes and 
mutations in genes that are involved in transcriptional regulation, including AFF4, 
ANKRD11, KMT2A and TAF6. This is discussed in more detail in section 1.2.8.4. 
1.1.2.4 Genotype-phenotype correlation  
Mutations in NIPBL cause the most typical and severe CdLS phenotypes, with mutations in 
the other genes contributing to a smaller number of milder cases – often lacking the major 
limb malformations and showing atypical growth or facial phenotypes (Ansari et al., 
2014)(Figure Ch1-1). A genotype-phenotype correlation also exists within NIPBL mutation 
positive cases; the most common NIPBL mutations in CdLS are nonsense, splice site, or 
frame shifts that result in truncation of the protein and NIBPL haploinsufficiency. These are 
associated with the more severe phenotypes. Missense mutations also occur, but are less 
frequent and cause milder phenotypes with the absence of  limb abnormalities and less severe 
developmental delay (Gillis et al., 2004; Mannini et al., 2013; Boyle et al., 2015). 
Figure Ch1-2. Phenotypic spectrum of NIPBL mutations. Patients with missense 
mutations have the mildest symptoms, whilst those with frameshift/nonsense mutations 




   
 
1.2 The cohesin complex 
1.2.1 Structural maintenance of chromosome complexes 
Structural maintenance of chromosomes (SMC) complexes are ring like structures, conserved 
from bacteria to humans, which can entrap DNA. The most well-known SMC complexes 
are cohesin and condensin, which regulate DNA loop formation (van Ruiten and Rowland, 
2018), mitotic chromosome condensation, sister chromatid cohesion, DNA repair, and 
transcriptional regulation (Murayama et al., 2018). 
The cohesin complex was first discovered in yeast for its role in sister chromatid cohesion, 
and this is thought of as its canonical role. However it also has non-canonical roles in the 
regulation of gene expression, chromatin organisation and the DNA damage response 
(DDR) (Bettini et al., 2018).  
1.2.2 Structure  
The cohesin complex (Figure Ch1-3) is composed of four subunits, known in vertebrates as 
SMC1, SMC3, RAD21 and STAG-1/-2 (Solomon, Kim and Waldman, 2014). The SMC 
proteins fold in half at ‘hinge’ domains, so that their N- and C-termini meet at one end, 
forming globular ATPase domains (Revenkova et al., 2009). These so called ‘head’ domains 
are separated from the hinge by antiparallel coiled coils. SMC1 and SMC3 hetero-dimerise 
by sandwiching two ATP molecules between them. The head domains are connected by 
RAD21, which binds to the SMC3 head at its N-terminal domain and the SMC1 head at its 
C-terminal domain (Makrantoni and Marston, 2018) (Figure Ch1-3). This forms a tripartite 



















1.2.3 DNA binding  
Cohesin is loaded onto chromatin during G1 phase, and this requires the loading factors 
NIPBL and MAU2, which together form a complex known as Kollerin (Zuin et al., 2014; 
Elbatsh et al., 2016). The binding of the RAD21 C-terminus to the SMC1 head domains 
induces a rearrangement of the SMC1a active site (AS1) (Figure Ch1-4A). This allows ATP 
hydrolysis, and in turn induces the ATPase activity of the SMC3 head domain (AS2) (Figure 
Ch1-4B). Once ATP hydrolysis has occurred at both active sites (Figure Ch1-4C), the 
ATPase heads separate and allow DNA to pass through the open structure (Figure Ch1-4D) 
(Marcos-Alcalde et al., 2017).  
Figure Ch1-3. Cartoon of the cohesin complex in human somatic cells.  SMC1 and 
SMC3 fold in half at a ‘hinge’ domain, where they interact to form a heterodimer. The 
hinge domain is separated from the N- and C-terminal globular ‘head’ domains by anti-
parallel coiled coils. RAD21 interacts with the head domain of SMC1 and the coiled-coil 
of SMC3, forming a tripartite ring-structure, and with SA1/SA2. PDS5 and WAPL are 
involved in the regulation of cohesin-chromatin binding. Adapted from (Villa-Hernández 
and Bermejo, 2018). 
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In the simplest ‘ring’ model of cohesin’s interaction with DNA, there are three functional 
states that may occur – 1. The non/pseudo-topological configuration (Figure Ch1-5A), in 
which DNA is ‘extruded’ through the cohesin ring until it reaches boundary sites (thought 
to be CCCTC-binding factor (CTCF) binding sites) (Makrantoni and Marston, 2018) (see 
section 1.2.7.1). This directs chromosomal organisation by forming DNA loops and can 
regulate gene expression by bringing linearly distal genomic regions into close proximity 
(Bouwman and de Laat, 2015). 2. The one-DNA-topological configuration (Figure Ch1-5B). 
This configuration posits that the cohesin ring entraps a single dsDNA, thought to be the 
product of cohesin loading and the precursor for establishment of sister chromatid cohesion. 
3. The two-DNAs-topological configuration (Figure Ch1-5C), where the cohesin ring 
entraps two dsDNA molecules, providing cohesion between them (Makrantoni and Marston, 
2018).  
Figure Ch1-4. Schematic model for ATP hydrolysis-driven head opening. Binding of the 
Rad21 C-terminus to the Smc1 head domain allows hydrolysis at AS1 (A). This induces 
a rearrangement and activation of AS2 (B), leading to ATP hydrolysis (C). ATP 
hydrolysis at AS1 and AS2 facilitates the separation of the ATPase head domains (D). 





   
 
 
The ‘two ring handcuff’ model has also been suggested, but remains to be thoroughly tested 
(Wendt, 2017). In this model two RAD21 molecules move into antiparallel orientation and 
are paired and tethered through their interactions with STAG1/2. Each ring entraps one 
sister chromatid, holding them together (N. Zhang et al., 2008).  
1.2.4 NIPBL  
1.2.4.1 Structure  
NIPBL consists of 47 exons that encodes a large multi-domain protein (Mannini et al., 2013). 
In higher eukaryotes, there are two isoforms - the canonical isoform (Isoform A) which is 
316 kDa and the slightly smaller 304 kDa isoform (Isoform B) (Jahnke et al., 2008). NIPBL’s 
domains include HEAT repeats, a HP1 interacting motif, a bipartite nuclear localisation 
sequence (NLS), a undecapeptide repeat, a coiled-coil, a glutamine rich region and a MAU2 
(Scc2) interacting region (Figure Ch1-6) (Mannini et al., 2013). HEAT repeats are flexible 
arrays of helices, made up of both hydrophobic and hydrophilic parts. They are found in 
many eukaryotic proteins and enable interactions with many different binding partners 
(Yoshimura and Hirano, 2016). The C-terminal HP1 interacting motif and HEAT repeats 
are required for the recruitment of NIPBL to sites of DNA damage (Oka et al., 2011) whilst 
Figure Ch1-5. Schematic model for three functional states of cohesin-DNA interactions. 
A) The ‘non/pseudo-topological’ cohesin-DNA interaction is thought to mainly drive 
loop extrusion, B) The ‘one-DNA-topological’ configuration is thought to be the product 
of cohesin loading, C) The ‘two-DNAs-topological’ form is thought to be the final 
product of cohesion. Taken from Makrantoni and Marston, 2018. 
A B C 
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NIPBL’s interaction with MAU2 is essential for the loading of cohesin at the G1 phase of 
the cell cycle (Zuin et al., 2014).   
CdLS-causing mutations occur throughout NIPBL, although the majority are found in 
coding regions. Exon 10 (marked on Figure Ch1-6), encoding the coiled-coil region and the 
undecapeptide repeat, harbours the largest number of CdLS mutations (49/278 as of 2013) 
(Mannini et al., 2013).  
1.2.4.2 Kollerin (NIPBL-MAU2) 
NIPBL forms the Kollerin complex with MAU2 (Scc2-Scc4), and this is essential for loading 
cohesin onto chromatin (Wendt, 2017). Surprisingly, MAU2 heterozygous mice are 
indistinguishable from WT, suggesting that it may play a different role to NIPBL in gene 
regulation, or is less sensitive to changes in dosage (Singh and Gerton, 2015). MAU2 is a 
tetratricopeptide repeat (TPR) superhelix, which entraps the N-terminus of NIPBL. The 
crystal structure of the Scc2-Scc4 complex shows that elongated Scc4 twists around a 
fragment of Scc2, which emerges at both ends of the structure (Hinshaw et al., 2015).  The 
complex is made up of a head, a body and a hook domain. 
Scc2 displaces Pds5 from cohesin, in order to bind to Scc1 (RAD21) and stimulate cohesin 
loading onto chromatin. Scc2 also stimulates the ATPase activity of the SMC head domains, 
catalysing translocation of cohesin along DNA, and may continue to regulate the ATPase 
activity after loading (Petela et al., 2018).  
Kollerin may also play a role in the loading of the condensin complex, which contains the 













































































































































































































































































































































































   
 
1.2.5 Genomic distribution of NIPBL/cohesion 
1.2.5.1 Drosophila and Yeast 
Many studies have aimed to determine the genomic localisation of Kollerin, and thus of 
cohesin loading. This appears to differ between species however, and the exact location of 
cohesin loading remains unknown (Wendt, 2017). In Drosophila, Nipped-B and cohesin 
colocalise throughout the genome, preferentially at transcribed regions and overlapping 
with RNA polymerase II (RNAPII) (Misulovin et al., 2008). This contrasts with yeast, 
where cohesin is loaded at Scc2 sites and pushed along chromosomes by transcribing 
RNAPII to accumulate at convergently oriented genes (Borrie et al., 2017).  
1.2.5.2 Mammals 
In mammalian cells cohesin positioning is thought to be determined by CTCF - an insulator 
protein that blocks enhancer activity and/or inhibits the spread of heterochromatic domains 
(Ball, Chen and Yokomori, 2014), – transcription, and WAPL (Busslinger et al., 2017).  
RAD21 ChIP-seq showed that around 50% of cohesin peaks overlap with CTCF (Wendt, 
2017), and are thought to be involved in the regulation of higher order chromatin structure. 
CTCF independent cohesin peaks are found at cis-regulatory elements (CRE) of active 
genes and overlap with RNAPII, transcription factors (TFs), the Mediator complex and 
NIPBL (Kagey et al., 2010; Mannini et al., 2015) (Figure Ch1-7A).  
NIPBL is required for the loading of cohesin onto chromatin (Wendt, 2017), but is often 
not present at CTCF-cohesin sites (Figure Ch1-7B), suggesting that cohesin is repositioned 
after DNA binding. Loss of CTCF causes accumulation of cohesin at the transcription 
start sites (TSS) of active genes, whilst in the absence of both CTCF and WAPL – a protein 
involved in removing cohesin from chromatin - cohesin was shown to accumulate at the 
3’ end of active genes. These data suggest that mammalian cohesin can be relocated by 
transcription, similarly to yeast cohesin, and removed from active genes by WAPL 
mediated release (Busslinger et al., 2017).  
In mouse embryonic stem cells (mESCs) NIPBL was originally found to co-localise with 
cohesin (Kagey et al., 2010) (Figure Ch1-7A), however ChIP-sequencing in human cells 
found that this is not always the case; a subset of low-enrichment NIPBL peaks overlapped 
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with those of cohesin, but a larger subset of ‘major’ peaks occurred at promoters of actively 
transcribed genes that were devoid of cohesin (Figure Ch1-7B) (Zuin et al., 2014).  
 
  
Figure Ch1-7. NIPBL binding at CTCF and non-CTCF cohesin sites. A) mESC 
ChIP-sequencing tracks from Kagey et al. 2010 show the co-localisation of NIPBL, 
SMC3, SMC1A, Mediator, TFs and the transcriptional apparatus at non-CTCF cohesin 
sites. Some co-localisation of these factors is observed at CTCF cohesin sites, but it is 
much decreased. B) ChIP-sequencing tracks from Zuin et al. 2013 show a lack of co-
localisation between NIPBL and cohesin at CTCF bound cohesin sites in human breast 
endothelial cell line HB2. NIPBL instead binds at cohesin free gene promoters.    
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1.2.6 Sister chromatid cohesion during the cell cycle 
1.2.6.1 Sister chromatid cohesion during mitosis  
During mitosis sister chromatids must be correctly distributed between the resulting 
daughter cells (Uhlmann, 2004). Efficient loading of sister chromatids onto the mitotic 
spindle (Uhlmann, 2004), prevention of premature chromatid separation (PCS), and accurate 
segregation of chromatids into new daughter cells, all require the physical tethering of sister 
chromatids to each other, a process mediated by the cohesin complex (Zheng and Yu, 2015).  
Cohesin binding is enriched at centromeres and nearby pericentromeric regions. Its targeted 
loading at centromeres requires phosphorylation of a kinetochore component, yeast Ctf19 
(CCAN in humans), by DDK, a cell cycle regulated kinase. Phosphorylated Ctf19 provides 
a binding site for Scc2/4 at kinetochores by interacting directly with a  conserved region of 
Scc4 that is required to recruit Scc2/4 to centromeres (Hinshaw et al., 2017).  
When cohesin rings are not in their cohesive state, they transiently associate with chromatin 
through the continuous entrapment and release of DNA (Elbatsh et al., 2016).  At this stage, 
the action of cohesin loading is actively opposed by PDS5-WAPL mediated release, keeping 
the chromatin bound cohesin in a highly dynamic state (Zheng and Yu, 2015). During S 
phase, the ESCO2 dependent acetylation of SMC3 antagonises the activity of PDS5-WAPL, 
resulting in stably bound cohesin that mediates cohesion between sister chromatids (Elbatsh 
et al., 2016). In vertebrates the displacement of WAPL-PDS5 by Sororin also contributes to 
the inhibition of cohesin release from chromatin (Nishiyama et al., 2010). 
Regulated removal of cohesin from the sister chromatids is essential for successful 
segregation during mitosis (Zheng and Yu, 2015). In prophase, cohesin is first removed from 
the chromosome arms by the WAPL-mediated opening of the SMC3-RAD21 gate (Beckouët 
et al., 2016). The SMC1 ATPase domain appears to be required for this removal, with 
mutations in this domain causing stable cohesion even in the absence of ESCO2 (Elbatsh et 
al., 2016). Centromeric cohesin is maintained by the protective role of Shugoshin (Haarhuis 
et al., 2013) and  is important for the correct orientation of sister chromatids on the mitotic 
spindle during metaphase (Tanaka et al., 2000).  
Correct attachment of the kinetochores to the microtubules of the spindle silences the 
spindle checkpoint and activates a protein called Separase. At the same time, Shugosin is 
redistributed, exposing the centromeric cohesin and allowing Separase to cleave RAD21 
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(Hauf, Waizenegger and Peters, 2001; Zheng and Yu, 2015). This leads to the removal of 
centromeric cohesin and triggers the onset of anaphase (Hauf, Waizenegger and Peters, 
2001.) HDAC8 is responsible for the deacetylation of the SMC3 subunit, imperative for the 
recycling of cohesin so it can be reloaded in the next cell cycle (Dasgupta et al., 2016).  
1.2.6.2 Sister chromatid cohesion during meiosis   
Cohesin is also essential for meiosis. Mammalian meiotic cells contain four meiosis specific 
cohesin subunits – the kleisin subunits REC8 and RAD21L, the SMC protein SMC1B, and 
STAG3 – in addition to the five ubiquitously expressed subunits. Varying combinations of 
subunits are known to form at least six different meiosis specific cohesin complexes, but the 
precise differences in their roles are not well understood (Biswas et al., 2016).   
In meiotic cells, cohesin along the chromosome arms, and physical connections between 
homologous chromosomes known as chiasma, generate tension between homologous 
chromosomes and ensures their faithful segregation. At anaphase I, chromosome arm 
cohesion is destroyed, causing the homologous chromosomes to separate to opposite poles 
of the cell. Pericentromeric and centromeric cohesin is protected at this stage, ensuring that 
the physical linkage of sister chromatids is maintained until anaphase of meiosis II (Kitajima, 
Kawashima and Watanabe, 2004). Furthermore the presence of cohesin around the 
centromeres acts to repress crossover recombination in these regions, which could otherwise 
result in the non-disjunction of sister chromatids in meiosis II (Vincenten et al., 2015). 
1.2.6.3 Sister chromatid cohesion in CdLS 
Developmental disorders caused by mutations in cohesin or its accessory factors are known 
as cohesinopathies (Zakari, Yuen and Gerton, 2015). Aside from CdLS the most classic 
example of a cohesinopathy is Roberts Syndrome (RBS) (OMIM 268300). Patients with RBS 
have mutations in both alleles of ESCO2, and present with symptoms similar to those of 
CdLS, such as craniofacial anomalies, growth retardation and limb malformation (Vega et al., 
2005). Loss of cohesion is known to cause PCS, mis-segregation, and aneuploidy in resulting 
daughter cells (Peters and Nishiyama, 2012). Whilst these cellular perturbations are features 
of RBS, they have not been observed in CdLS patients; metaphase spread analysis showed 




   
 
Nipbl transcripts levels are reduced by only ~30% in Nipbl heterozygous mice (Newkirk et 
al., 2017), and in NIPBL mutation positive CdLS patients (Zuin et al., 2017), most likely due 
to upregulation of the intact allele (Newkirk et al., 2017). This appears to be sufficient to 
maintain the cohesin fraction responsible for robust sister chromatid cohesion (Remeseiro et 
al., 2013), indicating that the canonical function of cohesin is not affected by the mutations 
that cause CdLS.  
1.2.7 The role of cohesin in chromatin structure and organisation 
1.2.7.1 Genome compartmentalisation  
Hi-C, a high throughput variant of the chromosome conformation capture (3C) techniques, 
revealed that the genome is organised into areas of active and inactive chromatin, known 
respectively as A and B compartments, and further compartmentalised into areas of highly 
interacting chromatin known as topologically associating domains (TADs) (Gong et al., 
2018). TADs can range from a few 100 Kb to 5 Mb in size, have sharp boundaries, and are 
highly conserved between cell types and throughout evolution, suggesting that they represent 
the fundamental unit of physical organisation of the genome (Rocha et al., 2015). Peaks (or 
loops) are visible as focal enrichments in contact frequency between pairs of loci and often 
form at the corners of TADs (Schwarzer et al., 2017).  
Compartmentalisation is thought to be established by the local chromatin state, whilst loop 
extrusion, regulated by CTCF and cohesin, is the preferred hypothesis for TAD formation 
(Nuebler et al., 2018). In the loop extrusion model, cohesin is loaded onto chromatin at sites 
distinct from CTCF (Barrington, Finn and Hadjur, 2017) and translocates along DNA until 
it reaches CTCF. CTCF is proposed to function as a boundary element that acts as a barrier, 
impeding further translocation (Barrington, Finn and Hadjur, 2017). This provides time for 
WAPL-mediated removal of cohesin; in the absence of WAPL, cohesin continues to 
translocate past TAD boundaries (Nuebler et al., 2018).  
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Multiple mechanisms exist for how the translocation of cohesin forms loops, and these are 
compatible with both the simple ring model of cohesin binding and the two-ring handcuff 
model (see section 1.2.3). Cohesin may bind at a small genomic region and translocate in two 
directions until it reaches CTCF sites (Figure Ch1-8A). Cohesin may also bind to regions 
that are physically proximal but linearly distant, resulting in the formation of larger domains 
(Figure Ch1-8B). However, the combination of these two alternatives is most likely to 
produce the observed multiple domains of genome structure – long-range TADs that are 
subdivided into smaller loops (Barrington, Finn and Hadjur, 2017) (Figure Ch1-8C). The 
translocation of cohesin is likely mediated by ATP hydrolysis, stimulated by interaction of 
cohesin with NIPBL (Petela et al., 2018). 
 
CTCF and cohesin co-localise at the anchors of TAD boundaries (Rao et al., 2017). The loss 
of NIPBL (and consequently chromatin bound cohesin) leads to a decrease in local TAD 
patterns (Figure Ch1-9A), without affecting CTCF binding, suggesting that the roles of 
cohesin and CTCF in loop extrusion are distinct (Schwarzer et al., 2017). Auxin induced 
Figure Ch1-8. Possible models for domain formation via loop extrusion. A) 
Cohesin binds within a small genomic region and translocates in opposing directions until 
it reaches CTCF. B) Cohesin binds to two spatially proximal but genomically distant 
regions, resulting in larger domains. C) A combination of A and B occurs, forming both 






   
 
degradation of CTCF causes the loss of TAD insulation – increasing inter-TAD 
interactions and decreasing intra-TAD interactions (Figure Ch1-9B), supporting the role 
of CTCF as a boundary element (Nora et al., 2017). WAPL depletion leads to an extension 
of chromatin loops and the accumulation of contacts at TAD corners (Figure Ch1-9C). This 
suggests that chromatin loops are formed through the processive enlargement of smaller 
loops - with TADs reflecting polyclonal populations of loops forming between two CTCF 
sites - and removal of cohesin by WAPL allows TADs to stay dynamic (Haarhuis et al., 2017). 
A and B compartmentalisation is not affected by NIPBL or CTCF depletion (Nora et al., 
2017; Schwarzer et al., 2017), but is slightly less defined in WAPL deficient cells; Loss of 
WAPL increased the switching between A and B compartments, indicating that cohesin acts 
to limit nuclear compartmentalisation  (Haarhuis et al., 2017).  
Figure Ch1-9. Effect of NIPBL, CTCF and WAPL loss on TAD patterning.            
A) NIPBL depletion (through a tamoxifen (TAM) inducible Cre driver) causes loss of 
local TAD patterns compared to a TAM control. Hi-C map shows a 2Mb region (top – 
TAM control, bottom – NIPBL deleted). Black bars show WT TADs. Taken from 
Schwarzer et al., 2017. B) Auxin induced CTCF degradation causes a loss of TAD 
insulation. Left - Snapshot of Hi-C data at the Prmd14 locus in untreated (left) and auxin 
treated (right) cells. Right - differential contact map showing more inter-TAD (red) and 
fewer intra-TAD (blue) Hi-C signal after auxin treatment. Taken from Nora et al., 2017. 
C) Loss of WAPL causes the extension of loops (left) and the accumulation of contacts 
at TAD corners (right). Hi-C contact matrices for a zoomed in region on Chr7 (left) and 
Chr2 (right) for WT and ΔWAPL. Contact matrices are normalised to 100 million 
contacts, shown resolution is 20 kb. Taken from Haarhuis et al., 2017. 
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1.2.7.2 Chromatin structural changes in CdLS  
Given the role of cohesin and NIPBL in chromatin interactions, it could be expected that 
mutations in the proteins that cause CdLS, might affect chromatin structure. Indeed, 
fluorescent in situ hybridisation (FISH) assays revealed a visible decompaction of chromatin 
in LCLs from CdLS patients positive for NIPBL mutations, and upon NIPBL siRNA (Nolen 
et al., 2013) - consistent with Hi-C data after NIPBL depletion  (Schwarzer et al., 2017). This 
decompaction was wide-spread, but correlated with gene density and the severity of the 
NIPBL mutations. Knockdown of SMC3 had a smaller effect on decompaction however, 
suggesting that the decompaction may result from perturbation of a cohesin independent 
role of NIPBL (Nolen et al., 2013). 
Overlap between the clinical phenotypes of CdLS and syndromes caused by mutations in 
chromatin remodelling complexes also suggest that changes in chromatin structure could 
underlie CdLS. Coffin-Siris syndrome (CSS, OMIM #135900) and Nicolaides-Baraitser 
syndrome (NCBRS, OMIM #601358) have similar phenotypes to CdLS and are caused by 
mutations in the SWI/SNF complex, a chromatin remodeller that shares some functions of 
cohesin.  In yeast, Scc2 is known to interact with the SWI/SNF complex to maintain 
nucleosome free regions (Lopez-Serra et al., 2014). Furthermore, the analysis of seven 
patients with CdLS-like phenotypes but no mutation in the known causative genes, found 
that 4/7 patients had mutations in the SWI/SNF complex (Parenti et al., 2017).  
1.2.8 Cohesin and the regulation of gene expression  
Cohesin regulates gene expression in a number of species, including mammals, drosophila 
and yeast, with depletion of cohesin and NIPBL resulting in changes in transcription (Lopez-
Serra et al., 2014; Zuin et al., 2014; Y. Wu et al., 2015; Mills et al., 2018).  
1.2.8.1 TADs  
The formation of TADs, regulated by cohesin and CTCF (see section 1.2.7), is thought to 
be of functional importance for regulation of gene expression. Sequences within TADs 
interact with high frequency and show similarities in expression and histone marks 
(Bouwman and de Laat, 2015). Furthermore TADs are thought to regulate cohesin mediated 
interactions between enhancers and promoters, by preventing interactions across TAD 
boundaries (Lupiáñez et al., 2015).   
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However, loss of TADs upon NIPBL/cohesin depletion does not correlate with changes in 
gene expression; Hi-C maps show that TAD patterns vanish equally in regions with 
unchanged gene expression, or with up- and down-regulated transcription, when NIPBL is 
depleted (Schwarzer et al., 2017). Furthermore, whilst cohesin deletion eliminates all loop 
domains, it only affects the expression of a subset of genes. If cohesin regulated gene 
expression via TADs, one might expect to see a global change in gene expression, caused 
by ectopic interactions between enhancers and targets from other loop domains, (Rao et al., 
2017). These results suggest that regulation of gene expression by cohesin is largely 
independent of TAD patterning.   
1.2.8.2 Enhancer-promoter looping 
Cohesin-mediated looping regulates gene expression independently of CTCF. CTCF 
independent cohesin was found to colocalise with the Mediator complex at the anchoring 
sites of enhancer-promoter interactions of active genes (Kagey et al., 2010). Mediator is a 
large multi-subunit cofactor complex, which controls the transcriptional programs of most 
genes in eukaryotic cells, through interactions with RNAPII and other pre-initiation complex 
(PIC) components (Allen and Taatjes, 2015).  
Mediator had been shown to bind at enhancers, and transiently interact with promoters. 
However, recent evidence that a single Mediator complex occupies the enhancer and 
promoter of any given gene, has led to the idea that Mediator interacts with the PIC bound 
at promoters, and forms transient chromatin loops that link enhancers to core promoters 
(Petrenko et al., 2016). Cohesin localisation at these sites may act to stabilise the loops (Allen 
and Taatjes, 2015) (Figure Ch1-10).  
Other models for transcriptional activation through promoter-enhancer interactions have 
been proposed, such as the tracking model, where enhancer-bound transcription complexes, 
including active RNAPII, move towards the target promoter in a unidirectional manner. 
These enhancer-bound proteins may not leave the enhancer, bringing the enhancer to the 
promoter. It is thought that different mechanisms of enhancer-promoter interactions may 
regulate expression of different genes (Meng and Blaine, 2017) 
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Cohesin and Mediator localisation differs between different cell types, suggesting that they 
may be important for cell-type specific gene expression. For instance, in mESCs cohesin and 
Mediator occupy the promoters of genes such as Oct4 and Nanog, which are essential for 
pluripotency. Loss of cohesin or Mediator caused reduced OCT4 protein levels, loss of ES 
cell colony morphology, and changes in transcription, consistent with differentiation, 
suggesting they are important in maintaining a stem-cell like state (Kagey et al., 2010). 
 
1.2.8.3 NIPBL and gene regulation 
NIPBL co-localises with Mediator and cohesin at many sites, suggesting that it is also 
involved in gene expression through enhancer-promoter looping. However it is possible that 
NIPBLs role at these sites is simply to load cohesin (Kagey et al., 2010). As discussed in 
section 1.2.5.2, NIPBL also binds at a number of cohesin-free sites. Interestingly, depletion 
of NIPBL affected the transcription of the genes associated with these sites, whereas 
depletion of SMC3 had little effect, suggesting that NIPBL can regulate gene expression 
independently of its role in cohesin loading (Zuin et al., 2014). This may explain the more 
severe CdLS phenotype seen with NIPBL mutations (Figure Ch1-1)(Newkirk et al., 2017); in 
NIPBL-deficient patients both cohesin dependent and independent mechanisms of 
transcriptional regulation may be perturbed.  
Figure Ch1-10. Mediator regulates the formation of transient chromatin loops that 
link enhancers to core promoters. Interactions between Mediator TFs and cohesin 




   
 
1.2.8.4 Transcriptional changes in CdLS 
Dysregulation of gene expression is now the favoured mechanism for CdLS, and has been 
implicated more generally as a cause of cohesinopathies (Bose and Gerton, 2010). Many 
studies have shown altered gene expression profiles in cells from CdLS patients. These 
studies use mainly differentiated cell lines such as LCLs and report subsets of dysregulated 
genes (~300-500 genes), rather than global changes, and a correlation with cohesin binding 
(Liu et al., 2009; Mannini et al., 2015; Yuan et al., 2015; Boudaoud et al., 2017; Mills et al., 2018). 
Mills et al., (2018) found that the genes dysregulated in NIPBL+/− patient-derived 
cardiomyocytes were involved in processes such as chromatin modifications, nucleosome 
assembly and transcriptional regulation, and reduced immunological functions, regulation 
of apoptosis and proteasome dynamics (Mills et al., 2018). 
The profiles of transcriptional dysregulation have been shown to correlate with patient 
phenotype severity, and similar transcriptional profiles were observed between NIPBL 
truncating mutations from CdLS patients, and two patients with RBS, consistent with both 
disorders being caused by mutations in the cohesin complex (Liu et al., 2009).  
Given the proposed roles of cohesin and NIPBL in chromatin loop formation, and the 
loss of loop domains in the absence of cohesin (Rao et al., 2017), I would expect that these 
changes in transcription occur through decreased interactions between promoters and 
their distal enhancers. Indeed, it’s been shown that mutant cohesin reduces both RNAPII 
recruitment to promoters and the levels of elongating RNAPII, leading to decreased 
transcription initiation and elongation (Mannini et al., 2015). Furthermore, the 
transcriptional changes that occur upon NIPBL deletion were found to be concentrated 
within regions that form larger TADs in WT, consistent with defective long-range regulatory 
interactions in the mutant cells (Schwarzer et al., 2017).  
Recent studies have identified a number of transcription related genes whose mutation can 
also cause CdLS-like phenotypes. Missense mutations in AFF4 were identified in three 
unrelated patients with a phenotype overlapping that of CdLS. AFF4 is a component of the 
super elongation complex -  a complex that strongly activates transcription elongation by 
RNAPII and is known to interact with the cohesin complex (Izumi et al., 2015). 
Three patients with CdLS-like phenotypes were found to have de novo mutations in 
ANKRD11. These consist of a frameshift mutation, an intragenic deletion and a  
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heterozygous LOF mutation (Ansari et al., 2014). ANKRD11 is an ankyrin repeat-containing 
cofactor that represses ligand-dependent transcriptional activation and mutations in this gene 
are known to cause KBG syndrome (Sirmaci et al., 2011).  
There is also some overlap between CdLS and Wiedemann-Steiner syndrome (WDSTS, 
MIM # 605130), a syndrome caused by mutations in the histone H3 methyltransferase, 
KMT2A. Methylation mediated by KMT2A is associated with epigenetic transcriptional 
activation important for the regulation of embryogenesis, cell fate determination, cell-cycle 
progression and stem-cell function. Mutations in SMC1/SMC3 contribute to phenotypes 
resembling WDSTS, whilst a mutation in KMT2A was identified in a patient with CdLS 
(Yuan et al., 2015), indicating a possible role of histone modifications in CdLS.  
 
1.3 Experimental models of CdLS 
1.3.1 Mouse  
1.3.1.1 Viability  
The core cohesin subunits have all been shown to be indispensable for early embryonic 
development in mice. Homozygous knockout of Smc3 or Rad21 are embryonic lethal prior 
to E14.5, whilst Smc1a mutant mice have not been reported, suggesting that they are not 
viable. Smc3 heterozygous mice show phenotypes similar to CdLS patients, including reduced 
size and craniofacial anomalies. However, Rad21 heterozygous mice have defects in DNA 
repair, but no overt developmental phenotypes (Singh and Gerton, 2015).   
1.3.1.2 Nipbl+/- 
A mouse model for NIPBL haploinsufficiency (Nipbl+/-), the most common cause of CdLS, 
was created by introduction of a gene trap into intron 1 of the Nipbl gene.  Nipbl+/-mice 
present with some of the phenotypic features observed in CdLS patients, including reduced 
body size (Figure Ch1-11), microbrachycephaly, reduced body fat, craniofacial anomalies and 
heart defects. These symptoms arise despite Nipbl transcript levels decreasing by only ∼30%, 
indicating a large sensitivity to small changes in NIPBL activity during development 
(Kawauchi et al., 2009).  
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Using mouse embryonic fibroblasts (MEFs) from Nipbl+/- mice, it was shown that Nipbl 
haploinsufficiency causes a global decrease in cohesin binding. Cohesin-bound genes were 
disproportionately downregulated in the mutant MEFs, accounting for more than half of the 
significantly dysregulated transcripts, and there was evidence of reduced promoter-enhancer 
interactions, suggesting that transcription may be affected through disruption of chromatin 
interactions. Downregulated genes were enriched for those involved in development, 
providing a direct link between decreased NIPBL/cohesin and the dysregulation of 
development, which is likely to contribute to the CdLS phenotype (Newkirk et al., 2017).  
Nipbl+/- mice have significant reductions in body fat compared to their WT litter-mates, and 
defective adipogenic differentiation (Kawauchi et al., 2009).  Analysis of adipogenesis genes 
in Nipbl+/- MEFs, found that these are often bound by cohesin, and dysregulated compared 
to WT cells. This suggests that multiple adipogenesis genes are sensitive to Nipbl 
haploinsufficiency (Newkirk et al., 2017), and may explain the reduced body fat phenotype 
found in patients with CdLS (Kawauchi et al., 2009).   
Atrial septal defects (ASD), one of the congenital heart defects (CHDs) found in CdLS 
patients, were observed in around half of Nipbl+/- embryos (Kawauchi et al., 2009). Santos et 
al., 2016 used the targeted trapping allele, Flip-Excision, to conditionally knockout Nipbl in 
specific tissues. Loss of Nipbl in the developing myocardium or endoderm caused ASD at an 
incidence of ~30%, the same as that caused by global Nipbl-deficiency, suggesting non-
additive effects of Nipbl-deficiency in different cardiac developmental lineages. Conditional 
Nipbl expression in either the developing myocardium or the endoderm, in the context of 
Figure Ch1-11. Reduced body size and growth in Nipbl+/- mice.  Nipbl+/-  mice are 
smaller than their WT litter-mates at birth (A) and at 4 weeks (B). Taken from  Kawauchi 
et al., 2009 
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global Nipbl knockout, rescued ASD, despite the lack of expression in the other tissue. 
Therefore, Nipbl deficiency in just one of these tissues was sufficient for ASD in a Nipbl-WT 
embryo, whilst expression of Nipbl in the other tissue was sufficient to rescue ASD in a Nipbl-
deficient embryo. This suggests that the risk of ASD, a defect of the heart, is actually 
determined by factors in the rest of the embryo. This study thus identified the presence of 
complex interactions between different lineages in the aetiology of CHDs - the risk conferred 
by a mutation in one lineage is modified by the status of other lineages – and may help explain 
the diverse cardiac phenotypes seen in CdLS patients (Santos et al., 2016). 
Not all of the phenotypic features of CdLS are recapitulated in the mouse model. For 
example, limb abnormalities occur in 20-30% of CdLS cases, but were originally not noted 
in Nipbl+/-  mice (Kawauchi et al., 2009). More recently 25-30% of Nipbl+/− mice were found 
to have postaxial polydactyly (Lopez-Burks et al., 2016) and modest changes in the expression 
of genes involved in normal limb development, such as Shh, Hox genes, and genes of the Fgf, 
Bmp and Wnt signalling pathways (Muto et al., 2014). Reduced Bmp and Hox expression were 
found to enhance the polydactyly observed in Nipbl+/- mice to around 96% and 63% 
respectively, suggesting that these pathways are directly involved in limb abnormalities in 
CdLS. The limb reduction phenotypes, that are seen in some CdLS patients however, were 
still not observed.  
1.3.2 Zebrafish 
Translation blocking morpholinos (MOs) were used to knockdown the expression of nipbla and nipblb, the 
two zebrafish nipbl genes, and to create Nipbl-deficient zebrafish embryos (nipbl morphants). The 
zebrafish nipbl morphants exhibit phenotypes common to CdLS patients, such as growth 
retardation and heart deficits, by 24 hours postfertilisation (hpf). These phenotypes become 
more pronounced over time and the morphants die in the larval stages (Figure Ch1-12) 
(Kawauchi et al., 2016).   
nipbl morphant larvae exhibited a range of defects in early heart development, resulting in 
impaired heart function, circulation defects and pericardial edema (Figure Ch1-12) later in 
development, and ultimately, premature death. 
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nipbl morphants also have malformations of the developing gut, including reduced size, 
patterning defects and absence of the associated organs. Gastrointestinal reflux is a hallmark 
of CdLS, which causes death in a number of patients. Transcriptomic analysis of mRNA 
from embryos at 6 hpf showed small but significant changes in expression upon nipbl 
reduction, consistent with what has been seen for other model organisms. Dysregulated 
genes included regulators of endoderm development, such as sox17 and foxa2, which are 
important during the development of the heart and visceral organs (Kawauchi et al., 2016).    
Genes involved in the regulation of vertebrate limb growth and patterning, such as fgfs, shh 
and hox genes, are also among those dysregulated in nipbl morphant embryos. This 
dysregulation precedes size reduction and patterning defects of the pectoral fin (forelimb). 
Knockdown of the mediator complex subunit Med12, mimicked both the gene expression 
changes and structural changes seen upon nipbl reduction, and combined reduction had a 
synergistic effect. Furthermore, 3D-FISH in zebrafish fin buds revealed that nipbl and 
Med12 modulate chromatin organisation near the hoxda cluster. These results suggest 
NIPBL and Mediator together regulate the expression of genes needed for correct growth 
and patterning of the vertebrate limb, by modulating long-range enhancer-promoter 
interactions (Muto et al., 2014). Interestingly, MED12 mutations in humans cause an X-linked 
recessive intellectual disability syndrome characterised by dysmorphic features (Yamamoto 
and Shimojima, 2015), but do not cause CdLS. This suggests that disruption of NIPBL and 
Mediator regulated gene expression alone is not sufficient to cause CdLS.  
Figure Ch1-12. Reduced body size and growth in Nipbl+/- mice. Nipbl morphant 
(nipbla-MO1/nipblb-MO1) zebrafish larvae resemble WT (uninjected) and control at 
18.5 hpf but show pericardial edema (asterisk) and tail defects (arrow) by 34 hpf and these 
progress over time. Scale bar = 25 mm. Takgen from Kawauchi et al., 2016 
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1.3.3 Drosophila  
In Drosophila Melanogaster, Nipped-B is critical for transcription and development. It was 
discovered during a screen for factors that aid expression of the cut homeobox gene in the 
developing wing margin; Nipped-B facilitates interactions of the cut promoter with a distal 
upstream enhancer that drives it’s expression (Rollins, Morcillo and Dorsett, 1999). 
Heterozygous Nipped-B LOF mutant (Nipped-B 407/+) adult flies display similar 
phenotypic features to CdLS patients, including reduced growth, learning and memory, 
relative to matched WT flies. 
The growth defects were found to be caused by a decreased number and size of cells, rather 
than differences in systemic growth control or developmental timing. Over-expression of 
dm (the drosophila C-MYC ortholog), a gene regulated by cohesin, rescued this phenotype, 
suggesting that the reduced size is caused, at least in part, by decreased dm expression. 
Furthermore RNA-seq revealed a modest decrease in the expression of a large number of 
genes in Nipped-B mutant flies.  
The deficiencies in learning and short-term memory in Nipped-B 407/+ flies was caused by 
abnormal brain structures; 48% of Nipped-B 407/+ flies had abnormal mushroom body (MB) 
morphology, compared to just 4% of WT flies. MBs are the primary brain structures involved 
in associative learning and memory in Drosophila and aberrant axon pruning of the 
Drosophila MB γ-neurons has also been seen in homozygous deficiencies of SMC1 
and Rad21 (Y. Wu et al., 2015).  
1.3.4 Yeast 
In S. cerevisiae, cohesin has been implicated in chromatin condensation during mitosis. Scc2-
Scc4 mutant cells have chromatin condensation defects that were mediated by the loss of 
cohesin deposition, rather than the loss of condensin. Cohesin promotes the condensation 
of chromatin through cis tethering interactions that are formed during prophase (Shen and 
Skibbens, 2017). Recreation of RBS and CdLS mutations in the homologous yeast genes 
(eco1-W216G and scc2-D730V respectively) lead to chromosomal decondensation, indicating that 
perturbations in cohesin cause changes in chromatin structure that may contribute to CdLS 
(Gard et al., 2009). This is consistent with reports of chromatin decompaction in CdLS 
patient cells (Nolen et al., 2013). 
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The RSC chromatin remodelling complex recruits Scc2-Scc4 to promoters that are 
characterised by large nucleosome free regions. Scc2-Scc4 was shown to help maintain these 
regions and thus regulate gene expression. This suggests that changes in transcription 
underlying CdLS could be the result of nucleosome positioning defects, rather than changes 
in long-range chromatin interactions. Mutations in the human ortholog of RSC (SWI/SNF) 
cause CSS, which has a similar phenotype to CdLS, supporting this idea (Lopez-Serra et al., 
2014) 
In another study, the inactivation of Scc2 was found to alter the overall transcriptional 
profile, but this did not correlate with changes in cohesin binding, differing from what has 
been seen in CdLS patient cells. When a DSB was induced, many genes involved in cellular 
responses to DNA damage, DNA repair and DNA recombination were downregulated in 
Scc2 deficient cells compared to WT cells, revealing that Scc2 influences the transcriptional 
response caused by induction of a DSB. Furthermore, in Scc2 deficient cells there was 
concurrent activation of genes and decreased cohesin binding, in a 50kb region surrounding 
a DSB. This indicates that cohesin may be needed for the silencing of DSB proximal genes 
(Lindgren et al., 2014). 
 
1.4 BRD4 
1.4.1 Acetylated lysine recognition  
Histones are subject to post-translational modifications (PTMs). These include 
phosphorylation, methylation, ubiquitination and acetylation, which can impact the 
interactions between histones and DNA, affecting DNA-templated processes such as 
transcription, DNA replication, DNA repair, and recombination (Su and Denu, 2016). In 
histone acetylation, the addition of an acetyl group to a lysine residue by a histone 
acetyltransferase (HAT), neutralises the positive charge of histones, decreasing their affinity 
for negatively charged DNA. This relaxes chromatin structure, promoting a conformation 
more accessible to regulatory factors (Koprinarova, Schnekenburger and Diederich, 2015) 
and associated with active transcription (Struhl, 1998). Additionally, specific PTMs, or 
combinations of multiple PTMs, provide docking sites for histone ‘readers’ – chromatin 
binding proteins that contain domains which recognise and bind the modified residues 
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(Gillette and Hill, 2015). Acetyl-lysines can be recognised by a number of domains. These 
include the YEATS domain, found in just four human proteins (Hsu et al., 2018), tandem 
PHD fingers (Ali et al., 2012) and the bromodomains (BD) (Jung et al., 2014). 
BDs are found in 42 different human proteins (Fujisawa and Filippakopoulos, 2017), 
including nearly all known HATs (Zeng and Zhou, 2002), in a number of chromatin 
remodellers such as SWI/SNF (Clapier and Cairns, 2009a), and in BD and extra-terminal 
domain (BET) proteins (Gillette and Hill, 2015). Chromatin-bound BD proteins act as 
scaffolds for the assembly of protein complexes, function as TFs or catalyse various 
chromatin modifications (Fujisawa and Filippakopoulos, 2017).  
The BET protein family is made up of BRD2, BRD3, BRD4 and BRDT, all of which contain 
two N-terminal BDs (BD1 and BD2) and an extra-terminal (ET) domain. BRD4 also has a 
unique C-terminal domain (CTD) that can recruit proteins for transcriptional activation 
(Decker et al., 2017) (Figure Ch1-11).  
1.4.2 BRD4 
BRD4 is the best studied of the BETs, and is known to have many functions, including 
transcriptional regulation (Hajmirza et al., 2018), cell cycle regulation (Maruyama et al., 2002) 
and DNA repair (Li et al., 2018). It has been proposed that BRD4 also regulates higher order 
chromatin structure, however the evidence for this is contradictory; on the one hand BRD4 
has been shown to condense chromatin (Wang et al., 2012; Floyd et al., 2013), whilst others 
have found that it inhibits heterochromatin formation and leads to decondensation (Pongas 
et al., 2017). Given the role of BRD4 in transcriptional activation, I would expect BRD4 to 
promote an open chromatin structure. BRD4 null mice are embryonic lethal, highlighting 
the importance of BRD4 for proper embryonic development (Houzelstein et al., 2002). 
1.4.2.1 Structure of BRD4 
Alternate splicing yields three different mRNA isoforms from the Brd4 gene (Figure Ch1-
13). The N-terminal BDs and the ET domain are common to all three isoforms, meaning 
that they are all able to bind acetylated histones. The CTD however, important for 
transcriptional regulation (Rahman et al., 2011), is absent in the two shorter isoforms (B&C). 
In isoform B, the CTD is replaced with a 75 amino acid (aa) unique sequence, differentiating 
it from isoform C. This sequence may be important for BRD4s role in the DDR (Floyd et 
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al., 2013) (see section 1.5.5). In mice and humans, the majority of BRD4 is isoform A, and 
this longer isoform accounts for much of BRD4s biological activity (Wu and Chiang, 2007).  
1.4.2.2 Acetyl lysine binding by BRD4  
The crystal structures of BRD4 BD1 and BD2 show that they exhibit the classical BD fold 
(found in all BD proteins) (Filippakopoulos et al., 2012) - a left-handed four-helix bundle 
(αZ, αA, αB, αC) with long intervening loops between the αZ and αA helices (ZA loop) and 
the αB and αC helices (BC loop) (Figure Ch1-14A, left) (Vollmuth, Blankenfeldt and Geyer, 
2009). The loop regions form a hydrophobic cavity for acetyl-lysine binding, in which many 
interactions take place (Figure Ch1-14A, right); acetyl-lysines are anchored to the BD via 
hydrogen binding to a conserved Asn residue (Figure Ch14-6B, highlighted in green), and 
this is enhanced by several residues within the loop regions (Figure Ch1-14B, highlighted in 
purple). A second interaction is formed between the acetyl carbonyl oxygen atom (OE1) and 
a conserved Tyr (Figure Ch1-14A, right). Finally a hydrophobic region of the BC loop known 
as the “WPF shelf” (W81, P82, F83 in BD1) (Figure Ch1-14A&B, highlighted in green) is 
also important for acetyl-lysine binding (Z. Liu et al., 2017).  
In BRD4, BD1 and BD2 were found to interact most strongly with di- and tetra- acetyl-
lysines in H4 N-terminal tails (Jung et al., 2014). However, despite their sequence similarity, 
there are some differences between BD1 and BD2’s interaction preferences; BD1 binds to 
the H4K5AcK8Ac mark, recruiting BRD4 to promoters and enhancers, whilst BD2 interacts 
with H3K4AcK9Ac. BRD4-BD2 has also been shown to recruit non-histone proteins such 
as TWIST (Z. Liu et al., 2017).  
Figure Ch1-13. Three isoforms of BRD4. Schematics of BRD4 isoforms A, B and C. 
Domains are labelled. BD= bromodomain. ET = extraterminal domain. CTD= c-
terminal domain. Isoform B contains a unique 75aa sequence at the C-terminus. Predicted 
molecular weights are shown in red. Taken from Shi and Vakoc, 2014 
200 kDa  
110 kDa  
90 kDa  
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1.4.2.3 BET inhibitors  
BET proteins, particularly BRD4, have been implicated in cancer. For instance, in NUT 
midline carcinoma (NMC) a translocation-induced fusion between BRD4 and NUT causes 
hyperacetylated nuclear foci and transcriptional dysregulation (Alekseyenko et al., 2015). This 
made BET proteins an attractive therapeutic target, and led to the development of the first 
BET inhibitors (BETi), JQ1 and IBET762, in 2010 (Ferri, Petosa and McKenna, 2016). Many 
more BETi now exist, and a number of these have entered clinical trials (Galdeano and Ciulli, 
2016).  
All BETi compete with acetylated peptides for binding to the BD pocket, displacing BET 
proteins from chromatin (Ferri, Petosa and McKenna, 2016). BRD4 inhibitors have head 
moieties that form critical hydrogen bonds with the conserved Asn and Tyr residues (Asn140 
and Tyr97 in BD1), can interact with the WPF shelf and often have small hydrophobic 
groups that occupy the base of the acetyl-lysine binding pocket (Z. Liu et al., 2017) (Figure 
Ch1-15A).    
Figure Ch1-14 Conserved regions of BD1 and BD2. A) (Left) Ribbon representation 
of BRD4 BD1 (PDB IF: 3UW9). (Right) Surface representation of the acetyl-lysine 
binding pocket of BRD4 BD1. Asn140 is highlighted in red, WPF shelf is highlighted in 
green and ZA loop highlighted in blue. B) Conserved sequences of BRD4 BD1 and BD2. 
Conserved Asn residues and WPF shelf are highlighted in green. Loop residues that may 





   
 
One drawback of most BETi is the lack of selectivity between BDs and BETs. Caused by 
the high conservation of BDs, especially at the residues important for acetyl-lysine binding, 
this limits the conclusions that can be drawn from BETi studies (Galdeano and Ciulli, 2016). 
Development of more selective inhibitors is ongoing, and would help elucidate some of the 
functions specific to each BD (Galdeano and Ciulli, 2016).  
JQ1 (Figure Ch1-15B), is the most well studied of the BETi. It is selective for the BET 
family with a KD of 50 nM for BRD4-BD1 and of 60–190 nM for the other family members 
(Ferri, Petosa and McKenna, 2016), is effective against NMC (Filippakopoulos et al., 2010) 
and decreases the transcription of BRD4 target genes (Horne et al., 2015; Korb et al., 2015). 
Furthermore the existence of the stereoisomer (−)-JQ1 (Figure Ch1-15C), which shows no 
significant interactions with BDs, provides a useful negative control for validating the 
biological effects of (+)-JQ1 (Liu et al., 2017). 
 
1.4.3 BRD4 and gene regulation 
ChIP-seq experiments have shown that BRD4 is bound to enhancers and promoters of its 
target genes. BRD4 at these regions is important for the activation and elongation of 
transcription via interactions with Mediator and positive transcription elongation factor B 
(P-TEFb) (Hajmirza et al., 2018).  
Figure Ch1-15. JQ1 inhibits BRD4 by mimicking acetyl-lysine binding to BDs. A) 
Co-crystal structure of (+)-JQ1 with BRD4 BD1 (PDB ID:3MXF). Residues Asn140 
(N140), Tyr97 (Y97), Leu94 (L94), Val87 (V87) and Leu92 (Leu92) are highlighted. B) 




   
 
1.4.3.1 BRD4 at enhancers and super enhancers  
Enhancers are CREs that recruit trans-acting factors such as TFs and other components of 
the transcription apparatus (Sabari et al., 2018), and interact with target gene promoters to 
regulate the expression of cell type–specific genes (Zabidi and Stark, 2016). Active enhancers 
are identified by the accumulation of specific histone PTMs. These include  H3K4me1, 
histone tail acetylations - H3K27ac and H4K16ac – and histone globular domain 
acetylations - H3K64ac and H3K122ac (Pradeepa et al., 2016). Lysine acetylation at 
enhancers results in the binding of BRD4. BRD4 recruits a number of trans-activators to 
enhancers (Rahnamoun et al., 2018), including the Mediator complex (Bhagwat et al., 2016). 
Mediator is thought to regulate gene expression by promoting the formation of transient 
chromatin loops that bring distal enhancers into contact with promoters (see section 1.2.8.2). 
Inhibition of BRD4 causes the loss of Mediator subunits at enhancers and the repression of 
target genes (Bhagwat et al., 2016).  
BRD4, MED12 and MED1 are most highly enriched at large clusters of enhancers, termed 
super enhancers (SEs) (Di Micco et al., 2014). SEs, first identified in ESCs (Whyte et al., 2013), 
can span 10s of Kb (McKeown et al., 2017), are bound by very high levels of Mediator and 
master regulatory factors, and regulate the transcription of genes involved in cell identity 
(Whyte et al., 2013; Klein et al., 2017; Brown et al., 2018). BETi treatment causes preferential 
loss of BRD4 at SEs, and preferentially affects genes associated with SEs (Chapuy et al., 2013; 
Lovén et al., 2013). 
Recently it’s been proposed that BRD4 is involved in the formation of SEs (Winter et al., 
2017). BRD4 and Mediator are thought to form phase-separated condensates that 
compartmentalise and concentrate the transcription apparatus at SE regulated genes, 
ensuring  robust gene expression (Sabari et al., 2018). 
Whether SEs represent a new paradigm – a functional element that is more than the sum of 
its parts –, or whether their transcriptional effect is simply the additive effect of their 
constituent enhancers, has been debated (Hay et al., 2016; Shin et al., 2016). Personally, I 
believe that regardless of whether individual enhancers function additively or synergistically 
within SEs, their clustering, and recruitment of large amounts of regulatory factors, is enough 
to render them important. This is supported by substantial evidence that SEs are enriched 
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for disease-associated sequence variations (Hnisz et al., 2013; Vahedi et al., 2015; W. Sun et 
al., 2018). 
1.4.3.2 RNAPII pause release 
At a large proportion of active genes, RNAPII transcribes between 20 and 100 nucleotides 
before pausing proximal to the promoter (Winter et al., 2017). Pausing involves the 
association of two negative factors - DRB sensitivity-inducing factor (DSIF) and negative 
elongation factor (NELF) – with the initiated RNAPII (Lu et al., 2016). RNAPII pausing is 
released through the recruitment of P-TEFb – made up of CDK9 and Cyclin T1 -  to 
promoters, where it mediates the phosphorylation of Ser2 in the RNAPII CTD, and of DSIF 
and NELF (Lu et al., 2016). It has been suggested that BRD4 itself has a kinase activity that 
phosphorylates Ser2 of RNAPII (Devaiah et al., 2012), but there is little further evidence to 
substantiate these claims.  
Promoter-proximal pausing is a rate-limiting step in the transcription of many genes, and the 
activity of P-TEFb is tightly regulated (Lu et al., 2016). The majority of P-TEFb is 
sequestrated in an inactive 7SK small nuclear ribonucleoprotein (snRNP) complex that 
contains 7SK snRNA, HEXIM1/2, MePCE and LARP7. Release of P-TEFb from this 
complex allows for the release of paused RNAPII (Figure Ch1-16)(Flynn et al., 2016). The 
BRD4 CTD interacts with both Cyclin T1 and CDK9 components of P-TEFb, whilst BD2 
can also interact with an acetylated region of Cyclin T1 (Hajmirza et al., 2018). BRD4 recruits 
P-TEFb to enhancers, thus regulating the pause release of RNAPII.  
1.4.3.3 Chromatin remodelling 
BRD4’s ET domain is also involved in transcriptional regulation through interactions with 
histone modifiers such as JMJD6 and the ATP-dependent chromatin remodellers SWI-SNF 
and CHD2 (Hajmirza et al., 2018).  
JMJD6 immunoprecipitates with BRD4 in complex with P-TEFb, and knockdown of JMJD6 
increases the RNAPII occupancy at promoter-proximal regions, suggesting it is also involved 
in RNAPII pause release (Taniguchi, 2016) (Figure Ch1-16). ChIP-seq locates BRD4 and 
JMJD6 at enhancer regions, suggesting that looping between the enhancer and promoter is 
also important for pause release (Liu et al., 2013). 
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During transcription elongation, histone exchange and nucleosome shifting is required to 
allow progression of RNAPII. This is achieved through chromatin remodelling by SWI-SNF 
and CHD2 (Cucinotta and Arndt, 2016), and BRD4 itself has been reported to act as a 
histone chaperone and support the progression of RNAPII through hyperacetylated 
nucleosomes. This activity is dependent on BD association with acetylated histones, but 
exactly how it is achieved remains to be elucidated (Figure Ch1-16) (Kanno et al., 2014).  
1.4.3.4 Enhancer RNA transcription  
Most promoters in mammalian genomes are inherently bi-directional. Similarly, transcription 
emanating from enhancers yields short, unstable enhancer RNAs (eRNAs). eRNAs are often 
a marker of active enhancers and their transcription generally increases with activation of 
specific TFs (Azofeifa et al., 2018). Whilst the importance of these eRNAs is not clear, it has 
been shown that  knockdown of eRNAs can cause the downregulation of the enhancer-
associated genes (Meng and Blaine, 2017).  
eRNAs have been found to promote interactions between promoters and distal enhancers 
(Hsieh et al., 2014; Yang et al., 2016), suggesting that they might form bridges between the 
two elements to facilitate DNA looping at genes (Meng and Blaine, 2017). eRNAs may also 
be involved in RNAPII pause release; upon induction of immediate early genes in neuronal 
cells, eRNAs directly bind to NELF and facilitate its release from paused RNAPII. This 
mechanism may be common to other genes and cell types (Schaukowitch et al., 2014).  
BRD4 inhibition by JQ1 inhibits eRNA synthesis, suggesting that BRD4 facilitates eRNA 
transcription, as well as normal mRNA transcription (Kanno et al., 2014). However it has 
also been shown that BRD4 functions to suppress pervasive eRNA transcription; BRD4 
Figure Ch1-16. Transcriptional regulation by BRD4. In the promoter-proximal 
region, RNAPII pauses due to sequestration of P-TEFb in the 7SK-snRNP complex. 
Enhanced recruitment of P-TEFb by BRD4 causes Ser2 phosphorylation in RNAPII, 
leading to RNAPII release. The pause release is also supported by the interaction of P-
TEFb with BRD4 and JMJD6 associated with distal enhancers. BRD4 may also promote 
RNA synthesis along the gene by interactions between the BD and hyperacetylated 
nucleosomes. Red circle – BDs, Green circle – CTD. Taken from Taniguchi, 2016 
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recruits a complex of 7SK snRNA and the chromatin remodelling complex BAF (distinct 
from the 7SK snRNP complex found at promoters) to enhancers, where BAF-dependent 
nucleosome remodelling decreases eRNA transcription. This activity is important for the 
inhibition of convergent transcription (convT) – the transcription of one region on both the 
sense and antisense strands at the same time – that can arise from excessive eRNA 
transcription (Flynn et al., 2016). 
 
1.5 Double strand breaks and their repair 
The integrity of DNA can be threatened by both endogenous and exogenous sources. 
Together these can induce up to 105 lesions in every cell every day. Unrepaired, these lesions 
can lead to mutations or larger genomic aberrations, resulting in decreased cell or organism 
fitness (Hoeijmakers, 2009). Double strand breaks (DSBs) are considered the most 
dangerous of the damage induced lesions, with the highest probability of causing cell death, 
mutation or a carcinogenic transformation (Schipler and Iliakis, 2013).  
1.5.1 Endogenous causes of DSBs  
1.5.1.1 Replication stress 
Slowing or stalling of the replication fork is known as replication stress, and often leads to 
the exposure of long stretches of ssDNA and activation of the replication checkpoint (Berti 
and Vindigni, 2016). Prolonged replication stress can lead to fork collapse - replisome 
components prematurely dissociate from the fork, and it can no longer support DNA 
synthesis. Nucleolytic processing of the ssDNA at collapsed fork results in DSBs (Toledo, 
Neelsen and Lukas, 2017).  
Endogenous impediments to the progression of the replication fork include head-to-tail 
collisions of adjacent forks (Alexander and Orr-Weaver, 2016), transcribing RNA 
polymerases, tightly-bound protein-DNA complexes, oncogene activation and unusual 
DNA structures (Berti and Vindigni, 2016) such as R-loops. 
R-loops are stable, three-stranded nucleic acid structures, that arise during transcription 
through the hybridisation of the newly transcribed RNA with the DNA template, and 
exposure of the non-template DNA strand as a loop of ssDNA. Dysregulation or inefficient 
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removal of R-loops poses a barrier to replication fork progression (Chang and Stirling, 2017), 
and they have been shown to increase replication fork-stalling and replication-dependent 
DSBs (Gan et al., 2011).  
1.5.1.2 Transcription  
Transcription can cause the formation of R-loops which, as explained above, can result in 
DSBs by impeding the replication fork. DSBs may also arise through the head-on 
collisions of two RNA polymerases. In mammalian cells, antisense noncoding transcripts 
and genes embedded within other genes (and transcribed in the opposing direction) are 
prevalent, and cause convT. ConvT can trigger recruitment of activation-induced cytidine 
deamination (AID) - the conversion of deoxycytidine residues into deoxyuracil, causing a 
UG mismatch that results in a DSB through base-excision repair or mismatch repair  (Khan 
and Ali, 2017) -  and RNAPII collisions, which may also lead to DSBs (Meng et al., 2014).  
1.5.1.3 Programmed DSBs 
1.5.1.3.1 Transcription 
As transcription proceeds, there is a necessity for RNAPII to travel along the helical DNA 
template (Liu and Wang, 1987). This results in negative DNA supercoiling (under-twisting) 
upstream of RNAP and positive supercoiling (over-twisting) downstream (Figure Ch1-17) 
(Ma and Wang, 2016). The resolution of such topological changes requires regulated DNA 
damage (Calderwood, 2016); Topoisomerase (TOP) enzymes catalyse the breaking and 
rejoining of DNA strands to relieve the torsional stress associated with supercoiling 
(Figure Ch1-17) (Wang, 2002). TOP1 introduces single strand breaks (SSBs), allowing the 
broken strand to rotate around the intact strand (Pommier et al., 2016), whilst 
homodimeric TOP2 enzymes induce DSBs and catalyse the ATP-dependent passage of 
one DNA double helix through another (Wang, 2002). 
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This function of TOP enzymes is required for transcriptional elongation of certain genes 
(Pommier et al., 2016). TOP2B induces programmed DNA breaks at promoters. These 
DSBs are critical for RNAPII pause release and transcriptional activation caused by heat 
shock, serum induction and responses to nuclear receptors (Ju et al., 2006; Bunch et al., 
2015; Calderwood, 2016). TOP1 is bound at promoters and becomes fully active upon the 
BRD4-mediated phosphorylation of RNAPII CTD and subsequent RNAPII pause release. 
The transcriptional machinery regulates TOP1 activity throughout the transcription cycle, 
relaxing torsional stress in gene bodies - that would otherwise impede transcription 
elongation -, whilst maintaining negative supercoiling at TSS - to assist in DNA melting and 
transcription initiation (Baranello et al., 2016).  
Whilst controlled induction of DSBs promotes transcription, unregulated breaks are known 
to inhibit transcription. In mammals, RNAPII is degraded by the proteasome upon DNA 
damage, preventing the expression of aberrant transcripts from damaged loci  (D’Alessandro 
and d’Adda di Fagagna, 2017).  
1.5.1.3.2 Immunological functions of DSBs  
Programmed DSBs create the diverse repertoire of B and T cells that function in immune 
responses in mammalian lymphoid cells (Prochazkova and Loizou, 2016). V(D)J 
recombination allows lymphoid cells to generate enormous antigen-receptor diversity by 
recombining their germline variable (V), diversity (D), and joining (J) exon gene segments in 
Figure Ch1-17. Transcription produces torsional stress in the DNA double helix. 
Illustration of the torsion created by RNAP progression along the DNA template. 
Negative supercoiling is produced behind the RNAP, and positive supercoiling is 
produced ahead of RNAP. Supercoiling is relieved by the action of the topoisomerases 




   
 
various combinations. DSBs are crucial for this process,  marking the correct areas for 
recruitment of the recombinational machinery (Khan and Ali, 2017).   
After V(D)J, further programmed DSBs enhance antibody functionality of mature B cells 
through class-switch recombination (CSR) (Qiao et al., 2017). In CSR, DSBs initiate 
recombination of immunoglobulin (Ig) heavy constant chains, resulting in a switch in Ig 
isotypes. This allows B cells to produce a new class of antibodies, which retain the original 
antigen specificity of antibodies but have distinct effector functions. DSBs in CSR are 
generated by AID (Khan and Ali, 2017). 
1.5.1.3.3 Meiosis  
During meiosis I, crossovers (CO) occur between homologous chromosomes. At least one 
CO per chromosome is required for proper dysjunction. COs are formed through the 
programmed induction of hundreds of DSBs along the chromosome and their repair by 
homologous recombination (HR) (Borde and de Massy, 2013) (see section 1.5.4.2 for 
description of HR).  
1.5.2 Exogenous sources of DSBs and studying DSBs 
DSBs can also be caused by exogenous agents. These may occur naturally, such as ionising 
radiation (IR) from high energy cosmic rays and radioactive materials in the earth’s crust  
(Bibbo and Piotto, 2014). However, DSBs can also be induced artificially through a range of 
damaging agents. A number of these, described in detail below, can be utilised to study DSB 
repair and cellular mechanisms of DDR.  
1.5.2.1 IR and radiomimetic drugs 
IR can lead to a variety of lesions, including DSBs. IR leads to extensive base damage and 
produces reactive oxygen species that attack the sugar-phosphate backbone and produce 
SSBs (Mehta and Haber, 2014). The frequency of DSBs increases linearly with increasing IR 
(Lomax, Folkes and O’Neill, 2013) as, with higher doses of IR, the likelihood of two SSBs 
occurring in close proximity in complementary DNA strands also increases (Mehta and 
Haber, 2014).  
Radiomimetic drugs mimic the effects of IR by generating free radicals that damage DNA 
and result in DSBs. They can be added to culture medium to induce nonspecific DSBs in 
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cells. Bleomycin is clinically available as an anti-tumor drug, whilst others such as 
neocarzinostatin (NCS) are solely used for research purposes (Andros et al., 2015).  
1.5.2.2 Replication inhibitors  
Replication inhibitors that impair the progress of the replication fork, resulting in the fork 
collapse, can also be used to induce DSBs. 
Hydroxyurea (HU) causes replication fork stalling through the inhibition of ribonucleotide 
reductase, the enzyme required for the production of deoxyribonucleotides (dNTPs), and 
therefore inhibits DNA synthesis (Singh and Xu, 2016). Aphidicolin (APH) specifically 
inhibits B-family DNA polymerases by binding at, or near, the dNTP binding site of the 
polymerase and inhibiting the incorporation of specific dNTPs (Baranovskiy et al., 2014). 
1.5.2.3 Targeted endonucleases 
Site specific endonucleases can induce DSBs at defined sites in the genome (Bryant and 
Johnston, 1993), giving them an advantage over other exogenous DSB inducing agents, 
where the site of DSBs is largely unknown. This has been utilised to generate stable cell lines 
in which multiple site specific DSBs can be induced; Iacovoni et al., fused the AsiSI restriction 
enzyme to a modified oestrogen receptor hormone-binding domain that responds only to 4-
hydroxy tamoxifen (4OHT). Expression of the fusion protein in U2OS cells allows the 
induction of DSBs with 4OHT treatment (Iacovoni et al., 2010).  
Recently the DNA endonuclease Cas9, which can be targeted to a specific DNA sequence 
by a small “guide” RNA (gRNA), has emerged as a powerful molecular tool. Cas9 is routinely 
used for genome editing (Paix et al., 2017) and the recruitment of proteins to specific genomic 
loci (Tian et al., 2017), but also has the potential to inform us about DNA repair. It’s ability 
to induce site-specific DSBs has been utilised to induce several breaks throughout the 
genome, and allow the mapping of DDR factors in response to breaks (Iacovoni et al., 2010), 
whilst the addition of a repair template can be used to compare the efficiencies of repair by 
non-homologous end joining (NHEJ) and HR (Zaboikin et al., 2017).  
1.5.2.4 Others 
There are a multitude of other drugs that can induce DSBs, including: TOP inhibitors – 
which trap covalently linked topoisomerase-DNA cleavage complexes, preventing the 
religation of breaks (Mehta and Haber, 2014) – and DNA-alkylating agents - which introduce 
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an alkyl group into a nucleophilic site of DNA and cause inter- or intra-strand cross-linking 
(Siddik, 2002).   
1.5.3 The DDR to DSBs 
DSBs can cause the mis-segregation of chromosomes during mitosis (Bakhoum et al., 2017) 
and impair replication (Berti and Vindigni, 2016), leading to genomic instability. To avoid 
this, the cell employs several checkpoints that temporarily prevent progression through the 
cell cycle (Barnum and O’Connell, 2014). The DDR is a complex signal transduction pathway 
that co-ordinates this cell-cycle regulation with the sensing, signalling and repair of DNA 
damage (Figure Ch1-18) (Jackson and Bartek, 2010). 
1.5.3.1 Sensing of DNA damage  
The first stage of the DDR is the recognition of the DSB. Several sensor proteins recognise 
DSBs and result in the recruitment of different downstream proteins and different 
mechanisms of repair. Tight regulation is required to ensure the correct response to a DSB, 
and it is possible that interplay between different sensor proteins may be involved 
(Hartlerode et al., 2015). 
Figure Ch1-18. Model of the DDR. Illustration showing the key steps in the DNA 
damage response. DNA damage or stalled replication are detected by DNA damage 
sensors, initiating a signalling pathway that involves recruitment of mediating proteins 
and signal amplification and can result in a number of cellular responses. Taken from 
Jackson and Bartek, 2010. 
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The MRN complex is made up of MRE11, RAD50 and NBS1; the ATP binding globular 
domains of a RAD50 dimer interact with two molecules of MRE11, and these molecules 
directly bind DSBs and recruit NBS1 (Lavin et al., 2015). RAD50 recognizes the ends of the 
DSB and holds them in close proximity (Yang et al., 2018a). MRE11 has endo- and 
exonuclease activities that facilitate DSB end-resection, a pre-requisite for repair through HR 
(Goldstein and Kastan, 2015). NBS interacts with the downstream kinase ATM, to activate 
the DDR (Lavin et al., 2015), and serves as a scaffold for the recruitment of DNA damage 
repair proteins including MDC1, BLM, BRCA1 and CtIP (Schiller et al., 2014). Mutations in 
MRN components causes chromosomal instability, sensitivity to DNA damage and cell cycle 
defects in patients (Lavin et al., 2015).  
The Ku complex is a heterodimer of Ku70 and Ku80 (Ku70/80). Through recent super-
resolution fluorescent particle tracking, Ku70/80 has been identified as one of the earliest 
sensors to localise at DSBs (Yang et al., 2018b). It forms a ring around DNA, that achieves 
high affinity binding without sequence specificity (Walker, Corpina and Goldberg, 2001). 
Once bound it recruits and activates DNA-PKcs, which facilitate DNA repair by NHEJ 
(Yang et al., 2018b).  
The RPA complex, composed of RPA1, RPA2 and RPA3, recognises ssDNA that arises 
through the processing of DSB ends, and so is likely to be recruited later than the other DSB 
sensors (Yang et al., 2018b). Once bound, it mediates the activation of the signal transducing 
kinase ATR. RPA is important in DNA repair through HR, as it recognises ssDNA that 
results from DSB end-resection (Chen, Lisby and Symington, 2013). 
The PARP family of enzymes catalyse PARylation of proteins (including histones). 
PARylation is the addition of ADP ribose units, forming long poly ADP ribose (PAR) 
polymers (Schuhwerk et al., 2017). PARP1 senses SSBs and DSBs through N-terminal Zinc 
finger motifs (Yang et al., 2018b). It is rapidly recruited to breaks and PARylation is one of 
the earliest DNA damage responses (Schuhwerk et al., 2017). PARylation at DSBs mediates 
the recruitment of numerous factors involved in DNA repair (Yang et al., 2018b) through a 
variety of PAR-binding modules, that range from completely folded domains, to disordered 




   
 
1.5.3.2 Signal transduction   
DSB sensors recruit three kinases of the phosphoinositide-3-kinase-related protein kinases 
(PIKKs) - ATM, ATR and DNA-PKcs -, the most upstream kinases in the DDR (Maréchal 
and Zou, 2013). The PIKKs mainly target substrates proximal to the site of the DSB, but 
their targets are vast and can often diffuse freely, meaning that the signal is transduced to 
distant substrates (Maréchal and Zou, 2013).  
ATM is recruited to DSBs as an inactive dimer, by the MRN complex, and its retention at 
these sites relies partially on its interactions with MDC1 (see section 1.5.3.4). Upon 
recruitment to DSBs, the kinase domains of each ATM molecule phosphorylate Ser1981 in 
the FAT domain of the other. This causes them to undimerise, resulting in two active ATM 
monomers. Autophosphorylation on Ser1893, Ser19881 and Ser2996, and acetylation by 
Tip60 on Lys3016, are also important for ATM’s functions in DNA damage signalling 
(Guleria and Chandna, 2016). ATM phosphorylates a plethora of downstream effector 
proteins and further kinases, which themselves become active and phosphorylate their own 
repertoire of target proteins. For instance, ATM phosphorylates CHK2, a diffusible signal 
transducing kinase that regulates cell cycle progression (see section 1.5.3.5.3) (Shiloh and Ziv, 
2013).  
Inactivation of the ATR kinase in mice results in chromosome fragmentation and early 
embryonic lethality (Brown and Baltimore, 2000; De Klein et al., 2000). ATR exists in a 
complex with ATRIP that is recruited to ssDNA (Saldivar, Cortez and Cimprich, 2017). 
ssDNA is an intermediate in many damage pathways, meaning that unlike ATM that 
responds only to DSBs (Guleria and Chandna, 2016), ATR can respond to a broad spectrum 
of damage (Saldivar, Cortez and Cimprich, 2017). 
A conformational change in ATR (as yet undefined) is required for its activation. This change 
is triggered by the binding of an activator protein. Two ATR activator proteins have been 
identified in vertebrates – TOPBP1 and ETAA1 – and are thought to be recruited to damage 
independently of ATR. Similarly to ATM, ATR has a large number of target proteins. These 
include FANCI – which helps ensure robust replication and protect against replication stress 
(Awasthi, Foiani and Kumar, 2016) – and CHK1, which is involved in cell cycle checkpoint 
activation (see section 1.5.3.5.3).  
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Whilst ATM and ATR are thought to be the master DDR transducers, phosphorylating >900 
sites in over 700 proteins (Matsuoka et al., 2007), the DNA-PKcs regulates a small number 
of targets (Maréchal and Zou, 2013). DNA-PKcs is recruited to DSBs through interactions 
with the Ku70/80 heterodimer, forming the DNA-PK holoenzyme which boosts the kinase 
activity 5-10 times (Jette and Lees-Miller, 2015).  
The main target of DNA-PKcs is itself; Autophosphorylation of DNA-PKcs results in 
inactivation of its kinase activity and dissociation from Ku70/80 at the DSB, and is important 
for NHEJ (see section 1.5.4.1) (Davis, Chen and Chen, 2014). Cells lacking DNA-PKcs or 
Ku70/80 have problems with V(D)J recombination and increased sensitivity to DSB 
induction, caused by impaired NHEJ (Jette and Lees-Miller, 2015). DNA-PK is also involved 
in other aspects of the DDR. For instance, in response to replication stress DNA-PK 
phosphorylates Ser4/Ser8 of RPA32, a subunit of RPA. This regulates activation of the 
G2/M checkpoint and supresses HR (Ashley et al., 2014).    
Whilst each PIKK interacts with a distinct DSB sensing protein, their recruitment to DNA 
damage involves a common mechanism. An evolutionarily conserved C-terminal motif 
was first identified in NBS1, which when deleted resulted in the loss of ATM recruitment 
to DSBs. This motif was later found in the C-termini of Ku70/80 and ATRIP, where it 
serves to recruit their respective PIKK interaction partners, potentially through 
interactions with PIKK HEAT repeat containing regions (Falck, Coates and Jackson, 
2005) (Figure Ch1-19). Most DSB signal transduction pathways are thought to be regulated 
by the co-ordinated action of ATM and ATR, with DNA-PKc being dispensable for DSB 
signalling and the resulting checkpoint activation (Callén et al., 2009). 
Figure Ch1-19. PIKKs share domain organisation and various structural features. 
PIKK domain organization. Coloured boxes represent different domains and numbers 
represent amino acid residues. P - Major sites of phosphorylation sites Taken from 




   
 
1.5.3.3 Chromatin modifications during the DDR  
DSBs occur within the complex structure of chromatin, and certain chromatin contexts can 
hinder their efficient detection, signalling and repair (Price and D’Andrea, 2013). DDR 
kinases promote chromatin remodelling and histone modifications to produce a more 
conducive environment for repair (Sirbu and Cortez, 2013), and provide platforms for the 
recruitment of repair proteins. There is significant evidence for cross-talk between histone 
modifications – for instance phosphorylation of a specific histone residue can stimulate the 
acetylation of a different residue within that histone (Lee et al., 2010a) - suggesting that order 
in which these modifications occur could be important for proper DDR signalling and repair 
(House, Koch and Freudenreich, 2014). 
1.5.3.3.1 Acetylation and phosphorylation 
Nucleosome remodellers use energy from ATP hydrolysis to modulate chromatin structure 
and facilitate the DDR (Seeber, Hauer and Gasser, 2013). For instance p400, an ATPase of 
the INO80 family, exchanges H2A for H2AZ in response to DSBs, creating large domains 
of H2AZ containing nucleosomes around the DSB. This exchange precedes, and is required 
for, H4 acetylation by TIP60, which in turn leads to a more open chromatin structure (Figure 
Ch1-20). H2A to H2AZ exchange has been found to be required for loading of both 
Ku70/80 and BRCA1, implicating it in NHEJ and HR repair pathways. The loss of p400 
activity causes genomic instability (Xu et al., 2012).  
 
Figure Ch1-20. H2A.Z exchange drives H4 acetylation. P400 catalyses the exchange 
of H2A for H2AZ in response to DSBs. This expose the H4 N-terminal tail, allowing its 
acetylation by TIP60. The combination of H2A.Z exchange and H4 acetylation (Ac) shifts 
chromatin into the open, relaxed conformation required for DSB repair. Taken from Price 
and D’Andrea, 2013. 
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The chromatin remodeller CHD1, is essential for end resection during HR. CHD1 opens 
the chromatin at DSBs, potentially via nucleosome sliding or removal, and facilitates the 
binding of CtIP (Kari et al., 2016). Other members of the CHD family were also shown to 
be important for DSB repair (Rother and van Attikum, 2017). 
One of the earliest steps in the DDR is the S139 phosphorylation of H2AX (γ-H2AX) by 
the PIKKs. γ-H2AX recruits HATs such as GCN5 to acetylate H3 within the same 
nucleosome, and in the surrounding nucleosomes (Lee et al., 2010b). The BD containing 
SWI/SNF family of nucleosome remodelling complexes, recognise and bind acetyl-lysine 
residues (Clapier and Cairns, 2009b) and in turn facilitate further phosphorylation of S139, 
most likely by increasing the accessibility of the neighbouring nucleosomes. This results in a 
positive feedback loop between SWI/SNF, γ-H2AX and H3 acetylation, and an 
accumulation of γ-H2AX around the DSB (Iacovoni et al., 2010; Lee et al., 2010b) (Figure 
Ch1-21).  
Histone H4 is also acetylated by TIP60-TRRAP in response to DNA damage, increasing the 
accessibility of chromatin to the DDR complex (Murr et al., 2006). CBP/p300 HATs are 
recruited to sites of DSBs where they acetylate multiple lysines on both H3 and H4 and 
facilitate the recruitment of Ku70/80 (Ogiwara et al., 2011). 
Figure Ch1-21. Positive feedback loop between SWI/SNF, S139P and H3ac results 
in high levels of γ-H2AX. DSB-activated ATM initiates phosphorylation of S139, 
triggering the acetylation of H3 within the same and/or neighbouring nucleosomes. 
SWI/SNF interacts with the acetylated H3 via its BDs and facilitates ATM-mediated 
S139-P. Taken from Lee et al., 2010 
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1.5.3.3.2 Methylation 
A complex containing KAP-1, HP1 and the SUV39H1 methyltransferase is also recruited 
to DSBs, where SUV39H1 methylates H3K9 in the surrounding nucleosomes. HP1 
recognises H3K9me3, leading to further loading of the KAP-1/HP1/SUV39H1 complex. 
This cycle of methylation and loading causes the spreading of H3K9me3 tens of Kb away 
from the DSB, transiently forming domains of repressive chromatin. These domains act to 
stabilise the chromatin and activate TIP60 acetyltransferase (Ikura et al., 2007a). 
The constitutive histone modification, H4K20me2, plays an important role in the DDR 
through the recruitment of the effector protein 53BP1. H4K20me2 is usually masked by 
proteins such as L3MBTL1 (Acs et al., 2011), JMJD2A (Mallette et al., 2012) and TIRR (Drané 
et al., 2017), but becomes accessible to the tandem tudor domains of 53BP1 upon DNA 
damage (see section 1.5.3.5.1) (Hartlerode et al., 2012). This association can be limited by 
TIP60-dependent H4K16 acetylation (Tang et al., 2013).  
1.5.3.3.3 Ubiquitination 
In response to DSBs, TIP60 acetyltransferase associates with the ubiquitin-conjugating 
enzyme UBC13, inducing the acetylation and ubiquitination of H2AX, and release of H2AX 
from damaged chromatin. The reorganisation of chromatin via histone eviction and histone 
variant exchange, helps to recruit DDR factors to facilitate DNA repair (Ikura et al., 2007b).   
Ubiquitination can also directly recruit DDR proteins; Phosphorylated MDC1 is bound by 
the ubiquitin ligase RNF8, which extends pre-existing ubiquitin on H1 and stimulates the 
recruitment of RNF168 to DSBs (Mandemaker et al., 2017).. With UBC13, RNF168 initiates 
ubiquitination of H2A/H2AX at K13/15 (Bohgaki et al., 2013). This ubiquitination cascade 
results in the recruitment of the effector proteins 53BP1 and BRCA1 to DSBs (Citterio, 
2015). Mutations in RNF168 cause RIDDLE syndrome, a immunodeficiency and 
radiosensitivity disorder, likely through the perturbation of BRCA1 and 53BP1 binding at 
DSBs (Stewart et al., 2009). 
ATM-dependent monoubiquitination of H2B by RNF20-RNF40 is also induced by DSBs, 
and is required for the accumulation of NHEJ and HR proteins (Moyal et al., 2011).  
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1.5.3.4 Amplification and spreading of signal   
Following initial recruitment and activation, the PIKKs trigger a cascade of DDR signalling 
on the chromatin surrounding the site of damage (Maréchal and Zou, 2013).  
Activation of ATM or DNA-PKcs at DSBs causes the rapid S139 phosphorylation of H2A.X 
(Caron et al., 2015), and initiates the DDR (Ljungman, 2010). γ-H2AX function is mainly 
mediated by MDC1 (Caron et al., 2015). Two positive feedback loops involving MDC1 result 
in the spread of γ-H2AX up to 3 Mb from the break (Rogakou et al., 1999; Iacovoni et al., 
2010), amplifying the original signal and providing a platform for the recruitment of further 
proteins: 1. γ-H2AX must be dephosphorylated on Y142 (a constitutively phosphorylated 
residue), before MDC1 can bind. ZNF506 is recruited to DSBs in an ATM dependent 
manner, and recruits the protein phosphatase EYA, which carries out Y142 
dephosphorylation. MDC1 then facilitates the recruitment of further ZNF506 (Nowsheen 
et al., 2018). 2. γ-H2AX bound MDC1 recruits ATM, which phosphorylates adjacent H2AX 
molecules, MDC1 and ZNF506. MDC1 recruits more ATM to DSBs, resulting in a positive 
feedback loop that maintains ATM at the original DSB and facilitates spreading of the signal 
along the DNA (Maréchal and Zou, 2013) (Figure Ch1-22).  
The spread of the DDR signal results in microscopically visible foci, named irradiation 
induced foci (IRIF), made up of DDR proteins (Vignard, Mirey and Salles, 2013) (Figure 
Ch1-23). IRIF are a useful tool for the study of DNA damage and repair. These foci are 
Figure Ch1-22. Recognition of γH2AX by MDC1 triggers a feed-forward loop that 
spreads ATM and γH2AX over large chromatin domains. Illustration of γH2AX 
spreading. MRN recognises DSBs and activates and recruits ATM. ATM phosphorylates 
γH2AX, which is then recognised by MDC1. MDC1 recruits more ATM, which 





   
 
routinely imaged through fluorescence microscopy and, when coupled with fluorescent 
protein tags such as GFP, they allow in vivo visualisation of breaks and the estimation of the 
rate of turnover of proteins at their natural binding sites (Nagy and Soutoglou, 2009). This 
method can be used to assay endogenous breaks, or breaks can be induced in a random or 
site specific manner (see section 1.5.2) (Nagy and Soutoglou, 2009). 
 
 
1.5.3.5 Effector proteins of the DDR 
1.5.3.5.1 53BP1  
53BP1 is a large (350 kD) protein, that has no enzymatic activity of its own, but contains 
multiple domains (Figure Ch1-24) that allow both its own recruitment to DSBs, and the 
Figure Ch1-23. DDR proteins can spread Mb from the site of a DSB. Exponentially 
growing U20S cells were sensitised with BrdU and micro-irradiated with UV-A lasers. 
After 1 hour, cells were fixed and stained with the indicated antibodies. Insets show 
higher magnifications. Taken from Bekker-Jensen et al., 2006 
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further recruitment of DSB responsive proteins (Panier and Boulton, 2014). 53BP1 
recognises and binds H2AK15ub through its ubiquitination-dependent recruitment 
(UDR) domain (Kocyłowski et al., 2015).  RNF168 also interacts with 53BP1 before it is 
recruited to DSBs, and ubiquitinates it independently of γ-H2A.X–MDC1–RNF8. This 
ubiquitination is important for the initial localisation of 53BP1 to DSB sites (Bohgaki et al., 
2013). The BRCT domain recruits 53BP1 to DSBs through direct binding to γ-H2AX 
(Baldock et al., 2015), even in the absence of  RNF8 and RNF168 (Kocyłowski et al., 2015). 
The tandem Tudor domains of 53BP1 recognise H4K20me2 (Hartlerode et al., 2012) (see 
section 1.4.2.1). However, these modifications are present even in the absence of DSBs. 
It may be that changes in the higher order chromatin structure upon DNA damage are 
required to expose methylated histones for 53BP1 binding (Huyen et al., 2004). Once at 
DSBs, 53BP1 can form microscopically visible nuclear foci. 53BP1 focus formation is 
mediated by the minimal focus forming region, made up of an oligomerisation domain (OD), 
a Glγ- and Arg-rich motif (GAR) and the  UDR and Tudor domains (Panier and Boulton, 
2014) (Figure Ch1-24).  
The key role of 53BP1 is in the inhibition of DSB end resection, which inhibits HR and 
promotes NHEJ, and this is mediated through its interactions with RIF1 and PTIP (Figure 
Ch1-24) (see section 1.5.3.3. for more detail). 53BP1 is also important in the response to 
replication stress; 53BP1 is recruited to stalled replication forks (Her et al., 2018) where it can 
regulate the accumulation of BLM - a helicase that prevents replication fork collapse and 
resolves HR intermediates (Sengupta et al., 2004)- and recruit TOPB1- which activates CHK1 
in response to stalled replication forks (Kim et al., 2005). Loss of 53BP1 leads to defective 
CHK1 signalling and increased cell death in response to replication stress (Her et al., 2018).  
Furthermore, 53BP1 forms large nuclear bodies in G1 cells which are thought to represent 
DNA lesions that are generated when under-replicated DNA undergoes mitosis (Harrigan et 
al., 2011; Lukas et al., 2011). These foci are resolved during early S phase, raising the 
possibility that they are repaired by HR (Fernandez-Vidal, Vignard and Mirey, 2017). If this 
is the case, it’s possible that 53BP1 plays a protective role - sequestering the DNA lesions 
and shielding them from error-prone repair by NHEJ in G1, so that they can be repaired by 
HR in S phase (Harrigan et al., 2011). Finally, bivalent interactions of the 53BP1 BRCT 
domain with p53 and the ubiquitin-specific protease USP28, allow 53BP1 to directly 
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BRCA1 is a tumour suppressor gene that is mutated in a large percentage of hereditary breast 
and ovarian cancers. It codes for a protein of around 220 kDa, made up of multiple 
functional domains (figure Ch1-25). BRCA1 is recruited to DSBs through ubiquitinated 
K13/15 of H2A/H2AX. The ubiquitin chains act as docking sites for RAP80, which binds 
via its ubiquitin-interacting motifs (Li et al., 2017). RAP80 interacts with ABRA1, which 
in turn forms a complex with BRCA1 through the BRCT domains (Wang et al., 2013), 
thus recruiting BRCA1 to sites of DNA damage. 
Cells lacking BRCA1 are sensitive to a broad range of DNA damaging agents. BRCA1’s 
RING domain is an E3 ubiquitin ligase that ubiquitinates a number of proteins to promote 
DNA repair. For instance the ubiquitination of H2A provides a binding site for the 
chromatin remodeller SMARCAD1, which promotes the repositioning of 53BP1 at the 
periphery of repair foci, counteracting the 53BP1-mediated block on resection (see section 
1.5.5.3) (Densham and Morris, 2017). ATM-dependent phosphorylation of Ser1423 in 
BRCA1 is also important for the activation of the G2-phase cell cycle checkpoint (Xu et al., 
2001). 
Figure Ch1-24. Domain structure and interaction partners of 53BP1. 53BP1 
contains 28 N-terminal Ser/Thr-Gln sites that are phosphorylated by ATM to promote 
RIF1 and PTIP binding. The 53BP1 C-terminus contains tandem BRCT (BRCA1 
carboxγ-terminal) domains that bind to p53 and EXPAND1 and recruits 53BP1 to 
yH2AX. The minimal focus-forming region contains an oligomerization domain (OD), 
a Glγ- and Arg-rich (GAR) motif, a tandem Tudor motif that binds to H4K20me2 and 
an ubiquitination-dependent recruitment (UDR) motif that interacts with H2AK15ub. 
Amino acid positions are indicated. Taken from Panier and Boulton, 2014. 
 
  84
   
 
1.5.3.5.3 Checkpoint effector kinases 
Cyclin dependent kinases (CDKs) are a family of kinases that promote progression through 
the cell cycle. Activity of the CDKs is partly controlled by the cell-cycle regulated 
accumulation of their cyclin partners, which are required for their enzymatic activity. 
However, a second level of regulation is achieved through the cell division cycle 25 (Cdc25) 
family of phosphatases, made up of Cdc25A, Cdc25B and Cdc25C. These phosphatases 
remove inhibitory phosphatase groups from phosphor-Thr or phosphor-Tyr residues of the 
CDKs, inducing their activation (Donzelli and Draetta, 2003).  
In response to DNA damage, the cell cycle needs to be stalled until damage is resolved, to 
ensure that the damaged DNA is not inherited by subsequent generations of cells. This is 
achieved through the activation of G1-S, intra-S and G2-M cell cycle checkpoints by the 
DSB sensors ATM and ATR. This regulation is mainly carried out by the activation of the 
checkpoint effector kinases CHK1 and CHK2, however the complete story is complex, 
involves the activation of many downstream substrates, and varies depending on the type of 
damage detected and the stage of the cell cycle (Manic et al., 2015).  
 
In response to damage acquired during G1, ATM or ATR phosphorylate and activate CHK2 
and CHK1 respectively, although there is evidence of cross-talk between the ATM CHK2 
and ATR-CHK1 signalling pathways, and neither checkpoint effector kinase can be assigned 
unambiguously to a particular pathway (Cuadrado et al., 2006). These kinases in turn 
phosphorylate Cdc25A phosphatase, inactivating its activity. This leads to the accumulation 
of the phosphorylated, inactive form of CDK2 and the inhibition of progression into S 
Figure Ch1-25. Domain structure and binding partners of BRCA1. Domain map of 
BRCA1. RING, serine containing domain (SCD), and BRCT domains are indicated. NES 
and NLS sequences are also depicted. Horizontal solid black lines indicate protein binding 
domains for the listed binding partners. Red circles mark phosphorylation sites. Adapted 







   
 
phase. The p53-p21 pathway is also important; phosphorylated p53 induces p21, which binds 
both CDK2 and CDK4, inhibiting their  kinase activities and resulting in G1-S checkpoint 
signalling (Figure Ch1-26) (He et al., 2005).  
 
Cyclin B accumulates during S/G2 and binds to its CDK partner CDK1, which promotes 
progression into mitosis at the end of G2. However Cyclin B is not enough to fully activate 
CDK1; Cdc25C is also required to remove the inhibitory phosphatases deposited by the 
kinases WEE1 and MYT1 (Sherr and Bartek, 2017). Phosphorylation of Cdc25C by either 
CHK1 or CHK2 creates binding sites for proteins of the 14-3-3 family, which act to sequester 
Cdc25C in the cytoplasm and inhibit its ability to dephosphorylate and activate CDK1, 
leading to activation of the G2-M checkpoint (Stark and Taylor, 2006)(Figure Ch1-26) 
 
Despite the efforts of the G1-S checkpoint, some damaged DNA may remain in S-phase, 
and thus an intra-S checkpoint is employed to minimise any deleterious effects. ATR is active 
during unperturbed S-phases, where it regulates origin firing, and recognises RPA-ssDNA 
complexes which can occur when replication fork stalling exposes stretches of ssDNA, 
making it the more crucial of the two DNA damage sensors for intra-S checkpoint activation. 
During S-phase the phosphatase activity of Cdc25A is required for activation of CDK2 and 
the subsequent binding of Cdc45 to the pre-replicative complex and initiation of replication. 
Figure Ch1-26. Schematic checkpoint signalling during G1. ATM and ATR 
phosphorylate and activate CHK1 and CHK2, which in turn phosphorylate Cdc25A and 
Cdc25C. This results in CDKs remaining phosphorylated and preventing progression of 
the cell cycle. The P53-P21 pathway can also be activated by ATM and ATR, preventing 
the activation of CDK4 and CDK2. 
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ATR-mediated CHK1 phosphorylation of Cdc25A in response to DNA damage inhibits this 
pathway, and thus inhibits origin firing (Iyer and Rhind, 2017).  (Figure Ch1-27)  
1.5.3.6 Outcomes of the DDR 
Activation of the cell cycle checkpoints by CHK1 and CHK2 activation, can have three 
outcomes – cell cycle arrest, apoptosis or senescence. Transient cell cycle arrest, coupled with 
DNA repair, is the main outcome of the DDR, giving cells time to resolve the damage before 
the cell cycle is resumed. If the DNA cannot be repaired however, the cells may undergo 
apoptosis or become senescent. The determinants of the choice between senescence and 
apoptosis are not well understood, but may include cell type, the nature of the DNA damage, 
and the intensity and duration of the DDR. For instance, senescence appears to be associated 
with large DDR foci and prolonged signalling (D’Adda Di Fagagna, 2008).  
1.5.4 DSB repair  
As well as cell cycle checkpoint activation, recognition of DNA damage promotes DNA 
repair (Sirbu and Cortez, 2013). DSBs can be repaired by two main pathways – NHEJ and 
HR (Rodgers and Mcvey, 2016).   
1.5.4.1 NHEJ  
NHEJ mediates the direct ligation of the two DNA ends at a DSB, repairing the break 
without the need for an intact sister chromatid as a template. NHEJ can therefore occur at 
any stage of the cell cycle (Price and D’Andrea, 2013), and is now thought to predominate 
throughout (Chang et al., 2017a). The core NHEJ machinery consists of the Ku70/80 
heterodimer, DNA-PKcs, XRCC4, DNA ligase IV, Artemis and XLF (Figure Ch1-28) 
(Davis and Chen, 2013a)(Weterings and Van Gent, 2004), however various NHEJ proteins 
exist and the exact complement appears to depend on the structure of the DNA ends (Chang 
et al., 2017b).  
Figure Ch1-27. Schematic of intra-S checkpoint signalling. ATR phosphorylates and 
activate CHK1. Activated CHK1 phosphorylates Cdc25A, leading to its degradation. 
Loss of Cdc25A results in loss of CDK2 activation, which in turn inhibits the binding of 
Cdc45 to the PRC, activating the intra-S checkpoint.  
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NHEJ initiates with DNA-PK binding at DSB ends (Davis and Chen, 2013b). Cryo-EM 
suggests that Ku70/80 and the bound DNA causes a conformational change in the DNA-
PKc, which enhances its Ser/Thr kinase activity (Sharif et al., 2017) – a requirement for 
successful NHEJ (Kurimasa et al., 1999).  
Minimal DSB end processing is required during NHEJ (relative to HR), but some nuclease 
activity is needed to ensure the compatibility of the two DNA ends. This can be through 
minor degradation of 5′ or 3′ overhangs or through the generation of a small region of 
homology, termed microhomology, between the strands. Removal of overhangs is 
primarily carried out by Artemis which, when activated by DNA-PK, has 5’ and 3’ 
endonuclease activity (Chang et al., 2017b). In most human cells, DNA Pol μ and Pol λ 
interact with Ku70/Ku80 and create microhomology between the strands through template 
independent nucleotide addition to the DNA ends (Pannunzio, Watanabe and Lieber, 2017).  
XRCC4 and Ligase IV are recruited to the DSB as a complex, through interactions with 
Ku70/80, and ligate the two ends of the DSB. Ligation is promoted by XLF, which 
stimulates the activity of DNA Ligase IV towards mismatched and non-cohesive ends (Davis 
and Chen, 2013a). 
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In contrast to NHEJ, HR repairs DSBs by utilising the redundancy of genetic information 
that exists in the form of sister chromatids or homologous chromosomes, restricting its use 
to S and G2 in human cells (Wright, Shah and Heyer, 2018a). 
HR begins with the recognition of DSBs by the MRN complex. MRN recruits CtIP (Schiller 
et al., 2014), and this complex initiates DSB end resection with the endonucleolytic cleavage 
of the 5’ internal ends, creating short 3’ ssDNA tails (Figure Ch1-29). A more processive 
Figure Ch1-28. Illustration outlining the key steps of NHEJ. (A) A DSB is induced 
and B) recognised by Ku70/80. (C) Ku70/80 binds the broken DNA ends and serves as 
a scaffold for the recruitment of DNA-PKcs, XRCC4, DNA ligase IV, XLF and Artemis. 
(D) This results in the formation of a stable complex at the DSB. Modified from Davis 









   
 
resection is then carried out by the 5’-3’ exonuclease EXO1 and the action of the BLM-
DNA2 helicase-endonuclease complex (Symington, 2014).  
The resulting 3’-ssDNA filaments are initially stabilised by the loading of RPA. As the 
resection matures, RPA is replaced with RAD51 (Ochs et al., 2016), forming the RAD51-
ssDNA filament (Wright, Shah and Heyer, 2018a). RAD51 regulates the stretching of the 
ssDNA within the filament, increasing its length by up to 50% (Klapstein, Chou and 
Bruinsma, 2004), a process that is critical for the subsequent homology search (Wright, Shah 
and Heyer, 2018a). 
One strand of the genomic dsDNA is destabilised, opening the helix and allowing the 
RAD51-ssDNA filament to scan for a homologous template sequence from which to initiate 
DNA synthesis (Wright, Shah and Heyer, 2018b). Once a homologous region has been 
identified, RAD51 facilitates the formation of the synaptic complex, made up of the RAD51-
ssDNA and both strands of the homologous sister chromatid.  
The 3′ end of the broken strand must then invade the homologous duplex DNA template 
and intertwine with its complementary donor strand, forming a heteroduplex DNA known 
as the D-loop. The 3’ end of the invading strand acts as a primer for DNA synthesis by DNA 
polymerase δ, using the complementary strand as a template (Wright, Shah and Heyer, 
2018b).  
There are multiple possible outcomes of HR, which can result in integration of the template 
DNA with the broken DNA (CO) or no integration (non-CO) (Potts, Porteus and Yu, 2006). 
In somatic cells, the majority of DSBs are repaired through disruption of the D-loop and 
annealing of the new DNA with the other end of the DSB (Figure Ch1-29). This is known 
as synthesis dependent strand annealing (SDSA) and avoids CO, preventing loss of 
heterozygosity (Wright, Shah and Heyer, 2018). 
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1.5.4.3 DNA repair pathway choice  
1.5.4.3.1 Cell cycle  
The need for a homologous DNA template restricts HR to the S and G2 phases of the cell 
cycle (Wright, Shah and Heyer, 2018a), but its peak activity appears to occur during mid-S 
phase, whilst NHEJ predominates in G1 and G2. Cell-cycle regulation of repair pathway 
choice is mediated largely by CDK dependent phosphorylation of CtIP (Her and Bunting, 
2018) and RECQL4 (Lu et al., 2017).  
During S phase, phosphorylated CtIP promotes HR by stimulating end resection (see section 
1.5.4.2.1), whilst in G1 phase CtIP is degraded by the proteasome (Her and Bunting, 2018). 
Figure Ch1-29. The key steps of HR. 5’-3’ DSB resection exposes 3’ ssDNA at DSB 
ends. RAD51-ssDNA filaments promote homology search and strand invasion into the 
homologous duplex DNA template, leading to D-loop formation. D-loops can be 
resolved through SDSA, forming non-crossover products. Red arrows indicate key 









   
 
RECQL4, on the other hand, can promote both HR and NHEJ, but functions differently 
throughout the cell cycle to co-ordinate the two; in G1 - when overall CDK activity is low - 
RECQL4 interacts with Ku70 and promotes NHEJ. In S/G2 – when CDK levels are higher 
- RECQL4 is phosphorylated, enhancing its interaction with MRE11 and its recruitment to 
DSBs, and activating a helicase activity that contributes to end-resection (Lu et al., 2017).  
1.5.4.3.2 Chromatin state   
The genome is divided into distinct chromatin states, identifiable by their specific 
combinations of histone modifications and chromatin protein occupancies. These chromatin 
signatures are diagnostic of different functional genomic elements such as promoters and 
enhancers, and their regulatory state. Across the genome, DSBs are not necessarily repaired 
by the same pathway and it is thought that the choice of pathway is directed by the chromatin 
state, with many studies supporting the idea of ‘histone code driven’ repair pathway choice 
(Clouaire and Legube, 2015). 
A good example of this is the favoured use of HR in transcriptionally active chromatin, 
mediated by the enriched H3K36me3 mark at these regions. On DSB induction, 
(LEDGF)/p75 recognises H3K36me3 and recruits the resection promoting protein, CtIP. 
Depletion of the H3K36me3 methyltransferase, SETD2, impaired HR at these breaks, 
indicating the requirement for H3K36me3 (Clouaire and Legube, 2015).   
1.5.4.3.3 Antagonistic roles of BRCA1 and 53BP1  
53BP1 and BRCA1 act at the junction of NHEJ and HR, and regulate pathway choice 
(Aparicio, Baer and Gautier, 2014).  
53BP1 recruits RIF1 via its N-terminal Ser/Thr repeats (Panier and Boulton, 2014), and 
this localises the shieldin complex (C20orf196, FAM35A, CTC-534A2.2 and REV7) at 
DSBs through  interactions with the REV7 subunit. The FAM35A subunit binds ssDNA via 
OB-fold domains, protecting them from interactions with the resection promoting RPA. 
Loss of shieldin, or perturbation of the OB-fold domain, impairs NHEJ, suggesting that the 
binding of shieldin to ssDNA is essential for 53BP1 mediated NHEJ (Noordermeer, Adam, 
Setiaputra, Barazas, Pettitt, Ling, Olivieri, Álvarez-Quilón, Moatti, Zimmermann, 
Annunziato, Krastev, Song, Brandsma, Frankum, Brough, Sherker, Landry, Szilard, Munro, 
McEwan, Goullet de Rugy, et al., 2018). 
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BRCA1 on the other hand promotes DSB end resection, shifting the balance towards HR 
(Zámborszky et al., 2017). BRCA1 stabilises PALB2 and BRCA2 at sites of DNA damage, 
which in turn facilitates RAD51-ssDNA filament formation. Loss of BRCA1 abolishes 
RAD51’s localisation at breaks and impairs HR. Furthermore BRCA1 interacts with the 
MRN complex during HR, suggesting it may participate directly in end resection (Wu, Lu 
and Yu, 2010). 
BRCA1-/- cells show increased genome instability and sensitivity to DNA damage 
(Zámborszky et al., 2017), a phenotype which has been shown to be dependent on both 
53BP1 and DNA ligase IV (Bunting et al., 2010). This suggests that when BRCA1 is absent, 
breaks that are normally repaired by the high-fidelity HR pathway are instead aberrantly 
repaired by NHEJ.  
This antagonistic relationship between BRCA1 and 53BP1 regulates DNA repair pathway 
choice throughout the cell cycle; during G1, 53BP1 blocks recruitment of BRCA1 to DSB 
ends to supress resection and promote NHEJ, whilst in the S and G2 stages, BRCA1 is 
able to resect DNA ends for HR (Aparicio, Baer and Gautier, 2014).  
1.5.5 The role of BRD4 in the DDR  
BRD4 is well characterised as a regulator of transcription, but recently its overexpression in 
cancers, and evidence that its targeted inhibition can sensitise cancer cells to DNA damaging 
agents, has led to its identification as a key player in the DDR (Pongas et al., 2017; C. Sun et 
al., 2018; Zhang et al., 2018). BRD4 is recruited to DSBs via H4 tail lysine residues that 
become acetylated in response to damage (Dhar et al., 2017; Li et al., 2018), and regulates 
many steps of the DDR. 
BRD4 interacts with components of the DNA pre-replication complex, including CDC6, 
to regulate activation of the G2/M checkpoint in response to replication stress. Combined 
BETi and HU treatment (to induce replication stress) in U2OS cells caused a CDC6 
dependent decrease in CHK1 phosphorylation compared to HU treatment alone, resulting 
in decreased G2/M checkpoint activation and an increased sensitivity to replication stress 
(Zhang et al., 2018).  
BRD4 regulates DNA repair through both NHEJ and HR, and loss of BRD4 has been 
shown to result in defective repair of induced DSBs. BRD4 promotes NHEJ directly - by 
recruiting certain NHEJ DNA repair proteins, including 53BP1, to DSBs, forming a stable 
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DNA repair complex – and indirectly – through the regulation of NHEJ DNA repair genes 
expression (Li et al., 2018). BRD4 also regulates the expression of genes involved in HR, and 
inhibition of BRD4 induces a HR-deficient (HRD) gene expression signature. One of the 
HRD genes most significantly downregulated by BETi is CtIP, which stimulates DSB 
resection via the creation of ssDNA tails (see section 1.5.4.2), and thus promotes DNA repair 
by HR (C. Sun et al., 2018).  
Finally, BRD4 has been implicated in the regulation of the chromatin structure surrounding 
a DSB, altering the accessibility of chromatin to DNA damage signalling and repair proteins. 
However, reports regarding this function have been contradictory; BRD4 isoform B is 
thought to inhibit DDR signalling through the recruitment of the condensin II complex. The 
condensin complex compacts chromatin, promoting a more ‘closed’ structure that is less 
permissive to the binding of DDR proteins (Floyd et al., 2013). Conversely, BRD4 has been 
shown to inhibit heterochromatin formation and facilitate the DNA damage response, 
through the repression of HP1 gene expression and subsequent decrease in HP1 protein 
levels (Pongas et al., 2017). HP1 binds H3K9me3 histones, a hallmark of heterochromatin, 
and maintains the heterochromatic state (Machida et al., 2018). 
1.5.6 Cohesin and the DDR 
1.5.6.1 Cohesin recruitment to DSBs 
Cohesin accumulates at DSBs (Countryman et al., 2018) and at stalled replication forks 
(Frattini et al., 2017; Countryman et al., 2018; Villa-Hernández and Bermejo, 2018), where it 
is important in the regulation of cell cycle checkpoints and DNA repair.  
In S. cerevisiae, the WAPL homolog (Wpl1/Rad61) promotes efficient DNA repair through 
modulation of the Smc3p-Mcd1p (SMC3-RAD21) interface, which results in the removal of 
cohesin from DNA. Deletion of Wpl1 was shown to cause G2/M cell cycle delays, and it 
was suggested that it is needed for repair of multiple types of DNA damage induced during 
S-phase. Cohesin is loaded onto DNA prior to S-phase in order to establish cohesion, but is 
loaded de novo at sites of DNA damage and stalled replication forks. Wpl1’s regulation of 
cohesin removal may therefore be important to remove DNA-bound cohesin, allowing its 
recruitment to breaks (Bloom, Koshland and Guacci, 2018).   
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1.5.6.2 Cohesin in cell cycle checkpoint activation and DNA repair 
Cohesin binding at DSBs and phosphorylation of the SMC1 and SMC3 subunits recruits 
53BP1 (Watrin and Peters, 2009). Sororin, required for the establishment of cohesion by 
cohesin (Nishiyama et al., 2010),  is dispensable for checkpoint activation, suggesting that 
cohesin’s role in cell cycle checkpoint activation is independent of its function in sister 
chromatid cohesion (Watrin and Peters, 2009).  
In contrast, cohesin’s ability to regulate DNA damage repair relies on cohesion between 
sister chromatids. In S and G2, cohesin promotes the close association of sister chromatids, 
facilitating the repair of DSBs through HR (Frattini et al., 2017). In fission yeast, cohesin is 
methylated on two evolutionarily conserved lysine residues, K536 and K1200 of Pms1, the 
ortholog of SMC1. Mutations that inhibit this methylation render cells sensitive to DNA-
damaging agents. Evidence of an interaction between cohesin and Mus81-Eme1 - an 
endonuclease involved in the resolution of intermediate structures during HR - suggested 
that methylation of Pms1 promotes DNA repair through HR (Sanyal et al., 2018). 
Furthermore SA2 has been found to directly facilitate HR-mediated DSB repair 
(Countryman et al., 2018). 
Cohesin has also been implicated in the regulation of NHEJ. The accuracy of end-joining 
decreases with increased distance between double-strand ends (DSEs). This is a particular 
problem during S phase, where replication stress can generate one-ended DSEs, which 
require ligation with another, distant, one-ended DSE for NHEJ. Cohesin protects the 
genome against rearrangements by inhibiting the ligation of distant DSEs but maintaining 
the ligation of proximal DSEs (Gelot et al., 2016). 
1.5.6.3 NIPBL and the DDR in CdLS 
NIPBL may mediate the DDR simply through its role as a cohesin loader. However, two 
independent mechanisms of NIPBL recruitment to DNA damage have been shown, 
suggesting that it regulates the temporal and spatial specificity of cohesin binding, relative to 
the type of DNA damage. In response to endonuclease induced DSBs, NIPBL is recruited 
through an interaction with HP1γ, whilst in response to laser microirradiation induced 
damage, it is recruited through its HEAT repeats and redundant ATM/ATR activity (Bot et 
al., 2017).   
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Consistent with the roles of the cohesin complex and NIPBL in DNA repair, increased 
sensitivity to DNA damage has been seen in some CdLS patient derived cell lines (Vrouwe 
et al., 2007; Enervald et al., 2013). Fibroblast and LCLs derived from CdLS patients, both 
with and without identified NIPBL mutations, show reduced survival after exposure to the 
DNA interstrand cross-linking agent mitomycin C. Furthermore, upon exposure to X-rays 
in G2, CdLS cells undergo more chromatid breaks and chromatid exchanges than WT cells. 
This increase was not observed in G1 (Vrouwe et al., 2007), when DSBs are mainly repaired 
by NHEJ (Wright, Shah and Heyer, 2018b), suggesting a defect in HR-mediated DSB repair. 
Enervald et al., (2013) saw a similar increase in DNA damage sensitivity when they exposed 
NIPBL-deficient CdLS patient cells to γ-irradiation, although they attribute this to impaired 
NHEJ rather than HR; sequencing of CSR junctions from patient derived B-cells, which 
have been shown to reflect the repair pathway used for the re-joining of the broken DNA 
ends, showed a pattern resembling those of patients with known NHEJ defects 
(characterised by a lack of “direct end joining”) (Enervald et al., 2013).  
It has been shown that the reduction of cohesion to 30% of wild-type levels compromises 
its role in DNA repair, without affecting sister chromatid cohesion or chromosome 
segregation (Heidinger-Pauli et al., 2010).  This could explain how mutations in cohesin can 
cause disorders such as CdLS, without perturbing cell division to a great enough extent to 
cause embryonic lethality.  
1.5.7 Developmental disorders and the DDR 
Since 2005, several congenital disorders that are caused by mutations in components of the 
DDR have been identified (O’Driscoll, 2012).  
1.5.7.1 Shared phenotypic features 
Syndromes caused by disorders of the DNA damage response share a number of symptoms, 
some of which are also present in patients with CdLS.  
One of the most common is a predisposition to cancer (O’Driscoll and Jeggo, 2008); 
impaired cell cycle checkpoints or damage repair pathways may lead to the accumulation of 
genetic alterations that confer growth and survival advantages to a cell (Broustas and 
Lieberman, 2014).  
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DDR defective syndromes also cause many symptoms characteristic of developmental 
abnormalities, such as characteristic facial features and skeletal abnormalities, microcephaly, 
growth delay, and immune and neurological deficits. These symptoms are also seen in 
patients with CdLS. Symptoms such as growth delay and microcephaly could be explained a 
decrease in cell number, caused by increased apoptosis due to the inability to repair DNA 
damage (O’Driscoll and Jeggo, 2008). Immunodeficiency may be caused by impaired CSR, 
V(D)J recombination and/or somatic hypermutation, which require NHEJ to generate 
diversity in immune cells (Hwang, Alt and Yeap, 2015). 
1.5.7.2 Mutations in NHEJ proteins 
Mutations in components of the NHEJ repair pathway cause primary immunodeficiency 
syndromes, through the impairment of the processes required for correct lymphocyte 
development (X. Liu et al., 2017).  
DNA ligase IV deficiency syndrome (LiDS) patients present with a range of phenotypes 
including normal to severe combined immunodeficiency, sensitivity to IR, primordial growth 
failure, severe microcephaly and learning difficulties (Altmann and Gennery, 2016) (see table 
Ch1-1).  
1.5.7.3 Mutations in HR proteins 
The Fanconi Anaemia (FA) pathway is important for the repair of interstrand cross-links and 
the response to replication stress. There are 22 FA proteins that function in this pathway. 
Mutations in these proteins can cause FA - a chromosomal instability disorder characterised 
by progressive bone marrow failure, cancer predisposition and multiple developmental 
phenotypes such as small size and heads, and cardiac and skeletal anomalies (Nepal et al., 
2017). The HR proteins BRCA1, BRCA2 and RAD51 have also been shown to function in 
the FA pathway, and mutations in these proteins cause phenotypes overlapping those of FA, 
leading to their assignation as FA proteins (Michl, Zimmer and Tarsounas, 2016).   
1.5.7.4 Mutations in ATM and ATR 
Mutations in ATM and ATR also cause developmental syndromes. As these proteins are 
master regulators of the DNA damage response, their mutations can affect cell cycle 
checkpoint activation, DNA repair and metabolic responses to DSBs (Liu et al., 2016).  
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Mutations that truncate or destabilise ATM can result in Ataxia-telangiectasia (AT) (Liu et al., 
2016), characterised by a diverse range of symptoms including cancer predisposition, neuro-
degeneration, and immune dysfunction (Hartlerode et al., 2015). However, the loss of the 
ATM protein particularly affects cerebellar cells, causing the progressive loss of cerebellar 
neurons and debilitating ataxia (Liu et al., 2016). 
Hypomorphic mutations in ATR alleles cause Seckel syndrome (SS) (Saldivar, Cortez and 
Cimprich, 2017). SS is a rare developmental disorder, characterised by primordial dwarfism, 
intellectual disability, microcephaly and severe craniofacial dysmorphism. SS was first coined 
‘bird-headed dwarfism’ due to the characteristic facial phenotype – prominent beaked nose, 
large eyes and dysplastic ears. In addition, cardiovascular and central nervous system 
abnormalities have been described (Ramalingam et al., 2012). 
1.5.7.5 Perturbation of histone modifications 
As described in section 1.5.3.3 histone modifications are important regulators of the DDR. 
Monoallelic missense mutations affecting H4K91 were found in three patients with 
syndromic symptoms of growth delay, microcephaly, distinct facial features and intellectual 
disability. Recapitulation of these mutations in zebrafish found that the mutations affect 
H4K91 ubiquitination, which normally plays a protective role against DNA damage. Loss of 
this ubiquitination caused increased DNA damage, which led to abnormal cell cycle 
progression and apoptosis, suggesting that a perturbed DDR is responsible for the 
syndromic phenotype of the patients (Tessadori et al., 2017).  
RIDDLE is a developmental syndrome characterised by radiosensitivity, immunodeficiency, 
dysmorphic features and learning difficulties (Stewart et al., 2007). RIDDLE is caused by 
mutations in the E3 ubiquitin ligase, RNF168, which binds ubiquitinated H2A and promotes 
further ubiquitination, resulting in the recruitment of 53BP1 and BRCA1 (Stewart et al., 
2009). Cells derived from a patient with RIDDLE syndrome are hypersensitive to IR, and 
have defective cell cycle checkpoints and aberrant CSR (Stewart et al., 2007). This suggests 
that the RNF168 mutations cause RIDDLE syndrome through decreased accumulation of 














Mutation Syndrome Phenotype 
Shared with CdLS Not in CdLS 
NHEJ proteins 
DNA ligase IV LiDS Normal to severe combined 
immunodeficiency, sensitivity to IR, 
growth failure, severe microcephaly 
and learning difficulties 
 
HR proteins  
BRCA1 FA Short stature, microcephaly, 
developmental delay, dysmorphic 
face 
Early onset cancer, 
increased sensitivity to 
DNA damage 
RAD51 FA Developmental delay, skeletal 
anomolies 
Increased sensitivity to 
DNA damage 
Signal transducing proteins 
ATM AT Immune dysfunction Cancer predisposition,  
neuro-degeneration, 
ATR SS Intellectual disability, microcephaly, 
severe craniofacial dysmorphism, 
cardiovascular abnormalities 




H4K91  Growth delay, microcephaly, 
distinct facial features and 
intellectual disability. 
 
RNF168 RIDDLE Radiosensitivity, 
immunodeficiency, dysmorphic 
features and learning difficulties 
 




   
 
1.6 PhD aims 
The current literature regarding the mechanism of CdLS is moving away from the idea that 
CdLS is simply a cohesinopathy. Instead it focusses on the identification of causative genes 
that are not components of the cohesin complex, the transcriptional dysregulation observed 
in many patients, and the overlap between CdLS and other syndromes caused by regulators 
of transcription or chromatin structure.  
David FitzPatrick’s lab at the MRC human genetics unit have recently identified mutations 
in the BRD4 gene in three patients with CdLS-like syndromes. BRD4 is not a member of the 
cohesin complex, or involved in its regulation, and is best characterised as a transcriptional 
regulator. Given the current focus of the field, understanding how these mutations affect 
BRD4 and how this might cause CdLS is of importance.  
The aim of my PhD is therefore to determine the effects of one of these BRD4 mutations – 
Tyr430Cys (Y430C) – on BRD4 function by: 
• Recapitulating the Y430C mutation in mESCs 
• Identifying binding partners of WT and Y430C BRD4 
• Mapping the genome wide chromatin binding of WT and Y430C BRD4 




























































































   
 
2.1 Stock solutions, reagents and buffers 
4% paraformaldehyde – 20 g paraformaldehyde was added to 500 ml PBS and heated to 
60°C in a water-bath overnight. Dissolved 4% paraformaldehyde was aliquoted and frozen. 
4sU washing buffer: 100 mM Tris HCl pH 7.5, 10 mM EDTA, 1 M NaCl, 0.1% Tween 20 
5X DNA Loading Buffer: 50% glycerol; 5 mM EDTA pH8; 0.3% Orange G (v/v). 
ChIP elution buffer: (filtered 0.2-0.45 micron filter unit) 1% SDS, 0.1 M NaHCO3 
ChIP RIPA buffer: (filtered 0.2-0.45 micron filter unit) 1X PBS; 1% NP-40; 0.5% sodium 
deoxycholate; 0.1% SDS; Complete Mini EDTA-free protease inhibitor* (Roche) 
DNA lysis buffer: 10 mM Tris-HCl (pH 7.5); 10 mM EDTA; 0.5% SDS; 10 mM NaCl; 1 
mg/ml Proteinase K* 
PBS: PBS was made by technical services at MRC HGU, except for PBS used in culturing 
cells. 160 mM NaCl; 3 mM KCl; 8 mM Na2HPO4; 1 mM KH2PO4 from tablets (Oxoid, 
ThermoScientific, cat# BR0014). 
NaCl/EtOH: 0.3 M NaCl in 100% EtOH 
Farnham lysis buffer: (filtered 0.2-0.45 micron filter unit) 5 mM PIPES pH 8.0; 85 mM KCl; 
0.5% NP-40; Complete Mini EDTA-free protease inhibitor* (Roche) 
LiCl wash buffer: (filtered 0.2-0.45 micron filter unit) 100 mM Tris pH 7.5, 500 mM LiCl, 
1% NP-40, 1% Sodium deoxycholate 
RIPA buffer for nuclear IP: 50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, benzonase and Complete Mini EDTA-free protease inhibitor (Roche) 
RIPA buffer for protein extraction: 150 mM sodium chloride; 1.0% NP-40; 0.5% sodium 
deoxycholate; 0.1% SDS; 50 mM Tris, pH 8.0 
Swelling buffer: 10 mM Hepes; pH 7.9, 1.5 mM MgCl2; 10 mM KCl; 0.5 mM DTT*; 
Complete Mini EDTA-free protease inhibitor* (Roche) 
TAE buffer: 10mM Tris base, 20mM acetic acid, 1mM EDTA (prepared by technical services) 
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TBE buffer: 40 mM Tris base, 20 mM boric acid, 1 mM EDTA (prepared as 20X stock by 
technical services) 
TE buffer: 10 mM Tris-HCl pH7.6, 1 mM EDTA (prepared by technical services)  
TBS: 50mM Tris-HCl pH7.4, 150mM NaCl. (prepared by technical services) 
TBS-T: TBS with 0.1% tween 
Trypsin: 10X Trypsin (Sigma; 59427C), aliquoted and stored long term at -20ºC, and short-
term at 1X concentration at 4ºC. 
Western Transfer Buffer (wet transfer): 25 mM Tris base, 200 mM glycine, 20% methanol 




2.2 Cell culture  
2.2.1 mESCs  
BRD4-Y430C mutant and corresponding WT mESCs were generated by CRISPR Cas9 
genome editing in 46C mESCs (Ying et al., 2003)(RRID:CVCL_Y482),  as described below. 
46C cells were cultured on 0.1% gelatin coated tissue culture flasks (Corning) in GMEM 
medium (GIBCO; 11710035) supplemented with 10% Fetal Calf Serum (FCS), 5% penicillin-
streptomycin, 1 mM sodium pyruvate (GIBCO; 11360070), 1X non-essential amino acids 
(GIBCO; 11140050), 50 µM 2-Mercaptoethanol (GIBCO; 31350010), 2 mM L-glutamine 
and 500 U/ml Leukaemia Inhibitory Factor (LIF) (in house). Media was replaced every 24 
hours and cells were passaged every 48-72 hours, seeding at a density of 2x105 cells/ml. Cells 
were grown at 37°C in a 5% CO2 humidified atmosphere. Cells were frozen at ~3x10
6 
cells/ml in 80% mESC media, 10% FCS, 10% DMSO and stored in liquid nitrogen. 
2.2.2 Lymphoblastoid cells 
I1206del (Tonkin et al., 2004) and R2298H (Gillis et al., 2004) LCLs from CdLS patients and 
cultured in RPMI 1640 medium (GIBCO; 11875093) supplemented with 15% FCS and 2 
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mM L-glutamine. Cells were grown in suspension and passaged every 72-96 hours, seeding 
at a density of 2x105 cells/ml. Cells were grown at 37°C in a 5% CO2 humidified atmosphere. 
Cells were frozen at ~5x106 cells/ml in RPMI 1640 with 20% FBS and 6% DMSO and 
stored in liquid nitrogen.  
2.2.3 Drosophila Schneider 2 (S2) cells 
S2 cells were cultured in Schneider’s Drosophila Medium (Invitrogen; 11720-034), 
supplemented with 10% heat-inactivated FCS and 5% penicillin-streptomycin. Cells were 
passaged once they reached a density of ~2x107 cells/ml and seeded at a density of ~4x106. 
Cells were grown at 28°C in a 5% CO2 humidified atmosphere. Cells were frozen at a density 
of ~1x107 cells/ml in 45% conditioned Schneider’s Drosophila Medium media (containing 
10% FCS), 45% fresh Schneider’s Drosophila Medium supplemented with 10% FCS, and 
10% DMSO, and stored in liquid nitrogen.  
2.2.4 Induction of DNA damage  
Cells were incubated with mESC media supplemented with either neocarzinostatin (NCS) 
(Sigma; N9162), to a final concentration of 25 ng/ml, or with hydroxyurea (HU) (Acros 
Organics; 151680250), to a final concentration of 50 mM for 15 mins at 37°C.  
2.2.5 Aphidicolin treatment  
Aphidicolin (APH) (Sigma; A0781) was resuspended in DMSO to a concentration of 1.5 
mM and added to mESC media to a final concentration of 0.2 µM. mESCs were plated on 
gelatanised coverslips and incubated at 37°C for 24 hours, with APH supplemented media. 
Control cells were incubated with media containing equal percentage of DMSO.  
2.2.6 Transcriptional inhibition  
Cells were incubated with mESC media supplemented with 500 nM triptolide (Cayman; 
CAYM11973-5) (Trp) for 2 hours at 37°C, 20 µM alpha amanitin (Sigma; A2263) for 9 hours 




   
 
2.3 Cell cycle analysis 
2.3.1 Growth assay  
mESCs were seeded in 4 wells of a 6-well plate (1 x 104 cells/well). At 24, 48, 72 and 96 
hours post seeding, the cells from 1 well were trypsinised, centrifuged and resuspended in 
media. Cell counting was carried out manually using a haematocytometer. The addition of 
trypan blue dye (final concentration 0.32%) allowed for the exclusion of dead cells.  
2.3.2 Flow cytometry 
2 million mESCs or LCLs were fixed in 70% ethanol (in PBS) at 4oC for 1 hour. Fixed cells 
were centrifuged at 931 g at 4oC for 5 min, washed twice with PBS and resuspended in 500 
μl PBS. 20 μg RNase A was added and cells were incubated at 37oC for 10 min. Cells were 
stained with propium iodide at a final concentration of 50 μg/ml. Acquisition was carried 
out on a BD LSRFortessa cell analyser, collecting 25,000 events per sample. BD 
FACSDivasoftware (Becton Dickinson, Version 8.0.1) was used for instrument control and 
data analysis. Gated cells were manually categorized into cell cycle stages G0/G1, S and 
G2/M. 
2.4 Genome editing in mESCs 
BRD4-Y430C mESCs and their WT counterparts were generated using the CRISPR-Cas9 
nickase system. 
2.4.1 CRISPR-Cas9 construct design and cloning 
CRISPR plasmids were designed and cloned by Hemant Bengani of the FitzPatrick lab. 
Briefly gRNAs were designed across Y430 using the online tool DNA 2.0. The WT and 
mutant repair templates (chr17: 32,220,150–32,220,271; GRCm38) (Table Ch2-1) were 
synthesized by IDT as 122-bp UltramerssODNs bearing the desired sequence change. 
gRNAs 1 and 2 (Table Ch2-1) were cloned into PX461 (Addgene; 48140) (Figure Ch2-1A) 
and PX462 (Addgene; 62987) (Figure Ch2-1B) respectively. Plasmid DNA was purified using 
the QIAGEN Plasmid Plus Maxi Kit (Qiagen; 12963) and diluted to 50 ng/μl with 
DNAse/RNAse free water. 
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Figure Ch2-1. Full sequence map for CRISPR plasmids. A) PX461 and B) PX462 
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2.4.2 Transfections 
46C mESCs were co-transfected with the two resulting plasmids and either WT or Y40C 
mutant repair templates using Lipofectamine® 3000 Reagent (ThermoFisher Scientific; 
L3000001) as per the manufacturer’s instructions. Briefly, 1x106 ESCs were transfected in a 
6-well plate with 1 µg of each plasmid, 0.5 µg of repair template, 5 µl of lipofectamine and 2 
μl P3000 reagent. After 48 hours, double transfected cells were selected for, first by resistance 
to puromycin (PX462) and subsequently by FACS based on GFP expression (PX461). 
Surviving cells were plated at 5x103 cells/10 cm2 and grown for 1 week. Colonies were picked 
and plated in duplicate at 1 colony/well of a 96-well plate. Genomic DNA was extracted 
from the colonies and sequenced by Sanger sequencing, using Y430C genotyping primers 
(Table Ch2-1). Confirmed WT and p.Tyr430Cys homozygous clones were expanded and 









Cas9 gRNAs 1 2 
CAACCCCCCTGACCATGAAG AGCAGTTGGAGAACATCAAT 

















   
 
2.5 Preparation and handling of DNA and 
RNA  
2.5.1 DNA extraction  
For 96 well plates, DNA was extracted once cells were highly confluent and media had turned 
yellow. Wells were rinsed 2X with PBS. 50 μl DNA lysis buffer was added per well. Plates 
were sealed with parafilm and incubated overnight in a humid chamber at 55°C. Plates were 
allowed to cool to room temperature (RT) and lysed cells were transferred to a 
microcentrifuge tube. DNA was purified by phenol-chloroform extraction and recovered by 
ethanol precipitation. DNA was resuspended in 50 µl TE.  
For all other plates DNA was extracted using the Qiagen DNeasy blood and tissue kit 
following the manufacturer’s instructions, with the addition of RNase A. 
2.5.2 Resolution of DNA on agarose gels  
DNA was resolved on agarose gels made to the appropriate percentage; UltraPure™ Agarose 
(ThermoFisher Scientific; 16500500) was dissolved in TAE and ethidium bromide was added 
at 0.5 µg/ml. 5X DNA loading buffer was added to the sample to give a final concentration 
of 1X. 1 Kb Plus DNA Ladder (Invitrogen; 10787018) was loaded as a size marker and DNA 
was resolved by subjecting to 150 volts. Gels were visualised under UV light (BioDoc-It 
System, UVP). 
2.5.3 Quantification of DNA  
Routinely DNA was quantified using the NanoDrop 8000 spectrophotometer 
(ThermoFisher Scientific; ND-8000-GL) as per the manufacturer’s instructions. ChIP-DNA 
was quantified with the Qubit dsDNA HS Assay Kit (ThermoFisher Scientific; Q32851) and 
Qubit 4 fluorometer (ThermoFisher Scientific; Q33226) following the manufacturer’s 
instructions. Briefly the Qubit dsDNA HS reagent was diluted 1:200 in Qubit dsDNA HS 
buffer. 10 µl of each Qubit standard was added to 190 µl diluted buffer, and 1 µl of each 
DNA sample was added to 199 µl diluted buffer. Samples were vortexed for 2-3 seconds and 
incubated at RT for 2 min. Standards were read on the Qubit 4 fluorometer, and samples 
were then assayed.  
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2.5.4 RNA extraction and cDNA synthesis 
RNA was extracted from cells using the RNeasy Mini Kit (Qiagen; 74104) using spin 
technology, with an additional on-column DNA digestion using the RNase-Free DNase Set 
(Qiagen; 79254). cDNA was synthesised from 1 μg RNA using SuperScript II Reverse 
Transcriptase (ThermoFisher Scientific; 18064-014) as per manufacturer’s instructions. 
2.6 Expression analysis  
2.6.1 Expression analysis by RT-qPCR 
cDNA was diluted 1 in 25 for qPCR analysis. SYBR-green based qPCR reactions were 
performed (Table Ch2-2) in a final volume of 20 μl containing diluted cDNA, SYBR select 
master mix (ThermoFisher Scientific; 4472908) and 0.5 μM/l of region specific intron-









Pre-incubation  50 02:00 4.4 None 1 
95 02:00 
Amplification 95 00:15 4.4 None 
 
50 
60 00:50 2.2 
60 00:10 4.4 Single  
Melt 95 00:05 4.4 None 1 
65 01:00 2.2 
97 00:30 0.11 Continuous, 5 
acquisitions/ ºC 
Cooling 40 00:30 2.2 None 1 









2.6.2 JQ1 treatment  
1 mM BRD4 inhibitor (+)-JQ1, or its inactive form (-)-JQ1 (Merck; 500586) (diluted in 
DMSO), was added to mESC media at a final concentration of 300 nM JQ1+/-. mESCs 
were incubated at 37°C with JQ1+/- supplemented media for 48 hours. For qPCR analysis 
concentration of JQ1+ cDNA was calculated relative to JQ1- (arbitrarily set to 1).   
2.6.3 4-thiouridine (4sU) labelling  
4sU RNA was generated and isolated as in Pintacuda et al., 2017, with some minor changes; 
4-thiouridine (4sU, Sigma, T4509) was added to mESC media to a final concentration of 
500 μM and the media was warmed to 37°C. ~10 million cells were incubated at 37°C with 
4sU-supplemented medium for 20 min. Cell culture medium was rapidly removed from cells 
and total RNA was extracted with Trizol (Invitrogen) and treated with DNase using the 
DNA-free DNase treatment kit (Ambion; AM1906). After addition of inactivation reagent, 
RNA and beads were transferred to QIAshredder columns (Qiagen; 79656) and centrifuged 
at 1000 g for 1 min. Flow-through (RNA) was transferred to a new tube. For each μg of total 
RNA, 2 μl Biotin-HPDP, diluted to 1 mg/ml in DMF, and 1 μl 10xBiotinylation buffer 
(100 mM Tris HCl pH 7.4, 10 mM EDTA), were added. Reaction volume was made up to 
 Forward Reverse 
Klf4 GTGCAGCTTGCAGCAGTAAC  AGCGAGTTGGAAAGGATAAAGTC 








Brd4 CCTCCTCTCCTCTCATTCCCA CATTCTTCACCAGGCACTCCAT 
Gapdh TGCGACTTCAACAGCAACTC CTTGCTCAGTGTCCTTGCTG 




   
 
10 μl per μg of RNA used. The reaction was incubated with rotation for 1.5 hours at RT. 
RNA was transferred to Phase Lock Gel Heavy Tubes (Eppendorf), and an equal volume of 
chloroform was added. After vigorously mixing, tubes were left incubating for 3 min at 25°C 
and then centrifuged at 16,089 g for 5 min at 4°C. The upper phase was transferred to new 
Phase Lock Gel Heavy Tubes, and the process was repeated. The upper phase was again 
transferred to Phase Lock Gel Heavy Tubes. 1/10 reaction volume of 5M NaCl was added, 
followed by 1X reaction volume of isopropanol. Tubes were mixed to invert and incubated 
at RT for 10 min. Tubes were centrifuged at 10,000 g for 20 min at RT. The pellet was 
washed in 80% ethanol, centrifuged at 10,000 g for 10 min at 4°C and resuspended in 100 μl 
water. RNA was dissolved by heating to 40oC for 10 min in a shaker, and then put on ice for 
5 min.  
Biotinylated 4sU-RNA was recovered using the μMacs Streptavidin Kit (Miltenyi; 130-074-
101), with a modified protocol and buffers. 1 μl of streptavidin beads was added per μg of 
recovered biotinylated 4sU-RNA, in a total volume of 200 μl, and samples were incubated 
with rotation for 15 min at 25°C. μMacs columns supplied with the μMacs Streptavidin Kit 
were equilibrated in 900 μl of washing buffer at 65°C. Samples were added to the columns 
that were then washed 3 times with 900μl washing buffer at 65°C and three times with 900 
μl washing buffer at 25°C. RNA was eluted by adding 100 µl Elution Buffer (100 mM DTT) 
to the column and flow-through was collected. Elution was repeated 3 min later and flow-
throughs combined. RNA was further purified using the RNAeasy MinElute (Qiagen; 74204) 
according to the manufacturer’s guidelines, eluting in 20 μl water.  
2.6.4 Generation of spike-in RNA 
mESCs and S2 cells were harvested and counted. 0.2 million S2 cells were mixed with 10 
million mESCs, and RNA was extracted using the RNeasy Mini Kit (Qiagen; 74104) using 
spin technology, with an additional on-column DNA digestion using the RNase-Free DNase 




   
 
2.7 Cross-linked Chromatin 
Immunoprecipitation (ChIP)  
30 million cells were harvested by trypsinising and fixed with 1% formaldehyde (Thermo 
Fisher Cat. 28906) in media (25°C, 10 min). This reaction was quenched with 0.125 M 
Glycine. Cross-linked cells were re-suspended in Farnham lysis buffer for 30 min and 
centrifuged at 228 g for 5 min at 4°C. Nuclei were resuspended in RIPA buffer and sonicated 
using a Bioruptor® Plus sonicator (Diagenode) at full power for 60 min (30 seconds on, 30 
seconds off) to produce fragments of 100-500 bp. 5 µg of each antibody (Table Ch2-4) were 
incubated with Protein A Dynabeads (ThermoFisher Scientific; 10001D) in 5 mg/ml BSA 
in PBS on a rotating platform at 4°C for two hours. An arbitrary concentration of 200 µg 
chromatin was incubated with antibody bound Dynabeads in a rotating platform at 4°C for 





After incubation, beads were washed 5 times (5 min each) on a rotating platform with cold 
LiCl wash buffer and two times with RT TE buffer. ChIP complexes were eluted in 100 μl 
of ChIP elution buffer and shaken at 37°C for 15 min. The pH of eluted immunoprecipitates 
(IP) was reduced by the addition of 6 μl 2M Tris-HCl pH 6.8. 20 μg RNaseA was added to 
IP and 10% input and all samples were incubated at 65°C for 1 hour. 20 μg Proteinase K 
was added and samples were incubated at 55°C for a further 12 hours. DNA was purified 
using QIAquick PCR Purification Kit (Qiagen; 28104), eluting in 50 μl elution buffer, and 
quantified by Q-bit high sensitivity DNA assay. 
For qPCR analysis ChIP DNA was diluted 10-fold in ddH20, and qPCR was carried out as 
described (section 2.6.1), using primers designed for ChIP-qPCR (Table Ch2-5). 
Concentrations of IPs were calculated relative to 1% input.  
Name  Catalogue number  Dilution  
BRD4 Bethyl; A301-985A 5 μg/ml 
53BP1 Novus; NB100-904 5 μg/ml 
Table Ch2-4: ChIP Antibodies 
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2.8 Library preparation and sequencing 
2.8.1 ChIP-seq   
DNA libraries for ChIP-sequencing were prepared from 1 ng of total sheared chromatin 
(input) and ChIP-enriched fragments using NEBNext® Ultra™ II DNA Library Prep Kit 
for Illumina (NEB; E7645S), following the manufacturer’s instructions. Optional size 
selection steps were carried out, using SPRIselect (Beckman Coμlter; B23319). Libraries were 
indexed using NEBNext® Multiplex Oligos for Illumina® (Index Primers Set 1) (NEBnext; 
E7335) and amplified by PCR for 12 (Input) or 15 (IP) cycles. Library concentration and 
correct size distribution (100-500 bp) was confirmed on the Agilent 2100 Bioanalyser with 
the DNA HS Kit. For BRD4-ChIP sequencing was carried out at BGI (Hong Kong; 50-base 
single-end reads) using the HiSeq 4000 system (Illumina). For 53BP1 ChIP sequencing was 
carried out at WTCRF (Edinburgh; 75-base paired-end reads) using NextSeq 500/550 High-
Output v2 (150 cycle) Kit (# FC-404-2002) on the NextSeq 550 platform (Illumina Inc, #SY-
415-1002). 
 
   
   
   
   
   
   
   
   
   
Name Forward Reverse 
Sox2 SE TAGAGGAAGGAGCTGGAGGA AAGGAAAGAAGGAGGGACGG 
Klf4 SE  CACAATGCCAGCTATGCGAT TCCTGCCCAAATGTGAGGAT 
Nanog SE GTGAAGGTAGTTTGCTGGGC GGTCCTTTCCCACCCTCTAC 
Oct4 SE CCTTCGTTCAGAGCATGGTG GAGCCTACCCTGAACTTCCC 
Nanog TE AGTGATAGTGTGGCAGCAGT CCACCATTGTTACCACTGCC 
C-myc promoter  GACTCGCTGTAGTAATTCCAG GCAAAGCCCCTCTCACTCCA 
C-myc SE CAGAGCAGCCACGAAAGATC ACTGCAGAGGAATGTGAGCT 
Gsc promoter CTTCTCGGCGTTTTCTGACT AGCCAAGTGGAGACGACAG 
Table Ch2-5: ChIP primers 
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2.8.2 4sU-seq and spike-in RNA-seq 
To make 4sU sequencing and RNA-seq libraries, RNA was first depleted of rRNA using the 
Low Input Ribominus Eukaryotic System V2 (ThermoFisher Scientific; A15027) as per the 
manufacturer’s instructions. 600 ng of RNA was used as input and eluted in 5 µl RNase free 
water. All the resulting rRNA free RNA was then used to prepare 4sU sequencing libraries, 
using NEBnext ultra Directional RNA library prep kit of Illumina (NEB; E7420). RNA 
fragmentation was carried out at 94°C for 15 minutes, as suggested for intact RNA. Libraries 
were indexed with multiplex Oligos for Illumina® (Index Primers Set 1) (NEBnext; E7335) 
and amplified by PCR for 13 cycles. Library concentration and correct size distribution (100-
500 bp) were confirmed on the Agilent 2100 Bioanalyser with the DNA HS Kit. Libraries 
were sequenced at BGI (Hong Kong; 100-base paired-end reads) using the HiSeq 4000 
(Illumina). 
 
2.9 Protein extraction and analysis 
2.9.1 Protein extraction  
Ice-cold RIPA buffer was added to adherent cells growing on plates (1 ml/107 cells). Cells 
were scraped, and the suspension transferred into a pre-chilled microcentrifuge tube. Tubes 
were incubated with shaking at 4°C for 30 min before centrifugation at 16,089 g for 15 min. 
Supernatant was retained and quantified. 
2.9.2 Protein quantification  
The Bradford assay was performed to determine the concentration of protein samples. 5 μl 
of each sample was added to 1ml 1X Bradford dye and the absorption at 595 nm was 
measured using a spectrophotometer. The absorbance was compared to a standard curve 
drawn using BSA samples of known concentration (0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 mg/ml) to 
calculate protein concentration.  
2.9.3 Co-immunoprecipitation (Co-IP) 
30 x 106 WT and Y430C BRD4 mESCs were trypsinised, pelleted and resuspended in 5 ml 
ice-cold swelling buffer for 5 min on ice. Nuclei were pelleted by centrifugation at 931 g for 
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5 min at 4°C. The resulting nuclear pellets were sonicated in 2 ml RIPA buffer, using a 
Bioruptor® Plus sonicator (Diagenode) at 4°C, 30 seconds on, 30 seconds off. It was noted 
that prolonged (1 hour) exposure to the detergents in RIPA buffer affected the interactions 
of BRD4 as measured by mass spectrometry (MS). Nuclear extracts were cleared by 
centrifugation at 16,089 g for 10 min at 4°C. Protein A Dynabeads (Life Technologies) were 
blocked prior to antibody coupling by washing 3 times with 5% BSA in PBS. Antibodies 
(Table Ch2-6) were coupled to the beads at 5 mg/ml by rotation for 1 hour at 4°C. 
Equivalent nuclear protein amounts were incubated with antibody coupled beads for 1 hour 







2.9.4 Western blotting 
For western blot analysis beads (containing primary antibody and bound protein) were 
washed 5 times with RIPA buffer, bound proteins eluted by boiling in 1X NuPage LDS 
buffer (ThermoFisher Scientific) with 1X NuPage reducing agent (ThermoFisher Scientific) 
for 5 minutes and separated on a 3-8% tris-acetate gel (ThermoFisher Scientific; 
EA0375BOX) (reciprocal BRD4/SMC3/NIPBL IPs and MEF cell lysates) or 4-12% bis-
tris gel (BRD4 IPs for acetylated histone binding) (ThermoFisher Scientific; NP0322BOX). 
Following electrophoresis, proteins were transferred to nitrocellulose membranes 
(ThermoFisher Scientific) using an iBlot 2 Dry Blotting System (ThermoFisher Scientific) 
for 7 min (when probing for proteins <250 kDa only) or to PVDF membranes by wet 
transfer for 90 min (when probing for proteins >250 kDa) and incubated with primary 
antibodies (Table Ch2-7) overnight at 4°C. Membranes were washed 3 times in tris-buffered 
saline-tween (TBS-T) and probed with HRP-conjugated secondary antibodies (Table Ch2-7) 
for 1 hour at RT. After 3 more washes in TBST, membranes were incubated with Pierce 
Name  Catalogue number  Host Subtype Dilution  
NIPBL Bethyl; A301-779A Rabbit IgG 5 μg/ml 
SMC3 Bethyl; 0300-060A Rabbit IgG 5 μg/ml 
BRD4 Bethyl; A301-985A Rabbit IgG 5 μg/ml 
Normal rabbit IgG Santa Cruz; sc-2025 / / 5 μg/ml 
Table Ch2-6: Antibodies used for co-IP 
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ECL Western Blotting Substrate (ThermoFisher Scientific) for 5 min and imaged using an 
Image-quant machine (GE Healthcare). 
Acetylated histone western blots were quantified using ImageQuantTL, 1D gel analysis (GE 
Healthcare). Input bands were set to an intensity of 1, and IP bands calculated as a 
percentage of input.  
Name  Catalogue number  Host Subtype Dilution 
BRD4 Bethyl; A301-985A Rabbit IgG 1:3000 
CHK1 Abcam; ab47574 Rabbit IgG 1:1000 
CHK1-p Cell signalling technologies; 2348 Rabbit IgG 1:500 
PCNA Santa Cruz; sc-56 Mouse IgG2a  1:3000 
NIPBL Bethyl; A301-779A Rabbit IgG 1:1000 
SMC3 Bethyl; 0300-060A Rabbit IgG 1:1000 
ACTIN-B Abcam; ab8229 Goat IgG 1:500 
H3 Abcam; ab1791 Rabbit IgG 1:5000 
H3K9ac Abcam; ab10812 Rabbit IgG 1:500 
H4K8ac Abcam; ab15823 Rabbit IgG 1:1000 
H3K27ac Genetex; GTX128944 Rabbit IgG 1:1000 
Anti rabbit Santa cruz; sc2030 Goat IgG-HRP 1:10,000 
Anti mouse  Santa cruz; sc2031 Goat IgG-HRP 1:10,000 
 
 
2.9.5 MS  
For analysis by MS, beads (from co-IP) were washed 3 times with TBS and excess buffer was 
removed. The beads were taken to the IGMM MS facility for further analysis. Briefly, 
immunoprecipitations were digested on beads, desalted and analysed on a Q-Exactive plus 
mass spectrometer as previously described (Turriziani et al., 2014). Proteins were identified 
and quantified by MaxLFQ (Cox et al., 2014) by searching with the MaxQuant version 1.5 
Table Ch2-7: Antibodies for western blot  
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against the Mouse proteome database (Uniprot). Modifications included C Carbamlylation 
(fixed) and M oxidation (variable). Bioinformatic analysis was performed with the Perseus 
software suite (Tyanova et al., 2016). 
2.9.6 Immunofluorescence  
For immunofluorescence (IF) experiments mESCs were cultured on gelatinised coverslips 
and LCLs were grown in suspension. LCLs were harvested and resuspended in PBS to 1.8 x 
105 cells/ml. 500 μl of cell suspension was added to a Shandon Single Cytofunnel 
(ThermoFisher Scientific; 5991040), with a microscope slide attached. Slides were 
centrifuged in a Shandon Cytospin 3 (ThermoFisher Scientific) at 800 rpm for 5 min, after 
which the LCLs had attached to the slide. All cells were fixed in 4% paraformaldehyde for 
10 min and washed 3x 3 min in PBS. Cells were then permeabilised in 0.5% Triton (in PBS) 
for 10 min and washed 3x 3 min in PBS. Cells were blocked in 1% BSA in PBS for 30 min 
at RT, incubated with primary antibody (Table 8) diluted in 1% BSA for 1 hr at RT and 
washed 3x 3 min in PBS. Cells were next incubated with secondary antibody (Table Ch2-8) 
diluted in 1% BSA for 45 min at RT, washed 3x 3 min in PBS, incubated with DAPI in PBS 
(250 ng/ml) for 2 min, and washed 3x 3 min in PBS. Coverslips were mounted on slides in 









Name  Catalogue number  Host Subtype  Dilution 
OCT4 Santa-cruz; sc5279 Mouse IgG2b  1:400 
ESRRB R&D; PPH6705-00 Mouse IgG2a 1:500 
SOX2 Abcam; ab9759 Rabbit IgG 1:1000 
BRD4 Bethyl; A301-985A  Rabbit IgG 1:100 
53BP1 Novus; NB100-304 Rabbit IgG 1:1000 
RAD51 Calbiochem; PC130-100 Rabbit IgG 1:500 
Anti-Rabbit  Invitrogen; A11034 Goat IgG-Alexa Fluor 488 1:750 
Anti-Rabbit  Invitrogen; A10042 Donkey IgG-Alexa Fluor 586 1:750 
Anti-mouse  Invitrogen; A31571 Donkey IgG-Alexa Fluor 647 1:750 
Table Ch2-8: Antibodies for IF 
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2.10 Image capture and analysis  
2.10.1 Imaging 
All slides were viewed and images taken for counting/analysis using epifluorescence 
microscopes. Epifluorescent images were acquired using a Photometrics Coolsnap HQ2 
CCD camera and a Zeiss AxioImager A2 fluorescence microscope with Plan-neofluar 
objectives (Carl Zeiss, Cambridge, UK), a Mercury Halide fluorescent light source (Exfo 
Excite 120, Excelitas Technologies) and Chroma #89014ET three colour filter set (Chroma 
Technology Corp., Rockingham, VT) The single excitation and emission filters are installed 
in motorised filter wheels (Prior Scientific Instruments, Cambridge, UK). Image capture was 
performed using Micromanager (https://open-imaging.com/). 
Epifluorescent images were acquired using a Photometrics Coolsnap HQ2 CCD camera and 
a Zeiss AxioImager A1 fluorescence microscope with a Plan Apochromat 100x 1.4NA 
objective, a Lumen 200W metal halide light source (Prior Scientific Instruments, Cambridge, 
UK) and Chroma #89014ET single excitation and emission filters (Chroma Technology 
Corp., Rockingham, VT) with the excitation and emission filters installed in Prior motorised 
filter wheels. A piezoelectrically driven objective mount (PIFOC model P-721, Physik 
Instrumente GmbH & Co, Karlsruhe) was used to control movement in the z dimension. 
Hardware control, image capture and analysis were performed using Volocity (Perkinelmer 
Inc, Waltham, MA). FITC,Texas Red and DAPI signals were deconvolved using a calculated 
PSF with the iterative algorithm of Volocity (Perkinelmer Inc, Waltham MA).  
2.10.2 Counting foci  
Images (.tiff files) were opened in ImageJ as 2D stacks. The number of foci per cell 
(individual cells identified by DAPI staining) were counted, and cells were recorded as having 
0, ≥1, ≥5 or ≥10 foci. Those with ≥10 foci would therefore be included in those with ≥5 
and ≥1 foci. Results are plotted as a percentage of the total number of cells counted. ~50 
cells were counted per experiment.  
2.10.3 Foci size 
The area of foci were quantified running a script (written by Ahmed Fetit, Imaging resources, 
IGMM) as a macro in ImageJ. Channels are split automatically. Setting the threshold for foci 
 
  120
   
 
detection, and selection of the regions of interest (foci), are carried out manually.  The area 
of all the detected foci in the image are then calculated and output.  
2.11 Bioinformatics  
2.11.1 ChIP-seq mapping and peak calling 
Fastq files were quality controlled using FastQC and mapped to the mm9 genome using 
Bowtie2 (parameters: default). Sam files were converted to bam files and sorted using 
SamTools. Homer was used to make tagdirectories (makeTagDirectory, parameters: –unique, 
fragLength 150) and bedgraphs (makeUCSCfile, parameters: default). For visualisation of 
BRD4 ChIP data, bedgraphs were uploaded to the genome browser UCSC 
(https://genome.ucsc.edu). For visualisation of 53BP1 ChIP data, bedgraphs were converted 
to bigwig files using Homer (bedGraphToBigWig) and uploaded to UCSC via CyVerse.  
Peak calling was carried out using MACS2; Duplicates were filtered (filterdup, parameters:--
keep-dup=1), peaks called (callpeaks, parameters: -B --nomodel -p 1e-5) and differential 
peaks were found (bdgdiff, parameters: -g 60 -l 250).  
2.11.2 4sU-seq mapping and peak calling 
Fastq files were quality controlled using FastQC and mapped to the mm9 genome using 
tophat (parameters: --library-type fr-firststrand -r 200). Homer was used to make 
tagdirectories (makeTagDirectory, parameters: -unique -sspe -flip -fragLength 150), and to 
make bedgraphs for visualisation on UCSC (makeUCSCfile, parameters: -strand separate -
style rnaseq).  
Cufflinks was used for peak calling; transcripts were assembled for individual experiments 
(cufflinks, parameters: –m 200 –library-type fr) and both replicates of WT and Y430C were 
combined to form one assembly (cuffmerge, parameters: default).  Differentially expressed 
peaks were determined from this assembly using cuffdiff (Cuffdiff. Parameters: default).  
2.11.3 Dotplots 
Reads per kilobase per million mapped reads (RPKM) was quantified for all exons using 
Homer analyzeRepeats.pl (parameters: -count exons, --strand +, -norm 1e7, -rpkm). WT and 
Y430C Log2 (RPKM) were plotted against each other using custom R scripts. 
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2.11.4 Heatmaps 
deepTools2 was used to make heatmaps; score files were made across specific genomic 
regions (computeMatrix, parameters:  scale-regions scale regions –b 500 –a 500 –bs 50 –bl 
mm9 blacklist) and these were used to plot heatmaps (plotHeatmap, parameters: --colormap 
RdBluYl reverse).  
2.11.5 Genomic region enrichment 
Bioconductor package regioneR (Gel et al., 2016) was used to assess the relationship between 
the WT and Y430C peaks called by MACS2 (section 7.10.1) and the peaks identified as 
differentially bound between WT and Y430C.  
regioneR uses circular permutation (n=1000) to count the number of overlaps between two 
genomic regions. A z-score and p value is calculated between the observed number of 
overlaps and the random distribution of permuted regions. Only canonical, autosomal peaks 
and genomic regions were included in the permutation test.  
Genomic regions based on a chromHMM segmentation of the mm9 genome were obtained 
from https://github.com/gireeshkbogu/chromatin_states_chromHMM_mm9. SE, typical 
enhancer and promoter regions were those defined by Flynn et al., 2016.   
2.11.6 Functional annotation analysis 
DAVID functional annotation tool was used to identify GO (gene ontology) terms enriched 
in gene lists. Gene names were converted to ENTREZ_GENE_IDs using DAVIDs Gene 
ID conversion tool. This allows genes in the list to be recognised by DAVID. The lists were 
then uploaded for Functional Annotation, limiting annotations to Mus Musculus and using 
Mus Musculus as a background. The following GO terms - Biological processes 
(GOTERM_BP), cellular components (GOTERM_CC) and Molecular Function 
(GOTERM_MF) – and the functional category – UniProt Keywords (UP_KEYWORDS) 
were selected for functional annotation clustering. P-values were set to < 0.5. Results are 
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3.1 BRD4 haploinsufficiency causes a 
CdLS-like phenotype  
Approximately 55% of CdLS cases are caused by mutations in the cohesin loader NIPBL 
and <10% are a result of mutations in the other cohesin related genes (Newkirk et al., 2017) 
(see section 1.1). This means that for approximately 35% of patients, the causal mutation 
remains unknown. Studies have begun to identify patients with CdLS-like phenotypes that 
have mutations in genes unrelated to the cohesin complex (Ansari et al., 2014; Yuan et al., 
2015), indicating the necessity for non-candidate driven approaches (section 1.2.8).  
David FitzPatrick’s lab carried out whole exome sequencing in a group of 92 individuals with 
CdLS, in whom no plausibly diagnostic variants could be identified in the known causative 
genes. They first identified one individual with a de novo heterozygous 1.04 Mb deletion 
encompassing 29-protein coding genes, including BRD4 (Family 4198, Figure Ch3-1A). 
Targeted resequencing of this region in the remaining 91 individuals identified a second 
individual with a de novo mutation in BRD4, this time a missense mutation mapping to BD2 
(c.1289A>G, p.(Tyr430Cys), Family 3049, Figure Ch3-1B). Recently two more affected 
individuals have been identified with de novo frameshift mutations in BRD4, the first 
through ongoing screening of patients (c.1224delinsCA, p.(Glu408Aspfs*4), CDL038, 
Figure Ch3-1B) and the second through analysis of trio whole exome sequencing 
generated by the Deciphering Developmental Disorders study (DDD study) (McRae et al., 
2017) (c.691del, p.(Asp231Thrfs*9), DDD 264293, Figure Ch3-1B).  
The FitzPatrick lab reviewed the phenotypes of seven other individuals who had been 
reported to have heterozygous deletions encompassing BRD4 (Figure Ch3-2). The 
phenotypes of these individuals showed significant overlap with CdLS, with at least two 
of the seven individuals (28.6%) fulfilling the diagnostic criteria for CdLS (Kline et al., 
2007).  
Taken together, these data support BRD4 haploinsufficiency as the genetic mechanism 
for the CdLS-like phenotype of the patients in Figure Ch3-1.  
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3.2 Experimental models of the Tyr430Cys 
mutation  
In order to investigate the effects of BRD4 haploinsufficiency on cell function I focussed on 
proband 3409, who carries the Tyr430Cys point mutation in BD2 (hereafter termed 
Y430C).  
To assess the functional consequences of this mutation, CRISPR Cas9 (D10A) nickases 
were used to introduce the mutation into mouse embryos and mESCs; guide RNAs 
(gRNA) complimentary to the regions on either side of a target region direct the Cas9 
nickases to these sites where they introduce SSBs in the DNA. Homology directed repair 
(HDR) is promoted by providing a repair template, which contains some homology with 
the region, but can also carry the specific mutation that is to be introduced (Figure Ch3-
3).  
3.2.1 Mouse embryos 
David Fitzpatrick’s lab first generated Brd4Y430C/+ and Brd4Y430C/Y430C F0 mouse embryos 
through injections of Cas9 reagents into single-cell mouse zygotes. At E13.5, 
Brd4Y430C/Y430C and Brd4Y430C/+ were indistinguishable from Brd4+/+ embryos (Figure Ch3-
4A-C). They also generated apparently non-mosaic F0 embryos homozygous for a 15-bp 
in-frame deletion (:c.1288_1302del, p.(Cys430_Asn434del) 
designated Brd4C429_N433del/C429_N433del (Figure Ch3-4D), that abolished expression of BRD4 
(data not shown). Brd4C429_N433del/C429_N433del embryos showed significant growth restriction 
at E13.5 but had no other obvious phenotype. Such growth restriction has been seen by 
others in embryos heterozygous for a null Brd4 allele and is thought to be attributable to 
a reduced proliferation rate. However, the fact that the Brd4C429_N433del/C429_N433del embryos 
survive to E13.5 is contradictory to previous reports, which concluded that homozygous 
knockout of BRD4 is lethal early in embryonic development, due to failure to maintain 




























































































































































































































Figure Ch3-4. CRISPR targeting of Brd4 in mouse embryos. Images show E13.5 
mouse embryos after CRISPR targeting of Brd4. Knock-in of WT or mutated repair 
template generated A) WT, B) Brd4Y430C/+, C) Brd4Y430C/Y430C, and D) 
Brd4C429_N433del/C429_N433del mouse embryos. Scale bar = 0.5 cm. (Hemant Bengani).  
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3.2.2 Brd4Y430C/Y430C mESCs 
Pradeepa Madapura and I then individually engineered Brd4Y430C/Y430C mESCs. Cas9 
reagents were transfected into 46C mESCs and successfully co-transfected cells were 
selected based on their puromycin resistance and positive GFP expression. We plated the 
resulting cells at low densities and, after 1 week, picked 96 colonies to plate in duplicate 
(1 colony/well of a 96-well plate). We then began extracting DNA from these colonies 
and sequencing it using primers that flank the target sites (Table Ch2-1, Y430C-
genotyping); I sequenced 21 colonies and identified 1 homozygous clone (Figure Ch3-5A), 
giving a targeting efficiency of 5% (Table Ch3-1). A similar efficiency was found by 
Pradeepa. No heterozygotes were identified in either experiment. We expanded the two 
Brd4Y430C/Y430C clones for further use, giving me two independent cell lines.  
I chose to use mESCs as these are an easily manipulated model system, for which there is 
extensive pre-existing epigenetic profiling datasets, both publicly available and within our 
lab. Furthermore, BRD4 is known to be important in the maintenance of the pluripotency 
and self-renewal of mESCs (Di Micco et al., 2014). The mESCs were engineered to be 
homozygous for the Y430C mutation, in the hope that any phenotype might be more 
striking; Brd4Y430C/+ and Brd4Y430C/Y430C embryos did not show a phenotype, suggesting that 
the effect of the mutation in the cells may be subtle.    
Through qPCR analysis using primers for a region of the Brd4 gene body (Table Ch2-3), 
and immunoblots of BRD4 protein, I determined that the Y430C mutation did not alter 
the levels of BRD4 protein or mRNA (Figure Ch3-5B&C). A single band of ~200 kDa 
was detected for BRD4 protein, indicating that the majority of BRD4 in the mESC is 
isoform A.   
I also unsuccessfully attempted to introduce the Brd4C429_N433del/C429_N433del mutation into 
mESCs using CRISPR. A large proportion of the picked clones failed to expand after 
plating in 96 well plates. Those that did grow were screened by immunoblotting for BRD4 
(Figure Ch3-5D), but all showed expression of BRD4. A smaller percentage of clones 
expanded in this experiment compared to the Y430C CRISPR experiment, and it is 
possible that those that failed to expand were in fact homozygous for the targeted BRD4 
deletion. As others have seen that knockout of Brd4 is embryonic lethal (Houzelstein et 
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al., 2002), I concluded that this mutation may not be viable in mESCs and decided not to 
pursue this further.  
 
 
Experiment Clones sequenced Homozygous Heterozygous  Homozygous 
targeting efficiency 
(%) 
1 15 1 0 6.67 
2 21 1 0 4.76 
Average  18 1 0 5.56 
Table Ch3-1. Results of CRISPR-Cas9 experiments  
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3.3 BRD4 interactions with histone and 
non-histone proteins  
BRD4 is a member of the BET family of proteins (Rahman et al., 2011). BRD4 has a number 
of roles in the cell, including transcriptional regulation (Hajmirza et al., 2018), cell cycle 
regulation (Maruyama et al., 2002) and DNA repair (Li et al., 2018). In mESCs, BRD4 is 
important in the regulation of genes that maintain the pluripotent state (Di Micco et al., 2014). 
The N-terminal BDs of BRD4 mediate interactions with acetylated histones, whilst the CTD 
and ET domain interact with multiple non-histone proteins (domains indicated in Figure 
Ch3-1B). For instance the CTD recruits P-TEFb (CDK9 and Cyclin T1) to promoters (Lu 
et al., 2016) and the ET domain recruits JMJD6, SWI-SNF and CHD2 (Hajmirza et al., 2018) 
(see section 1.4 for more details). I was interested to see which proteins BRD4 may interact 
with specifically in mESCs, and whether these interactions would differ between the WT and 
Y430C BRD4.  
3.3.1 In silico modelling of Y430C mutation in BD2 
3.3.1.1 Effect on BD stability 
The homology between BDs of different proteinssuggests that the sequence and structure 
of the domain structure is important for its function, i.e. the binding of acetylated peptides. 
The Y430C mutation lies in the αB helix of BD2 of BRD4, just two amino acids away from 
the conserved Asn residue that mediates acetyl-lysine binding (Figure Ch1-9)(section 1.4.2.2). 
This proximity, and that Y430 is highly conserved between BDs, BETs and species (Figure 
Ch3-6) (Filippakopoulos et al., 2010), led me to hypothesise that this mutation would affect 
the affinity of BRD4-Y430C for acetyl-lysines. 
To investigate this further, Dinesh Soares, a computational structural biologist in the IGMM, 
modeled the Y430C mutation in silico. The crystal structure of BD2 in BRD4 has been 
determined many times, by both nuclear magnetic resonance (NMR) (PDB: 3JVL) and X-
ray crystallography (PDB: 2YEM) and is available in both its unbound state and bound to 
acetylated peptides (PDB: 4KV4). Dinesh made use of these publicly available structures to 
determine the likely function of the Y430 side chain in the structure.  
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Y430 protrudes into the space between the helices. Here it supports hydrophobic 
interactions (within 5 Å) with side-chains of completely buried residues F426 (also in αB), 
V440 (αC) and A443 (αC). Additionally, the OH group of Y430 forms a H-bond with OE1 
of Q447 (αC). All of these interactions are retained by the equivalent Tyr (Y137) in BD1 of 
BRD4 (PDB ID: 3MXF) (Figure Ch1-9) and are important in the packing of αB and αC for 
structural stability (Figure Ch3-7A).   
When Y430 is mutated to C430, the hydrophobic interactions and putative aromatic-
aromatic stacking interactions of Y430 with F426 are lost. Furthermore, the distance between 
this residue and the OE1 of Q447 increases, causing the loss of the important inter-helical 
H-bond. The overall result is a more open interface between the opposing αB and αC helices 
and a destabilisation of structure (Figure Ch3-7A).  
Dinesh used FoldX (Schymkowitz et al., 2005), a protein design algorithm that evaluates the 
effect of mutations on the stability, folding and dynamics of proteins, to predict the effects 
of the Y430C mutation in various BD structures from the RCSB Protein Data Bank (PDB). 
FoldX can be used to calculate the change in free energy (ΔΔG) between two protein 
conformations (eg. WT vs mutant, or bound vs unbound). ΔΔG correlates with 
experimentally observed changes in stability, with a higher value indicating a destabilisation 
of structure (Schymkowitz et al., 2005). Mutation of Y137/430 was found to destabilise the 
BD monomer in every structure tested. The three NMR structures (yellow bars in Figure 
Ch3-7B) suggest comparatively moderate destabilising effects, but all high-resolution crystal 








































































































































































































Figure Ch3-7. BRD4-BD2 in Y430 and C430. Crystal structure of BRD4-BD2 in 
WT (PDB ID: 2OUO (1.89 Å resolution) (from Filippakopoulos et al., 2012) (left)  
and predicted Y430C (right) conformations. B) Changes in free energy between WT 
and Y430C conformations of various BD structures. ΔΔG was calculated using FoldX 
for BD structures from PBD. Black box indicates structures of BRD4-BD2 
specifically. Others are various other BDs. Yellow bars - ΔΔG >0.8 to <1.6 kcal/mol: 
moderately destabilising. Red bars - ΔΔG >1.6 kcal/mol: severely destabilising. 







   
 
3.3.1.2 Effect on ligand binding 
To model the effect of the Y430C mutation, and it’s destabilisation of BD structure, on 
acetyl-lysine binding, Dinesh made use of available structures of BD2 in complex with the 
small molecule BET inhibitor, JQ1 (see section 1.4.2.3). No BRD4-BD2 structures were 
available however, so BRD4-BD2 in complex with JQ1 was modelled using structures of 
BRD4-BD2 in its unbound state (resolution 1.89 Å, 100% identity) and BRD3-BD2 bound 
to (+)-JQ1 (PDB ID: 3S92 resolution 1.36 Å, 79% identity) (Figure Ch3-8).  
The Y430 residue was predicted not to participate directly in the binding of JQ1. However, 
it is located within 5 Å of N433, the residue that is involved in critical hydrogen bonding 
with JQ1. Consequently, the destabilisation caused by the Y430C mutation is likely to perturb 
the local structural environment and affect JQ1 binding.  
Given the strong similarity between the binding of JQ1 and acetyl-lysines to BDs, it is likely 
that the mutation also disrupts BRD4’s binding to acetylated histones.   
3.3.2 BRD4 binding to acetylated histones  
To experimentally test the hypothesis that the Y430C mutation affects binding of BRD4 to 
acetyl-lysines, Pradeepa Madapura compared the binding of the BD2 domain containing the 
Y430C substitution with that of WT BD2 and WT BD1 domains (purified by the Edinburgh 
Protein Production Facility). Modified histone tail peptide arrays showed that binding to a 
number of histone tail acetylation marks is reduced for Y430C-BD2 (Figure Ch3-9A).  
I then coimmunoprecipitated BRD4 in the WT and Y430C mESCs and immunoblotted the 
co-precipitated proteins for various histone acetylation modifications. This revealed impaired 
BRD4-Y430C binding to H3K9ac and H3K27ac, confirming the in silico and in vitro results. 
Binding to H4K8ac was not affected (Figure Ch3-9B).
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Figure Ch3-9. Binding of BRD4 to acetylated histones in WT and Y430C mESCs. 
A) Specificity of binding to arrayed acetylated histone tail peptides of WT BRD4 BD1 
(BRD4 BD1 WT, dark grey bars), WT BRD4 BD2 (BRD4 BD2 WT, light grey bars) 
and BRD4 BD2 with the Y430C variant (BRD4 BD2 Y430C, red bars). B) Left - 
Cropped immunoblots showing co-IPs with an antibody to endogenous BRD4 and 
rabbit normal IgG (control) in WT and Y430C mESCs. Input is 1% of mESC nuclear 
extract. Antibodies used for immunoblotting are shown on the right of the images. 
Right - Graph shows intensity of bands in BRD4 IP lane as a percentage of input 




   
 
3.3.3 BRD4 interactions with non-histone proteins 
3.3.3.1 Co-immunoprecipitation-Mass spectrometry 
To identify BRD4 interacting proteins more globally, I carried out a co-IP using two different 
antibodies against BRD4 (Bethyl; A301-985A100, Abcam; ab128874) followed by label free 
quantitative mass spectrometry (LFQ-MS), on protein lysates from WT and Y430C mESCs. 
LFQ-MS eliminates the need for a chemical label or tag, which are expensive, require extra 
steps for sample preparation, and can introduce variability to the experiment (Drabik, 
Ciborowski and Silberring, 2013). There is a lot of variability between the two replicates, 
suggesting that more repeats should be carried out before definitive conclusions are made. 
This identified 1,082 proteins that were present in BRD4 IPs from both WT and Y430C cell 
lines. DAVID functional analysis (Huang, Sherman and Lempicki, 2009b, 2009a) of this 
protein list identified 65 enriched clusters (p<0.5) (data not shown), which included terms 
related to the known functions of BRD4. The most highly enriched cluster included 
ribosomal proteins and those involved in translation (score 109.72), however these proteins 
are known to be common MS contaminants (Mellacheruvu et al., 2013). Other highly 
enriched clusters included mRNA processing (score 54.68), cell division (score 14.82), 
nucleosome regulation (score 11.87), DNA damage and repair (score 11.42) and transcription 
(score 11.14). Scores order the relative importance of each identified gene group.  
90 of these proteins were absent in IgG controls (Figure Ch3-10), of which BRD4 was the 
top hit, indicating that the IP had worked well. Most proteins were present in both WT and 
Y430C IPs, with only 22 being differentially detected. I categorised the 90 proteins based on 
their known functions and found a number of common themes (Figure Ch3-10, boxed and 
labelled). 
Interestingly, of the 90 proteins present in both WT and Y430C IPs, 4 were cohesin related 
– NIPBL, RAD21, ESCO2 and PDS5B (Figure Ch3-10, red). Furthermore, 5 other cohesin 
subunits - SMC1A, SMC3, STAG2, PDS5A and PDS5B – showed evidence of enrichment 
over IgG, but were not consistent between BRD4 antibodies (Figure Ch3-11). Upon 
replication of this experiment in the second independent Y430C mESC line, certain cohesin 
component-BRD4 interactions were no longer detected, despite being consistently detected 
by co-IP-western blot. After some optimisation, I found that it was a prolonged (>1hr) 
exposure to detergents in the RIPA buffer that perturbed these interactions as measured by 
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MS. The protocol was thus modified to limit the time in RIPA buffer and the associations 
were successfully replicated (see section 2.9.3).  
Other categories enriched amongst these 90 proteins include proteins of the DDR 
(underlined) and transcriptional regulation (bold); both known functions of BRD4. The most 
common function I found in this group of 90 proteins was a role in splicing (Figure Ch3-10, 
yellow highlight). The BRD4 yeast homologue, bdf1, is involved in pre-mRNA splicing, with 
deletion of this gene causing a global defect in splicing (Albulescu et al., 2012). However, 
whilst BRD4 has been shown to regulate splicing during heat shock (Hussong et al., 2016; 
2017), it is unclear whether BRD4 would interact with these proteins under normal 
conditions. Furthermore the recruitment of BRD4 to nuclear stress bodies upon heat-shock 
is mediated through BD acetyl-lysine binding (Hussong et al., 2017), suggesting that, were 
these interactions specific, they would be stronger with WT-BRD4 than Y430C-BRD4. 
BRD4 has been seen by others to interact with a complex of 7SK snRNA and BAF (Flynn 
et al., 2016), and I will discuss this in greater detail later (section 4.4). BAF is a chromatin 
remodelling complex that can be composed of up to 15 subunits encoded by 29 genes 
(Panamarova et al., 2016). Four of these subunits - SMARCA4, SMARCC1, SMARCB1 and 
SMARCA5- are pulled down by in my BRD4 co-IP, however these are excluded from the 
specific list due to their presence in the IgG control. The lack of specific BRD4-BAF 
interaction is not surprising however; the interaction between BAF and BRD4, thought to 
be mediated by 7SK snRNA, is likely disrupted by the addition of the endonuclease 
benzonase, which degrades both RNA and DNA (Oristo, Lee and Maunula, 2018), to the 





   
 
Figure Ch3-10. BRD4 protein interactions in WT and Y430C mESCs. A. Heatmap 
of the label-free quantitative (LFQ) mass spectrometry values assigned to each protein 
following BRD4 immunoprecipitation from WT and Y430C mESCs. The colour scale 
indicates the Log (LFQ) value calculated as an average of 3 technical replicates. Proteins 
that interact with WT and Y430C (top), WT only (middle) and Y430C only (bottom) are 
indicated by dotted lines and named. Underlined - proteins involved in the DDR. Yellow 
highlight – splicing factors. Bold – transcriptional regulators. Red – components of 










Figure Ch3-11. LFQ intensity from BRD4 co-IP MS. Box plots show details of the 
MS results for members of the cohesin complex that are not highlighted in Figure Ch3-
6B.  The y-axis represents the LFQ intensity and the x-axis represents the reagent used 
for the immunoprecipitation in WT and BRD4Y430C/ Y430C (MUT) mESCs. Horizontal lines 
within boxes show medians, boxes are inter-quartile ranges and whiskers are range. 
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3.3.3.2 Western blot validation of cohesin interactions 
To validate BRD4 interactions I used co-IP followed by immunoblotting for the putative 
interactors. Reciprocal co-IP for BRD4/NIPBL and BRD4/SMC3 confirmed that BRD4 
interacts with the cohesin loader (Figure Ch3-13A&B) and core cohesin ring (Figure Ch3-
12C&D) respectively.  
Y430C- and WT-BRD4 show comparable levels of association with these cohesin 
components, both by western blot and by MS, suggesting that this interaction is unlikely to 
be mediated by co-binding to acetylated chromatin.  
Association of BRD4 with the cohesin complex and NIPBL, indicates that there might be a 
common mechanism for ‘classical’ cohesin-related CdLS cases and those caused by 
mutations in BRD4. This not only strengthens my hypothesis that BRD4 haploinsufficiency 
causes a CdLS-like phenotype, but may also help to identify cellular functions and 
































































































































































































































































   
 
3.3.3.3 Differentially bound proteins 
Only 22 proteins fit the criteria of being identified as differentially bound between WT and 
Y430C by both BRD4 antibodies, and absent from the IgG control (Fig Ch3-10). No 
obvious trends were seen in these protein lists and these were too small in number for 
functional analysis. I therefore looked at those proteins that were differentially detected in 
WT and Y430C cells by the Bethyl BRD4 antibody. This is the antibody that I have used for 
all other ChIP and immunoblot experiments. This gave me a list of 62 proteins enriched in 
the WT-BRD4 IP, and 54 in the Y430C-BRD4 IP (Figure Ch3-13A).  
I used the DAVID functional analysis tool to look for enriched GO terms and functional 
categories in these lists (p value <0.5). 8 and 7 clusters were identified in the WT and Y430C 
lists respectively (Figure Ch3-13B), with some overlaps between the two; Transcription and 
cell cycle related terms were enriched in both lists. The enrichment of DNA damage and 
repair terms, and chromatin binding and regulation, were seen in the WT protein list, but not 
in the Y430C list.  
BRD4 is known to be involved in the DDR (Floyd et al., 2013; Pongas et al., 2017) and loss 
of binding to these proteins may be relevant to topics described later in my thesis (Chapter 
5). It is possible that the loss of binding to chromatin regulators is a result of the Y430C 
mutation impairing the binding of BRD4 to acetylated histones.
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B A 
Figure Ch3-13. Proteins differentially enriched by BRD4 bethyl co-IP in WT or 
Y430C mESCs. A) Screenshots of heatmap shown in figure Ch3-8, highlighting proteins 
enriched by bethyl BRD4 antibody in WT mESCs (top) and Y430C mESCs (bottom). 
Colour bar = log (LFQ) intensities. B) Bar charts show clusters of GO terms and 
functional categories enriched in WT (top) and Y430C (bottom) specific protein lists 
from BRD4 co-IP MS. Categories were determined by DAVID (p < 0.05). Enrichment 




   
 
3.4 Conclusions 
Through targeted sequencing, David FitzPatrick’s lab identified three CdLS patients with de 
novo mutations in BRD4 and I’ve shown significant overlap between the phenotypes of 
these individuals and others with heterozygous deletions of BRD4. From these data, I 
conclude that BRD4 haploinsufficiency can cause CdLS. By engineering one of these 
mutations, Y430C, in mESCs, I was able to show that the mutation does not affect BRD4 
mRNA or protein levels. This indicates that the Y430C mutation must affect BRD4 function, 
rather than just decreasing the amount of protein. 
I have shown that BRD4 associates with both cohesin core ring components and the cohesin 
loader NIPBL. This is not perturbed by the Y430C mutation, suggesting it is mediated by 
the ET domain or CTD, rather than via BD binding. BRD4 was also found to interact with 
proteins involved in mRNA processing, cell division, nucleosome regulation, DNA damage 
and repair, and transcription, consistent with what is already known.  
The binding of BRD4 to a subset of 62 proteins was impaired by the Y430C mutation, and 
these proteins were enriched for terms related to DNA damage and repair, and chromatin 
binding and regulation. BRD4 has been shown by others to interact with, and regulate, 
proteins of the DDR and may be involved in their recruitment to DSBs (Li et al., 2018). 
Therefore, a loss of interactions between BRD4-Y430C and DNA damage and repair 
proteins could have significant implications for the DDR in these cells.  
In silico modelling strongly suggested a destabilisation of BD2 upon the Y430C mutation. 
Through in vivo experiments I showed that this causes a reduced association between BRD4 
and acetylated H3K9 and H3K27. This raises the possibility that the Y430C mutation may 
preferentially affect BRD4 binding to CREs (enhancers and promoters), and this will be 









































Chapter 4: Investigating the 
effect of decreased BRD4 












































   
 
4.1 Genome-wide chromatin and 
expression profiling. 
In this chapter I describe the use of the genome-wide profiling methods, chromatin 
immunoprecipitation-sequencing (ChIP-seq) and 4 thiouridine-sequencing (4sU-seq) to 
explore the consequences of the Brd4 Y430C mutation in mESCs. 
4.1.1 ChIP-sequencing 
A number of biological processes, including transcription; DNA replication, recombination 
and repair; and cell cycle progression, rely on interactions between DNA and proteins (Gade 
and Kalvakolanu, 2012a) and on epigenetic modifications of DNA and histones (Pillai, 
Dasgupta and Chellappan, 2015). Identifying and understanding these processes are essential 
for understanding cell and genome biology (Gade and Kalvakolanu, 2012b).  
ChIP assays are routinely used to characterise DNA-protein interactions and epigenetic 
marks (Gade and Kalvakolanu, 2012b). For histone modification ChIP, native chromatin can 
be used and fragmented by enzymatic digestion, as nucleosomes are relatively stable 
structures (Thorne, Myers and Hebbes, 2004). However, when studying the binding of 
proteins such as TFs which have shorter residence times on the genome, the cells must first 
be treated with formaldehyde - to cross-link DNA and proteins - and the resulting 
nucleoprotein complexes are fragmented by sonication (Pillai, Dasgupta and Chellappan, 
2015). DNA fragments are then immunoprecipitated using an antibody specific to the 
protein or histone modification of interest and de-crosslinked to separate the DNA and 
protein (Pillai, Dasgupta and Chellappan, 2015) (Figure Ch4-1A).  
qPCR analysis can be used for quantification of specific DNA regions enriched in ChIP 
material (relative to input)(Pillai, Dasgupta and Chellappan, 2015), whilst ChIP-Chip (ChIP 
followed by microarray hybridisation) and ChIP-seq (ChIP followed by sequencing) 
technologies allow for genome-wide identification of histone modifications or DNA-protein 
interactions (Ren et al., 2000; Johnson et al., 2007). ChIP-seq is less noisy, higher resolution, 
requires less input DNA and provides greater coverage than ChIP-Chip. With decreasing 
costs of sequencing technologies, ChIP-seq is becoming the preferred tool for studying gene 
regulation and epigenetic mechanisms (Park, 2009).  
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4.1.2 4sU-sequencing  
The transcriptome of a cell, that is, its total RNA population, specifies its identity and 
function (Mortazavi et al., 2008), and therefore differs between cell types, developmental 
stages, pathological conditions and in response to drugs (Casamassimi et al., 2017).  
The study of individual transcripts dates as far back as the 1970s, but the field is now 
dominated by microarrays and RNA-seq, which allow the analysis of multiple transcripts at 
once. Microarrays can be used to analyse thousands of transcripts simultaneously, saving 
time and money, through the hybridisation of transcripts to an array of complementary 
probes (Lowe et al., 2017). They are restricted however, by their reliance on prior knowledge 
of genome sequence, cross-hybridisation and limited dynamic range (Wang, Gerstein and 
Snyder, 2009).  
In RNA-seq, steady state RNA is converted to cDNA and sequenced in a high-throughput 
manner. The resulting reads can either be mapped to a reference genome or assembled de 
novo, producing a whole genome transcriptional profile for the analysis of transcriptional 
structure and gene expression (Wang, Gerstein and Snyder, 2009). This eliminates a number 
of the issues associated with microarrays, but the use of total cellular RNA still limits the 
biological questions that can be addressed; it is impossible to determine whether changes in 
total RNA levels are a result of changes in synthesis, or decay. mRNA degradation is an 
essential step in determining mRNA abundance and can be regulated for a particular 
biological function or in response to intrinsic and extrinsic stimuli (Wu and Brewer, 2012).  
A number of protocols have been developed to overcome this problem, by specifically 
detecting only newly synthesised (nascent) RNA. In 4sU-seq, cells are incubated with the 
uridine derivative 4sU, which is incorporated into new transcripts by RNA polymerases. 
RNA isolation followed by biotinylation of the 4sU fraction allows the separation of labelled 
(nascent) and un-labelled (pre-existing) transcripts with the use of streptavidin-coated 
magnetic beads. 4sU-RNA is recovered from the beads by addition of a reducing agent, 
which cleaves the disulphide bond between 4sU and biotin (Figure Ch4-1B).  
By varying the 4sU incubation time, different aspects of transcription can be probed; short 
incubations (minutes) provide a snapshot of gene expression independent of downstream 
processes, whilst incremental incubation times reveal the kinetics of RNA processing. RNA 
 
  155
   
 
half-lives can also be investigated through comparisons of nascent and total RNA abundance 
(Rutkowski and Dölken, 2017). 
4.1.3 The need for a spike-in control  
The two methods described above are often used to compare two different conditions. To 
do this they assume that the overall yield of DNA or RNA is the same in both conditions, 
and that any changes in transcription or DNA-protein binding are limited to specific loci. 
However, normalisation of the data based on these assumption can lead to misinterpretation 
of the data (Chen et al., 2016).  
For instance, if expression is globally increased in one RNA sample over another, 
normalising the reads to the same number will mask this change (Figure Ch4-2A). On the 
other hand, if expression at a specific genomic region is increased in one sample, this type of 
normalisation will cause an inappropriate reduction in the number of reads from other 
regions (Figure Ch4-2B).  
The use of ‘spike-in’ controls overcomes these problems; a spike-in is the addition of a small 
amount of DNA or RNA from a foreign genome, prior to immunoprecipitation or RNA 
extraction (for ChIP or 4sU respectively). The same spike-in is added for each condition 
tested, ensuring that any downstream differences between spike-in levels are solely due to 
differences in DNA or RNA yield, and not biological. The spike-in values for each condition 
are normalised to each other, and the ratio between the two can be used to normalise the 










Figure Ch4-1. Chromatin and expression profiling techniques Schematics 
illustrating A) ChIP-seq (taken from Daniel et al., 2014) and B) 4sU-seq protocols (taken 
















































































































































































































































   
 
4.2 Exploring BRD4 occupancy by ChIP-
seq in the genome of WT and Y430C 
mESCs 
Having shown in Chapter 2 that the Y430C mutation reduces BRD4’s association with 
certain acetyl-lysines of histone tails in mESCs and decreases the occupancy of BRD4 at 
specific target regions in MEFs, I next compared the genome-wide binding of BRD4 
between WT and Y430C mESCs.  
4.2.1 Choice of antibody 
I chose to use the BRD4 rabbit polyclonal antibody from Bethyl lab (A301-985A) for ChIP-
seq; this antibody had not been previously validated for ChIP but had been shown to work 
for IP and immunohistochemistry, making it a good candidate. Furthermore, I had 
previously shown that this antibody produces a specific band by western blot (Figure Ch3-
5D) and confirmed by IP-MS that it interacts with BRD4 in mouse cells (Figure Ch3-10).  
To verify that the chromatin recovered after ChIP would contain appreciably more BRD4 
targets than other genomic regions, and would therefore be worth sequencing, I first 
conducted preliminary ChIP-qPCR experiments in the WT mESCs (Figure Ch4-3). I used 
primers specific for regions where I expected BRD4 to bind - just upstream of the c-Myc 
promoter, within the c-Myc SE, and within the Nanog enhancer – and at a control region 
where I expected little BRD4 binding – the promoter region of Gsc, a gene that is not 
expressed in mESCs (Mfopou et al., 2014) (Table Ch2-5).  
BRD4 ChIP samples were significantly enriched for the BRD4 target regions compared to 
the IgG control, indicating that the antibody efficiently binds BRD4. The Gsc promoter, 
intended as a BRD4-free control region, also showed some significant enrichment in the 
BRD4 ChIP over IgG. Whilst this might suggest that the antibody is not specific, it is possible 
that some BRD4 binding at this promoter does occur. Furthermore, the relative enrichment 
of all three BRD4 target regions was significantly greater than that of the Gsc promoter region 
in the BRD4 ChIP sample. Therefore, I concluded that the antibody would be suitable for 
ChIP-seq and proceeded with the experiment.  
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Figure Ch4-3. Specificity of BRD4 ChIP. Graph shows qPCR results using material 
recovered from BRD4 ChIP experiment and IgG control in WT mESCs. X-axis shows 
primers used. Concentrations are calculated relative to input. Data is represented as mean 
+/- SEM from 3 technical replicates.   
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4.2.2 Choice of control 
I proceeded to make DNA libraries of BRD4 bound DNA and input controls (aliquot of 
cross-linked and fragmented chromatin prior to incubation with antibody bound beads). 
Biases can be introduced to ChIP-seq data at many steps of the protocol - during sonication 
due to non-uniform DNA breakage (Landt et al., 2012); during library preparation; and in 
mapping the DNA to the genome. Sequencing of a control profile, such as the input DNA 
or an IgG ‘mock’ ChIP, is therefore important as it provides a background profile that the 
enriched ChIP signal can be normalised to (Liu, Pott and Huss, 2010). It has been suggested 
that spike-ins are the best control for ChIP-seq (see section 4.1.3) (Chen et al., 2016). For my 
purposes the best organism to use would be drosophila; Drosophila cells are readily available, 
their genome is well studied, and sequences map to the mouse genome at a very low 
frequency (Orlando et al., 2014). However, the lack of a BRD4 homologue in Drosophila 
made this unfeasible.  
I chose to sequence an input control and have used this in downstream applications such as 
peak-calling to account for any technical biases, however this cannot replace the use of a 
spike-in as an appropriate control, meaning that it is difficult to make any conclusive 
comparisons between the two cell lines.  
I made and sequenced two biological replicate ChIP-seq libraries. These show similar trends 
throughout the analysis, except where mentioned, but the data I have shown comes from 
just one replicate.  
4.2.3 Quality control 
I used FASTQC (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc) to analyse the 
quality of the sequenced DNA and ensure that it was suitable for downstream analyses. A 
phred score from 10 to 50 is assigned to each base of every read, indicating the quality of the 
base call; a score of 10 means the probability of an incorrect base call is 1 in 10, whilst a score 
of 50 means the probability of an incorrect base call is 1 in 100,000 (Illumina, 2011). The per 
base sequence quality for this ChIP-seq was found to be acceptable for all samples (Figure 
Ch4-4); the scores rarely drop below 37, indicating a high base calling accuracy. There was 
also shown to be no adaptor content or over-represented sequences in any of the samples.  
The samples did show evidence of sequence duplication – that is when multiple sequence 
reads map to exactly the same region of the genome. These redundant reads may be artefacts, 
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caused by over amplification during the PCR step of library preparation, or they can 
represent true signal. There has been much debate in the field over how to treat such 
sequences, ie. To filter or not to filter. On the one hand, these duplicate sequences can 
increase false positives during peak calling, and their removal has been shown to increase the 
specificity of identified peaks (Chen et al., 2012). On the other hand, in most peak regions 
these redundant peaks are thought to represent true signal (Chen et al., 2012), meaning that 
their exclusion limits the dynamic range of ChIP signal (Carroll et al., 2014). Since the removal 
of duplicates was found to generally remove noise in non-enriched regions, with negligible 



























































































































   
 
4.2.4 Mapping and visualisation 
I mapped the sequenced DNA to the mm9 assembly of the mouse genome using Bowtie2 
(Langmead and Salzberg, 2012). For a protein such as BRD4, that can show broad regions 
of enrichment (Jang, Shen and McBride, 2014; Najafova et al., 2017), up to 60 million reads 
may be required per sample (Bailey et al., 2013). I therefore deemed the number of mapped 
reads in my ChIP-sequencing to be sufficient, ranging from 57 million to 87.5 million (Table 
Ch4-1), with percentage of reads aligned >88% for all samples.  
I converted my data to bedgraph format and visualised the data using the UCSC genome 
browser (http://genome.ucsc.edu). This enabled me to determine the binding profile of 
BRD4 over genes of interest and specific genome elements, and to compare its binding to 
the profiles of various histone modification marks (H3K122ac; GSM2054689, H3K9ac; 
GSM775313, H3K27ac; GSM594578, H3K4me1; GSM594577, DNAse I hypersensitivity 
signal; GSM1014154). Consistent with previous reports (Di Micco et al., 2014; T. Wu et al., 
2015; Gonzales-Cope et al., 2016), I found that WT-BRD4 occupied the promoters and 
enhancers of pluripotency genes such as Sox2, Kl4 and Nanog (Figure Ch4-5). Consistent with 
my ChIP-qPCR data (Figure Ch4-3), the number of reads at these regions is greater than at 
the Gsc promoter (Figure Ch4-6A), which shows no BRD4 occupancy. There is some 
enrichment of BRD4 over the c-Myc SE and promoter regions (Ch4-6B), however this is less 
striking than it appeared by ChIP-qPCR (Figure Ch4-3). There is very little binding of BRD4 
at Gapdh, which I have used as a control for qPCRs (Figure Ch4-6C).  
Y430C-BRD4 showed a similar binding pattern to that of WT-BRD4, however there was a 
noticeable decrease in the peak heights, particularly at SEs (Figure Ch4-5&6), where BRD4 
is known to preferentially bind (Di Micco et al., 2014). This is illustrated by heat-maps (Figure 
Ch4-7A), where BRD4 read coverage is decreased in Y430C mESCs compared to WT, and 
I confirmed this by ChIP-qPCR in the second independent mESC line (Figure Ch4-7B).  
 
Total reads Reads aligned to mm9 % Reads aligned 
WT BRD4 67,828,269 61,115,388 90.10 
Y430C BRD4 64,561,315 57,119,268 88.47 
WT input 80,073,231 77,698,782 97.03 
Y430C input 90,627,286 87,540,355 96.59 
Table Ch4-1. Mapping statistics for WT and Y430C ChIP-seq FASTQ files. Files 
were mapped with Bowtie2 and mapping statistics calculated with Samtools  
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Figure Ch4-5. Genome browser view of BRD4 binding at BRD4 target genes. 
UCSC browser screenshot showing reads per 10 million (RP10M) over the extended A) 
Klf4 locus, B) Nanog locus and C) Sox2 locus for various ChIP-seq experiments. Tracks 
1 and 2 = BRD4 ChIP-seq in WT and Y430C mESCs, tracks 3-6 = previously published 
ChIP-seq data for various histone modifications, track 7 = DNase I hypersensitivity.   
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Figure Ch4-6. Genome browser view of BRD4 binding at c-Myc and control 
regions. UCSC browser screenshot showing RP10M over the extended A) Gsc locus, B) 
c-Myc locus and C) Gapdh locus for various ChIP-seq experiments. Tracks 1 and 2 = 
BRD4 ChIP-seq in WT and Y430C mESCs, tracks 3-6 = previously published ChIP-seq 




   
 
 
Figure Ch4-7. Genome wide binding of BRD4. A) Heatmaps show distribution of 
BRD4 ChIP-seq reads across SEs, typical enhancers, promoters and gene bodies in 
WT and Y430C cells. Colour scale represents log2 RPKM. Regions are scaled to 4 Kb. 
B) ChIP-qPCR measuring concentration of BRD4 ChIP DNA from WT (white bars) 
and Y430C (black bars) mESCs, relative to input across the SEs of Oct4, Klf4, Nanog, 
and Sox2. Data is represented as mean +/- SEM from 3 technical replicates.  
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4.2.5 Peak Calling 
To analyse the data more quantitatively, I used the peak-calling software MACS2 (Model-
based Analysis of ChIP-Seq data) to call significant peaks of BRD4 in WT and Y430C 
mESCs. MACS normalises the data against both local background and the provided input 
background, allowing for robust prediction of peaks (Y. Zhang et al., 2008). As expected, I 
found a decrease in the total number of BRD4 peaks in Y430C cells compared to WT cells 
(Table Ch4-2).  
Graeme Grimes (IGMM Bioinformatics Analysis Core) used the Bioconductor package 
regioneR (Gel et al., 2016) to assess the relationship between the different peak sets and 
defined genomic regions. This uses circular permutation (n=1000) to count the number of 
overlaps between two genomic regions and calculates a z-score and a p-value between the 
observed number of overlaps and the random distribution of permuted regions. We 
compared the WT and Y430C peak files to mESC chromatin states based on a chromHMM 
segmentation of the mm9 genome (Ernst and Kellis, 2012) (Figure Ch4-8), and to mESC 
promoters, typical enhancers (TEs) and SEs defined by others (Flynn et al., 2016). We found 
that promoters showed the highest levels of enrichment, followed by SEs and TEs, whilst 
heterochromatin, repressed regions and transcribed regions were the least enriched (Figure 
Ch4-9).  
I then used the MACS2 function for differential peak calling (bdgdiff), to identify those 
regions that are occupied by BRD4 in the WT cells but not in the Y430C cells, and vice versa. 
I found that, whilst there were 1693 peaks that were specific for WT (Table Ch4-2) – ie. 
Where mutant BRD4 was not significantly bound - there was only one region that was 
specific for Y430C. This region maps to the promoter of Snrpn, but was not detected as a 
differential peak in the other BRD4 ChIP-seq replicate. GO enrichment analysis using 
GOrilla (Eden et al., 2007, 2009), found no terms to be enriched in the list of genes associated 
with the BRD4 peaks specific to WT cells (p <0.001).  
In the absence of any enrichment in gene terms, we looked to see if the WT specific peaks 
were enriched for any functional genomic categories. Using regioneR we detected that WT 
specific peaks were enriched at TEs, SEs and active promoters, and were least enriched for 
weakly transcribed and repressed regions (Figure Ch4-9).  
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From these results I concluded that Y430C-BRD4’s decreased affinity for acetyl-lysines 
mostly affects its binding to CREs, causing a decrease in the occupancy of BRD4 at SEs, 
















    
    
    
Peak calling results  
 Total peaks Specific peaks % specific peaks 
WT 20,691 1693 8.2 
Y430C 11,775 1 0.8 x 10-5 
Table Ch4-2. Peak calling results. MACS2 was used to call peaks in WT and Y430C 
BRD4 ChIP-seq data, using input data as a control (p value < 0.00001) (Total peaks). 
MACS2 bdgdiff was used to identify regions of differential BRD4 occupancy in WT and 
Y430C ChIP-seq data (Specific peaks).  
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Figure Ch4-8. Combination of chromatin marks used to define different 
chromatin states by ChromHMM. ChIP-seq datasets for the labelled factors or 
histone marks were collected and a Poisson-based multivariate hidden markov model 
was used to identify regions or states enriched in specific combinations of histone 
modifications, splitting the genome into 15 different states. These were compacted into 










































































































































































































































































































   
 
4.2.6 JQ1 treatment decreases BRD4 binding to SEs 
(+)-JQ1 (see section 1.4.2.3) competitively binds to bromodomains of BET proteins and has 
been previously shown, by ChIP-qPCR (Patel et al., 2013; K. L. Cheung et al., 2017) and 
ChIP-seq (Zhang et al., 2012), to displace BRD4 from chromatin. Therefore, it provides me 
with a useful tool for inhibiting BRD4 binding to acetyl-lysines.  
I carried out ChIP-qPCR using the BRD4 bethyl antibody in WT and Y430C cells treated 
with 300 nM (+)-JQ1 or (-)-JQ1 (the active and inactive enantiomers respectively) for 24 
hours. The results were in accordance with what had previously been seen; (+)-JQ1 treatment 
significantly decreased the amount of Oct4 and Klf4 SE DNA in the BRD4 ChIP DNA 
(shown as a percentage of input DNA), compared to (-)-JQ1 treatment, in mESCs (Figure 
Ch4-10). The amount of Sox2 SE DNA also decreased, but this was not significant. This 
corroborates the results of others, that (+)-JQ1 binding to BRD4 bromodomains inhibits 
BRD4 binding to SEs.  
The decrease in BRD4 binding caused by (+)-JQ1 treatment was more pronounced than that 
which occurs due to the Y430C mutation. Furthermore, (+)-JQ1 treatment had a significant 
effect on both WT and Y430C BRD4 binding (Figure Ch4-10). These data suggest that the 
Y430C mutation has a mild effect on BRD4 binding, relative to (+)-JQ1. This is in agreement 
with the BRD4 ChIP-seq profiles (Figure Ch4-5&6), which show that peaks of BRD4 




















Figure Ch4-10. (+)-JQ1 treatment decreases BRD4 binding to SEs. ChIP-qPCR 
measuring concentration of BRD4 ChIP DNA relative to input across the SEs of Sox2, 
Oct4 and Klf4 in WT and Y430C cells after treatment with (+)-JQ1 (+) or (-)-JQ1 (-). 




   
 
4.3 Assessing the effect of reduced BRD4 
CRE-occupancy on transcription  
4.3.1 Comparing mRNA levels of BRD4 target genes with and without JQ1 treatment 
The well documented roles for BRD4 in transcriptional regulation, coupled with evidence of 
altered gene expression profiles in some CdLS patients (Liu et al., 2009) (Boudaoud et al., 
2017), led me to hypothesise that the loss of BRD4 at CREs in Y430C Brd4 mutant cells 
would cause dysregulated expression of the associated genes. Indeed, inhibition of BRD4 
acetyl-lysine binding by BETi is known to disrupt expression of target genes, and it has been 
suggested that genes regulated by SEs are the most sensitive to this inhibition (Lovén et al., 
2013). To confirm that this BD inhibition-induced transcriptional phenotype could be 
observed in my mESCs, I treated the WT cells with the BET inhibitor (+)-JQ1 and the 
inactive stereoisomer (-)-JQ1 at 300 nM for 24 hours.  
RNA isolation, followed by RT-qPCR for the SE associated genes Nanog, Myc, Klf4 and Oct4, 
confirmed that inhibition of BRD4 binding by (+)-JQ1 in WT mESCs causes a decrease in 
gene expression relative to treatment with (-)-JQ1. mRNA levels are normalised to the 
housekeeping gene Gapdh, which I would expect to show no change in expression in 
response to (+)-JQ1(Figure Ch4-11A).  
4.3.2 Comparing mRNA levels of BRD4 target genes in WT and Y430C cells 
I next used RT-qPCR to compare the expression of Nanog, Klf4, Oct4 and Sox2 between WT 
and Y430C cells, to see if the decreased BRD4 binding in the Y430C cells would have a 
similar effect on transcription as the inhibition of BRD4 binding by (+)-JQ1 did. I found 
that there was no significant difference in the levels of Sox2, Nanog, Klf4 and Oct4 mRNAs in 
Y430C cells compared to WT (Figure Ch4-11B), suggesting the BRD4 that remains bound 
at CREs of these genes in Y430C mESCs is sufficient for their transcription.  
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Figure Ch4-11 Effect of decreased BRD4 binding on transcription of target genes. 
A) RT-qPCR measuring mRNA concentration of BRD4 target genes after treatment with 
(+)-JQ1 (JQ1+) as a percentage of concentration after treatment with (-)-JQ1 (JQ1-). 
Data are represented as mean +/- SEM from 3 technical replicates. B) RT-qPCR 
measuring mRNA concentration for BRD4 target genes in WT and Y430C mESCs. 
Y430C mRNA concentration is shown relative to WT concentration, set at 1. Data are 




   
 
4.3.3 4sU sequencing 
Given the decreased occupancy of Y430C-BRD4 at the CREs associated with BRD4 target 
genes (Figure Ch4-5&9), it was surprising that there was no change in their mRNA levels in 
Y430C cells. Cellular mRNA content,  however, is not only dependent on its synthesis, but 
also on its processing and decay (Wu and Brewer, 2012). It is therefore possible that the 
transcription of these genes is decreased in the mutant cells, but somehow compensated for 
– eg. By enhanced mRNA stability. To examine this possibility, I carried out 4sU-seq to 
analyse nascent RNA transcripts in WT and Y430C cells. I did this for two biological 
replicates, and both gave comparable results. Quality control, genome browser screenshots 
and heatmaps are shown for just one replicate, but Cufflinks analysis and expression plots 
use an average of both replicates.  
4.3.3.1 Quality control and mapping 
As for my ChIP-seq files, I first ran FASTQC on the 4sU-seq data to check their quality. The 
overall per base sequence quality was slightly lower than that of the ChIP-seq, with many 
values in the second mate-pairs dropping as low as 30 (Figure Ch4-12). However, this is still 
considered to be within an acceptable range. The samples showed no evidence of adaptor 
content. WT pair 2 did show overrepresentation of one sequence, but this was at a very low 
percentage (0.1014) and didn’t match any common contaminants. 
Since the files all passed the quality control step, I then mapped them to the mm9 genome 
using TopHat. TopHat aligns reads using Bowtie, as for ChIP-seq, but also provides 
information about splice junctions between exons (Trapnell, Pachter and Salzberg, 2009). 
100% of the reads were mapped to mm9 for both WT and Y430C, with 82.83% and 85.08% 
of these having corresponding paired reads (Table Ch4-3).
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  Passed QC Aligned to mm9 Properly paired  
WT 
Number of reads  355,979,124 355979124 197958934 
% of total reads  100 100 82.83 
Y430C 
 
Number of reads  388,181,585  388,181,585  246,358,506  
% of total reads  100 100 85.08 
Figure Ch4-12. 4sU-seq per base sequence quality. Graphs show quality (phred) 
scores at each base position for the four 4sU-seq FASTQ files, as calculated by FASTQC 
Table Ch4-3. Mapping statistics for WT and Y430C 4sU-seq FASTQ files. Files 




   
 
4.3.3.2 Visualisation and peak-calling  
I made bedgraphs from the mapped reads and visualised them on the UCSC genome 
browser. As expected, peaks were observed mainly over the gene bodies of genes transcribed 
in mESCs, and are present on either the + or – strand, consistent with strand specific 
sequencing.  
At the BRD4 target genes, where I had seen decreased occupancy of BRD4 at the associated 
SEs, I found a similar number of 4sU-seq reads between WT and Y430C (Figure Ch4-
13&14&16B). At Gsc, where there was little BRD4 occupancy at the promoter in WT and 
Y430C cells, I saw no transcription as expected (Figure Ch4-14). Heatmaps comparing the 
score distributions of WT and Y430C reads across gene bodies, showed that the similarity in 
transcript levels seen at BRD4 target genes is consistent across a majority of genes (Figure 
Ch4-15), and comparison of Y430C and WT expression profiles over exons showed that 
there was a good correlation overall (Figure Ch4-16A). The 4sU data therefore confirms the 
RT-qPCR results, suggesting there is little change in the transcription of Klf4, Nanog, Sox2 
and Oct4 despite the loss of BRD4 CRE binding. 
I used the Cufflinks programme (Trapnell et al., 2010, 2013) to assemble the aligned RNA-
seq reads into parsimonious sets of transcripts. Combining the assembled transcripts from 
both replicates of WT and Y430C mapped reads generated a file of 313,343 transcripts 
corresponding to 23701 genes. Cufflinks estimates the number of cDNA fragments that 
originate from each transcript – the FPKM (Fragments Per Kilobase of transcript per Million 
mapped reads) - which is proportional to the expression of that transcript. 
I then used the Cuffdiff module to identify transcripts that were differentially expressed in 
the WT and Y430C cells. Cuffdiff analysis showed that the majority of transcript levels were 
similar between WT and Y430C mESCs, corresponding with what I had observed for the 
SE associated genes. 40 genes were found to be expressed significantly more in WT over 
Y430C, whilst 114 were significantly enriched in Y430C over WT (p<0.05, fold enrichment 
>2). The DAVID functional analysis tool identified an enrichment of terms associated with 
‘heparin binding’ in the WT enriched genes, and terms associated with GTP binding, immune 
response, nucleosome assembly and proteolysis in Y430C enriched genes (p <0.05) (data not 
shown). Most of these terms are not relevant to the loss of BRD4 binding in ES cells, and 
the genes do not correlate with regions of decreased BRD4 binding, suggesting they may be 
indirect targets of Y430C-BRD4.  
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As I will discuss in Chapter 5, the Y430C mESCs have an altered cell cycle, with a greater 
proportion of cells in G2/M phase and less in G1, compared to WT cells. It is possible that 
the transcription of these differentially expressed transcripts is coupled to the cell cycle, in 
which case I would expect to see an increase in the transcription of genes that are upregulated 
in G2/M in the Y430C cells.  
The Y430C enriched term ‘nucleosome assembly’, represents a number of histone genes. In 
my 4sU-seq I see an increase in the transcription of histone cluster genes in Y430C cells 
(Figure Ch4-16C). Visualisation of the 4sU peaks using the UCSC genome browser, shows 
that transcription is increased in histone cluster 1 (Figure Ch4-17), 2 (Figure Ch4-18A&B) 
and 3 (Figure Ch4-18C), in Y430C cells compared to WT. This difference is most striking at 
histone cluster 3 genes, Hist3h2bb-ps and Hist3h2a, and BRD4 BD2 is known to bind to H3 
(Z. Liu et al., 2017). 
A subset of histone genes are known to be highly cell cycle regulated; during each round of 
cell division new histones must be rapidly synthesised during S phase in order to maintain 
normal DNA-histone ratios (Mei et al., 2017). In contrast, overexpression of the core histones 
outside of S phase is toxic to the cell (Kurat et al., 2011). This results in 35-fold more histone 
mRNA in S phase compared to G1 and G2 phases (Harris et al., 1991), achieved through 
both repression in G1 and G2 and transcriptional activation just prior to S phase (Gunjan, 
Paik and Verreault, 2005). Therefore, the upregulation of histone genes may be a result of 
the increased proportion of Y430C cells that are in S-phase (Figure Ch5-2).  
Overall I concluded that the decreased BRD4 binding at CREs in Y430C mESCs does not 
directly affect the transcription of associated genes.  
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Figure Ch4-13. Genome browser view of nascent transcription at BRD4 target 
genes. UCSC browser screenshot showing 4sU-seq (RP10M) over A) Klf4, B) Sox2 and 
C) Nanog genes. Tracks 1 and 2 = 4sU-seq in WT and Y430C mESCs, tracks 3-6 = 









Figure Ch4-14. Genome browser view of nascent transcription at Gsc and c-Myc. 
UCSC browser screenshot showing 4sU-seq (RP10M) over A) Gsc and B) c-Myc genes. 
Tracks 1 and 2 = 4sU-seq in WT and Y430C mESCs, tracks 3-6 = previously published 





   
 
 
Figure Ch4-15. Nascent transcription over gene bodies. Heatmaps show distribution 
of reads across transcribed regions in WT and Y430C 4sU-seq data. Colour scale 
represents log2 read coverage normalised by RPKM. Regions 1 Kb upstream and 3 Kb 
downstream of the transcription start sites are plotted.  
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Figure Ch4-16. Nascent expression of exons in WT vs Y430C mESCs. A) Log2 
(FPKM) for exons in WT 4sU data (x axis) plotted against Log2 (FPKM) for Y430C 4sU 
data (y-axis). B&C) Same plots as in A), with a set of pluripotency genes and histone 
cluster genes respectively, highlighted in orange. Values are the average of 2 biological 
replicates. Grey dotted line = regression line 
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Figure Ch4-17. Genome browser view of nascent transcription at histone cluster 1 
genes. UCSC browser screenshot showing 4sU-seq (RP10M) over histone cluster 1 
genes. A) Hist1h1c, Hist1h3c, Hist1h2bb, Hist1h2ab, Hist1h3b, Hist1h4b, Hist1h4a, Hist1h3a 
and Hist1h1a. B) Hist1h2ba and Hist1h2aa. C) Hist1h2ac, Hist1h2bc, Hist1h1ht and Hist1h4c. 
Tracks 1 and 2 = 4sU-seq in WT and Y430C mESCs, tracks 3-6 = previously published 









Figure Ch4-18. Genome browser view of nascent transcription at histone cluster 2 
and 3 genes. UCSC browser screenshot showing 4sU-seq (RP10M) over histone cluster 
2 - A) Hist2h2ab, Hist2h2ac, Hist2h2be, Hist2h3c1, Hist2h2aa2, Hist2h3c1 and B) Hist2h4, 
Hist2h2bb and Hist2h3b – and Histone cluster 3 - C) Hist3h2bb-ps and Hist3h2a. Tracks 1 
and 2 = 4sU-seq in WT and Y430C mESCs, tracks 3-6 = previously published –ChIP-




   
 
4.3.4 RNA-sequencing with spike-in control 
In my 4sU-seq data I have seen no difference in the levels of expression between WT and 
Y430C for most genomic regions. However, by normalising WT and Y430C to each other, 
it is possible that a global change in transcription is being masked (Chen et al., 2016). 
I therefore used RNA-seq to compare the overall transcription in WT and Y430C mESCs, 
this time spiking in a small amount of drosophila RNA. The spike-in and test samples were 
combined at the cell stage (200,000 drosophila cells were combined with 10,000,000 mESCs), 
so the samples were treated the same from this point on. I did this for three biological repeats, 
with similar results for each. Genome browser screen shots and heatmaps show results from 
one replicate, whilst expression plots represent an average of all three replicates. After 
normalisation to the spike-in control, I found that the results largely corroborate those of 
the 4sU data – there is little difference in transcription of the BRD4 target pluripotency genes 
(Figure Ch4-19,20&22B), or overall (Figure Ch4-21&22A), between WT and Y430C mESCs. 
There is a noticeable decrease in nascent c-Myc transcripts in the Y430C cells (Figure Ch4-
20B), but this is not present in the other 2 replicates.  
Plotting expression of WT vs Y430C (Figure Ch4-22A), does show more divergence in this 
experiment than that of the 4sU data without the spike-in (Figure Ch4-16A). These 
differences are in part accounted for by the expression of histone cluster genes. In the 4sU 
data, these show a near consistent increase in expression in Y430C over WT. This general 
trend is also seen in the spike-in experiment, however there are a few outliers, that show 
greatly differential expression between WT and Y430C (Figure Ch4-22C). Some of these are 
much more highly expressed in the Y430C cells than in WT, which is similar to what was 
seen in the 4sU data (Figure Ch4-16C,17-19), however a couple are also shown to be 
expressed more in the WT (Figure Ch4-22C). I checked the profiles across these differentially 
expressed histone cluster genes on UCSC, and this confirmed their differences in expression 
(Figure Ch4-23). The increased variability of expression of these genes in the total RNA-seq 
could be a reflection of their post-transcriptional regulation (since 4sU-seq measures only 
nascent transcripts). For instance these transcripts are known to be rapidly degraded at the 
end of S phase (Kaygun and Marzluff, 2005). 
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Figure Ch4-19. Genome browser view of transcription at BRD4 target genes after 
normalisation to spike-in. UCSC browser screenshot showing RNA-seq (RP10M) over 
A) Sox2, B) Klf4 and C) Nanog genes. Tracks 1 and 2 = 4sU-seq in WT and Y430C 
mESCs, tracks 3-6 = previously published ChIP-seq data for various histone 




   
 
 
Figure Ch4-20. Genome browser view of transcription at Gsc and c-Myc after 
normalisation to spike-in. UCSC browser screenshot showing RNA-seq (RP10M) over 
A) Gsc and B) c-Myc genes. Tracks 1 and 2 = 4sU-seq in WT and Y430C mESCs, tracks 
3-6 = previously published ChIP-seq data for various histone modifications, track 7 = 





   
 
 
Figure Ch4-21. Transcription over gene bodies, with spike-in control. Heatmaps 
show distribution of reads across transcribed regions in WT and Y430C RNA-seq data, 
after normalisation to spike-in. Colour scale represents log2 read coverage normalised by 
reads per kilobase per million. Regions 1 Kb upstream and 3 Kb downstream of the 
transcription start sites are plotted.  
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Figure Ch4-22. Expression of exons in WT vs Y430C mESCs, normalised to spike-
in control. A) Log2 (FPKM) for exons in WT data (x axis) plotted against Log2 (FPKM) 
for Y430C data (y-axis). B&C) Same plots as in A), with a set of pluripotency genes and 
histone cluster genes respectively, highlighted in orange. Values are the average of 3 
biological replicates. Grey dotted line = regression line 
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Figure Ch4-23. Genome browser view of transcription after normalisation to spike-
in. UCSC browser screenshot showing RNA-seq (RP10M) over A) Hist2h2aa2 and 





   
 
4.4 Assessing the effect of reduced BRD4 
CRE-occupancy on enhancer 
transcription  
Like promoters, active enhancers themselves recruit RNAPII, resulting in the bi-directional 
transcription of a novel class of transcripts, termed eRNAs (Kim et al., 2010). These eRNAs 
are short (<2 Kb ) (Kim et al., 2010) and they are rapidly degraded by the exosome (Ogami, 
Chen and Manley, 2018). It has been suggested that the transcription of eRNAs may have a 
functional role in the regulation of gene expression (Meng and Blaine, 2017).  
BRD4 has been implicated in the regulation of eRNAs. On the one hand BRD4 has been 
shown to facilitate eRNA transcription (Kanno et al., 2014). Others suggest however, that 
BRD4 inhibits eRNA synthesis through the recruitment of a complex of 7SK snRNA and 
the chromatin remodelling complex BAF to enhancers. BAF remodels chromatin and 
decreases the binding of certain TFs. 7SK is particularly enriched at SEs and these regions 
were found to be most sensitive to 7SK depletion (Flynn et al., 2016).  
eRNAs are hard to study through steady-state RNA assays such as RNA-seq, due to their 
unstable nature, however their transcription can be captured through nascent transcription 
assays such as 4sU-seq (Azofeifa et al., 2018). To address whether the decreased BRD4 
occupancy at enhancers and SEs in Y430C cells causes an increase in eRNA transcription, I 
looked at my 4sU-seq data specifically over enhancer regions. 
I found that reads were indeed generated over active TEs and SEs (Figure Ch4-24, 25&26A), 
but none over sonic brain enhancers 2 and 4 (SBE2 and SBE4) (Figure Ch4-26B), which are 
inactive in mESCs. At these specific regions I was unable to see an obvious difference 
between the amount of transcription in WT and Y430C cells (Figure Ch4-24&25). The 
ATAC-seq track shown in figures Ch4-24-26 was generated in mESCs by Yatendra Kumar 
(Bickmore Lab) and allows me to identify regions of open chromatin, where I would expect 
transcription to occur; ATAC-seq uses a hyperactive Tn5 transposase to insert sequencing 
adapters into chromatin. These adapters are inserted specifically into regions accessible to 
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the transposase, meaning that the sequencing reads can be used to identify regions of 
increased accessibility and to infer nucleosome positioning (Buenrostro et al., 2015).  
I generated heatmaps showing the distribution of 4sU-seq reads across SEs and TEs (figure 
Ch4-26A&B), and confirmed that there was little difference in read coverage between WT 
and Y430C cells. TEs showed a very small enrichment of reads compared to a 60 Kb 
surrounding area (Figure Ch4-27A). However when I looked specifically at those TEs that 
were bound by BRD4 (identified by intersecting TE regions with peaks called in WT BRD4 
ChIP-seq), I saw an increase in the read coverage over TEs (Figure Ch4-27C). A similar 
increase was also seen for SEs that are bound by BRD4 (Figure Ch-27D). These data suggest 











Figure Ch4-24. Nascent transcription at SEs of BRD4 target genes. UCSC 
browser screenshot showing 4sU-seq (RP10M) over A) Nanog SEs and B) Sox2 SE. 
Tracks 1 and 2 = 4sU-seq in WT and Y430C mESCs, tracks 3-6 = previously 




   
 
 
Figure Ch4-25. Nascent transcription at Klf4 SE and the inactive SBE2 enhancer. 
UCSC browser screenshot showing 4sU-seq (RP10M) over A) Klf4 SE and B) a region of 
Chr5 including SBE2 (SBE2 = Chr5: 29202018-29203152, red bar). Tracks 1 and 2 = 
4sU-seq in WT and Y430C mESCs, tracks 3-6 = previously published 4sU-seq data for 
various histone modifications, track 7 = DNase I hypersensitivity 
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Figure Ch4-26. Nascent transcription at TEs. UCSC browser screenshot showing 
4sU-seq (RP10M) over TEs associated with A) Lrrc8c, B) 2310015A10Rik and C) Gnai1.  
Tracks 1 and 2 = 4sU-seq in WT and Y430C mESCs, tracks 3-6 = previously published 
4sU-seq data for various histone modifications, track 7 = DNase I hypersensitivity. Black 
bars indicates strong enhancers as defined by ChromHMM  
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Figure Ch4-27. Nascent transcription over enhancers. Heatmaps show distribution 
of reads across A) TEs, B) SEs, C) TEs with BRD4 peaks and D) SEs with BRD4 
peaks in WT and Y430C 4sU-seq data.  Colour scale represents log2 read coverage 
normalised by RPKM. Plots show regions +/- 30Kb.  
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4.5 Effect on pluripotency 
BRD4 binding to CREs has been shown to maintain self-renewal and pluripotency in mESCs 
(Di Micco et al., 2014). I therefore wondered whether the decrease in BRD4 at these sites 
would cause a loss of the pluripotent stem-cell state of Y430C mESCs. 
To address this I used IF to compare the levels of NANOG, ESRRB, SOX2 and OCT4 in 
WT and Y430C mESCs. These TFs are all involved in maintaining the ES cell genetic 
programme, with NANOG, SOX2 and OCT4 being considered ‘master regulators’ (X. 
Zhang et al., 2008). Furthermore expression of Sox2, Nanog and Esrrb has been shown to be 
downregulated upon differentiation (Nair et al., 2015), making their expression a good marker 
of ESCs.  
Both WT and Y430C mESCs expressed all four stem-cell markers as expected (Figure Ch4-
28). Expression of these proteins, particularly NANOG and ESRRB, was somewhat 
heterogeneous. This is not surprising however, as pluripotency-related genes are known to 
show heterogeneous expression and temporal fluctuations in mESCs cultured in standard 
LIF containing serum (Marucci and Lucia, 2017). These fluctuations are thought to correlate 
with potency of the cells; mESCs are pluripotent at the population level, but subpopulations 
may show varying propensities towards differentiation (Marucci and Lucia, 2017). Growing 
the cells in 2I media – which uses a combination of LIF and two inhibitors to maintain ESCs 
in a naive ground state (Sim et al., 2017) – might overcome this heterogeneity.  
I observed very little difference between the intensity of stem-cell markers in WT and Y430C 
mESCs, suggesting that there is no difference in the expression of these genes at the protein 
level, as well as at the transcript level. I would therefore expect the Y430C mESCs to behave 
similarly to WT cells in terms of their stem-cell properties.  IF is not a quantitative measure 




   
 
Figure Ch4-28. Expression of stem cell marker proteins in WT and Y430C mESCs. 
Representative images of WT and Y430C mESCs upon A) DAPI staining, and OCT4, 





   
 
4.6 Conclusions  
The aim of this chapter was to assess how the decreased affinity of BRD4-Y430C for acetyl-
lysines affects genome wide binding of BRD4, and what consequences this has for gene 
expression.  
I found that BRD4 is enriched at CREs compared to other genomic regions, but that this 
enrichment is seen in both WT and Y430C mESCs. However I did find decreased binding 
the Y430C-BRD4 compared to WT. The decreased affinity of BRD4-Y430C to acetyl-lysines 
appears to affect binding at TEs, SEs and promoters more than other regions. Given the 
known regulatory roles of BRD4 at these regions, it might be assumed that the loss of BRD4 
at these sites would influence gene expression.   
I was able to show that the inhibition of BRD4 binding by (+)-JQ1 did decrease the 
expression of pluripotency related genes – known targets of BRD4 in mESCs. However, 
despite decreased BRD4 binding at CREs in Y430C cells, there was no change in the nascent 
transcription of BRD4 target genes, nor on a more global level. These discrepancies could 
be explained by the lack of JQ1 selectivity for BET proteins; JQ1 has been shown to 
effectively inhibit BRD2, BRD3 and BRD4 (Filippakopoulos et al., 2010). This lack of 
selectivity is common amongst many of the available BETi and is likely due to the high degree 
of sequence conservation, especially at those residues important for acetyl-lysine binding (Z. 
Liu et al., 2017). Some more specific BETi are available and could be used to test this. For 
instance, RVX-208 is specific to BRD4-BD2 (Ferri, Petosa and McKenna, 2016), whilst 
BAY1238097 shows some selectivity for BRD4 - binding to BRD4 BDs 10-fold and 39-fold 
more than BRD3 and BRD2 respectively – but is no longer in development (reasons 
undisclosed)(Z. Liu et al., 2017).  
I observed no differences at the protein level for BRD4 target genes, with IF for stem cell 
markers showing similar expression in WT and Y430C cells. These results were surprising, 
and somewhat contradictory to recent publications that report transcriptional misregulation 
in CdLS patients. Nevertheless, I conclude that the diminished level of BRD4 present at 
CREs in Y430C mESCs is sufficient for its roles in transcriptional regulation and stem-cell 
maintenance, at least in the context of mESCs. Moreover, the results in this chapter are 
compatible with the absence of any major developmental abnormalities in the Y430C mouse 
embryos (Figure Ch3-4). 
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BRD4 has been implicated in the stimulation of eRNA elongation, in a manner dependent 
on BD-mediated acetyl-lysine interactions (Kanno et al., 2014), but also in the suppression 
of eRNA transcription, through 7SK-BAF recruitment (Flynn et al., 2016). Whilst I was able 
to detect transcription at TEs and SEs in the mESCs, I found that there was no difference 
in the amounts of transcription at these regions between WT and Y430C cells. I found that 
eRNA transcription is more common at enhancers occupied by BRD4, which could support 
either of the proposed roles of BRD4 in eRNA regulation, or a combination of them both -  
BRD4 at enhancers may promote the transcriptional elongation of eRNAs, and at the same 


























Chapter 5: An altered DNA 













































   
 
5.1 Comparing the cell cycles of WT and 
Y430C mESCs 
5.1.1 Y430C mESCs proliferate more slowly than WT  
During routine culturing of the Y430C-BRD4 mESCs and their WT counterparts, I noticed 
that the mutant cells were doubling in number more slowly. To quantify this difference, I 
conducted some simple cell growth assays, plating the cells at a known density and counting 
them every 24 hours for the following 4 days (Figure Ch5-1). This confirmed my observation 
– by day 3 the WT cultures had reached saturation, whilst the number of cells in the Y430C 
cultures were less than half those of the WT and continued to double over the next 24 hours. 
This suggests that the mutant cells may be dividing twice as slowly as the WT cells, and 
therefore have a slowed cell cycle. Alternatively, the Y430C cells could be doubling at the 
same rate as the WT cells but undergoing apoptosis, resulting in a slower increase in cell 
number. The lack of a G1/S phase cell cycle checkpoint renders ESCs prone to apoptosis in 
response to DNA damage (Wang et al., 2009).  
5.1.2 Flow cytometry profiles of WT and Y430C mESCs 
Flow cytometry with propidium iodide stained WT and Y430C mESCs, showed that there 
was indeed a difference in the cell cycle profiles of these cells (Figure Ch5-2A&B). A larger 
proportion of Y430C cells were in the G2/M and S phases of the cell cycle compared to WT 
(Figure Ch5-2). Figure Ch5-2 shows the results for one biological replicate, but the second 
replicate showed a similar trend. I did flow cytometry for the biological replicate cell lines 
and found similar trends.  
As ES cells lack a G1 checkpoint (Aladjem et al., 1998), the differences in cell cycle between 
WT and Y430C mESCs cannot be caused by impaired activation of the G1/S checkpoint in 
the mutant cells. Instead, the Y430C profile could be the result of a problem with DNA 
damage during replication, activating the intra-S checkpoint and slowing the synthesis of new 
DNA (Willis and Rhind, 2009) or activation of the G2/M checkpoint, delaying the cells from 
transitioning into mitosis (Liu et al., 2000).  
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5.1.3 Comparing CHK1-P levels in WT and Y430C mESCs in response to DNA 
damage 
Cell cycle checkpoints can be activated as a result of the DDR. Recognition of DNA damage 
by sensor proteins initiates a signalling cascade that results in the phosphorylation and 
activation of the checkpoint kinases CHK1 and CHK2. These kinases activate cell cycle 
checkpoints to delay progression through the cell cycle, preventing propagation of the 
damage to the next generation of cells (Bartek and Lukas, 2003).  
CHK1 is the main checkpoint kinase required for activation of the G2/M (Zhao, Watkins 
and Piwnica-Worms, 2002), and intra-S cell cycle checkpoints, including in mESCs (Liu et al., 
2000). To determine whether the altered cell cycle in the Y430C mESCs was caused by 
increased G2/M checkpoint activation I used immunoblotting to analyse the 
phosphorylation of CHK1 in response to DNA damage in WT and Y430C mESCs.  
Cells were treated with NCS, a radiomimetic drug which mainly induces DSBs (Povirk, 2012), 
and allowed to ‘recover’ for various lengths of time before nuclear protein extraction. 
Immunoblotting showed an increase in phosphorylated CHK1 (CHK1-P) in both WT and 
mutant ESCs 1 hour post NCS treatment, which is resolved by 16 hours. However, the levels 
Figure Ch5-2. WT and Y430C cell cycle profiles determined by flow cytometry. 
Overlaid flow cytometry profiles for WT and Y430C cells. Graphs illustrate the cell count 







   
 
of CHK1-P are greater in the Y430C mESCs, suggesting an increase in checkpoint activation 
in the mutant cells (Figure Ch5-3A). Lamin B was used as a loading control; the similar band 
intensities across the different time-points indicates that a similar amount of protein has been 
loaded in each lane, meaning the differences in CHK1-P intensity are not a result of variable 
loading.  
Increased CHK1-P supports the theory that the altered cell cycle in the Y430C mESCs is a 
result of a G2/M delay and/or prolonged S phase, indicating that there may be increased 
DNA damage signalling in the BRD4 mutant cells.
Figure Ch5-3. CHK1 phosphorylation in response to DSBs. Immunoblot for CHK1-
P and Lamin B (control) in WT and Y430C mESCs after time-course of NCS treatment. 
Cells were treated with NCS and allowed to recover for 1, 16 and 20 hours. –NCS = 




   
 
5.2 Analysing the DDR in WT and Y430C 
mESCs  
5.2.1 The effect of NCS treatment on DDR signalling in WT and Y430C mESCs  
The increased G2/M cell cycle checkpoint activation made me question whether Y430C 
mESCs were more prone to DNA damage than WT cells. BRD4 is known to regulate DNA 
damage signalling and repair through cell cycle checkpoint activation, recruitment of DDR 
proteins and chromatin remodelling (Floyd et al., 2013; Pongas et al., 2017; Li et al., 2018; 
Zhang et al., 2018). An increased sensitivity to DNA damage has been observed in some cell 
lines derived from CdLS patients, including those with NIPBL mutations. Increased 
sensitivity occurs especially in G2 and this has been suggested to be due to defective repair 
of DSBs by HR (Vrouwe et al., 2007).  
I therefore set out to compare the responses of both cell lines to DNA damage. 
Phosphorylation of the histone H2A variant H2AX (γH2AX) occurs early on in the DDR 
(Figure Ch1-22) and is often the preferred marker of DNA damage. However, mESCs are 
known to have high basal levels of γH2AX, even in the absence of genotoxic stress 
(Turinetto et al., 2012). Indeed, through some preliminary experiments, I found that a large 
proportion of untreated WT mESCs contained >10 γH2AX foci. These γH2AX foci did not 
colocalise with 53BP1, a marker of DNA damage that functions downstream of γH2AX  
(Zimmermann and De Lange, 2014) (data not shown). This indicated that γH2AX was not 
an appropriate marker for this experiment and I instead chose to use 53BP1 to mark sites of 
DNA damage.  
53BP1 forms large foci at DSBs (Zimmermann and De Lange, 2014) (Figure Ch1-23), and 
is important for the regulation of DNA repair pathway choice (Ochs et al., 2016) and 
promotion of cell cycle checkpoint signalling (Ljungman, 2010). 53BP1 can be recruited to 
DSBs by BET proteins including BRD4 (Stanlie et al., 2014; Li et al., 2018).   
I treated both WT and Y430C cells with NCS, allowed them to recover for various lengths 
of time, and then carried out IF for 53BP1 (Figure Ch5-4). Nuclei contained a small number 
of foci prior to induction of damage, and this increased dramatically 1 hour after NCS 
treatment, indicating the induction of a large number of DSBs. By 16 and 20 hours these foci 
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were reduced in number, likely due to the repair of these breaks and a decrease in DNA 
damage signalling.  
Interestingly, there were some notable differences in 53BP1 foci size and kinetics between 
the WT and Y430C cells. Firstly, the 53BP1 foci in the Y430C cells appeared to be larger 
than those in WT cells (Figure Ch5-4). To determine whether this observation was 
quantifiably significant, I used a macro script in ImageJ to measure the area of the foci in 
each cell. This confirmed that the foci were larger in Y430C cells at all time points and was 
highly significant after NCS treatment (Figure Ch5-5A). Secondly, whilst the number of foci 
decreased from 1 hour to 16 hours in both cell lines, this decrease was smaller in the Y430C 
cells (Figure Ch5-5B); between 1 and 16 hours after NCS treatment the number of cells with 
> 5 foci decreased around 46-fold in WT cells, compared to just 4.6-fold in Y430C cells.  
The greater size and number of persistent 53BP1 foci in the Y430C cells could be a result of 
increased DNA damage signalling; as the DDR progresses the associated factors and 
modifications spread from the original site of damage, and this is reflected in the size of the 
protein foci (Polo and Jackson, 2011). BRD4 is known to play a role in limiting this spread 
and to shield chromatin from ATM kinase signalling. After depletion of Brd4 (RNAi 
knockdown), there is an increase in the number and size of 53BP1 (and H2AX) irradiation 
induced foci (IRIF) (Floyd et al., 2013). This is very similar to the observation I have made 























































































































































































   
 
 
Figure Ch5-5. Counting and measuring 53BP1 foci in WT and Y430C cells in 
response to DSB induction. A) Box-plot shows area of 53BP1 foci (m2) in WT and 
Y430C cells after treatment with NCS and release for the indicated times. –NCS = 
untreated cells. Horizontal lines within boxes show medians, boxes are inter-quartile 
ranges and whiskers are range. Outliers are shown as circles. P-values were calculated 
with t-test. B) Graph shows percentage of cells that contain > 5 53BP1 foci after release 
from NCS treatment for given time points. NCS- = untreated cells. Data are represented 





   
 
5.2.2 The effect of BRD4 inhibition on DNA damage response signalling in WT and 
Y430C mESCs  
If the increased size and number of 53BP1 foci in Y430C cells after treatment with DNA 
damage inducing agents is indeed attributable to the reduced binding of the mutant BRD4 
to chromatin, then inhibition of BRD4 binding by JQ1 should cause a similar phenotype. To 
test this, I treated WT and Y430C cells with (+)-JQ1 or (-)-JQ1 before repeating the NCS 
treatments, followed by 53BP1 IF.  
Treatment with (+)-JQ1 caused increased numbers of 53BP1 foci in both WT and Y430C 
cells compared to (-)-JQ1, both before and after treatment with NCS (Figure Ch5-6). This is 
in contrast to the previous experiment where, in the absence of any JQ1, significant 
differences between the number of foci in WT and Y430C cells were only seen after NCS 
treatment (Figure Ch5-5). This is not surprising as I have shown by ChIP that binding of 
BRD4 is more strongly perturbed by (+)-JQ1 than by the reduced acetylated histone affinity 
of the Y430C mutation (Figure Ch4-10). Furthermore, RT-qPCR showed that (+)-JQ1 
treatment causes dysregulation of BRD4 target gene transcription (Figure Ch4-11A) which I 
have shown does not occur in the Y430C mESCs (Figure Ch411B). The significant 
difference in the number of cells with >5 53BP1 foci between the mutant and WT cells was 
lost with (+)-JQ1 treatment. 
I conclude that the increased DDR phenotype observed in the Y430C cells could indeed be 
explained by the impaired binding of BRD4 to chromatin.  
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Figure Ch5-6. Percentage of cells with >5 53BP1 foci after NCS treatment, with or 
with JQ1+/-. Graph shows percentage of cells that contain > 5 53BP1 foci after release 
from NCS treatment for given time points. NCS- = untreated cells. Data is represented 
as mean +/- SEM from 3 biological replicates. P-values calculated with t-test. JQ1- = (-




   
 
5.3 Investigating potential causes of 
increased 53BP1 foci in Y430C mESCs 
The increase in the number and size of persistent 53BP1 foci after DNA damage induction, 
associated with the reduced BRD4 binding to chromatin in Y430C cells, suggests that the 
role of BRD4 in inhibiting the spread of DNA damage signalling (Li et al., 2018) could be 
perturbed in the Y430C cells.  I hypothesise that the decrease in affinity of BRD4 to acetyl-
lysines causes decreased recruitment of BRD4 to DSBs, resulting in the increased spread of 
DNA damage signalling. However, there are other potential explanations for this phenotype, 
which I will discuss in more detail.  
5.3.1 Sensitivity to replication stress? 
Activation of the G2/M and/or intra-S checkpoints can also occur in response to replication 
stress; the presence of stalled replication forks induces the phosphorylation of CHK1, 
leading to the phosphorylation and subsequent degradation of CDC25A (Zhao, Watkins and 
Piwnica-Worms, 2002), which is required for the progression through the cell cycle 
(Timofeev et al., 2010). I therefore thought it was possible that the increased DDR phenotype 
in the Y430C mESCs could be caused by an increased sensitivity to replication stress.  
5.3.1.1 The effect of HU treatment on DDR signalling in WT and Y430C mESCs  
I tested the response of WT and Y430C mESCs to DNA damage induced by HU, to 
determine if damage induced by replication stress would result in a greater increase in 53BP1 
foci number than damage induced by NCS.  
HU is an inhibitor of ribonucleotide reductase, the enzyme responsible for the reduction of 
ribonucleoside diphosphates to deoxyribonucleotides, required for DNA replication and 
repair. Consequently, HU treatment reversibly inhibits DNA synthesis, resulting in 
replication stress – the stalling of replication forks and DNA damage (Singh and Xu, 2016).  
I treated WT and Y430C cells with 50 mM HU and left them to recover for 1, 16 and 20 
hours, before carrying out IF for 53BP1. The overall trend was similar to that seen with NCS 
treatment (Figure Ch5-7).  
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If the Y430C cells were more sensitive to DNA damage caused by replication stress, I would 
expect to see a greater difference between the WT and Y430C cells when treated with HU 
than with NCS. However, the difference in the size of 53BP1 foci between WT and Y430C 
cells wasn’t as large after HU treatment as it was for NCS. Whilst a slight increase in foci area 
was observed in Y430C cells at all time points, this was only significantly higher than the WT 
cells at 1 hour after HU treatment (Figure Ch5-7A).  
As for NCS, I found that there were significantly more cells with >5 and >10 foci 20 hours 
after HU treatment in the mutant Y430C cells compared to WT (Figure Ch5-7B). 
Furthermore, the Y430C cells were still slower to recover from the treatment (return towards 
the levels of 53BP1 foci seen before HU treatment). The magnitude of the difference 
between WT and Y430C cells in response to HU however, was not strikingly larger than that 
seen with NCS treatment, suggesting that the mutant cells are not specifically sensitive to 







   
 
 
Figure Ch5-7. Counting and measuring 53BP1 foci in WT and Y430C cells in 
response to replication stress. A) Box-plot show area of 53BP1 foci (m2) in WT and 
Y430C cells after treatment with HU and release for the indicated times. –HU = untreated 
cells. Horizontal lines within boxes show medians, boxes are inter-quartile ranges and 
whiskers are range. Outliers are shown as circles. P-values were calculated with t-test. B) 
Graph shows percentage of cells that contain greater than 5 53BP1 foci after release from 
HU treatment for given time points. HU- = untreated cells. Data is represented as mean 




   
 
5.3.1.2 Do 53BP1 foci represent OPT domains? 
Another explanation for the presence of persistent 53BP1 foci, is that they represent OPT 
(OCT1/PTF/transcription) domains – nuclear foci that arise in G1 but disappear in S phase, 
which were originally thought to represent sites of active transcription (Pombo et al., 1998). 
53BP1, along with γH2AX and MDC1, co-localise with these OPT domains (Harrigan et al., 
2011). These sites are enriched at common fragile sites, which often arise after incomplete 
DNA replication, and their incidence increases in response to replication stress. This suggests 
that these domains form in G1 as a consequence of incomplete DNA synthesis in the 
previous S phase and the induction of the DDR (Harrigan et al., 2011).  
If the 53BP1 foci that persist in Y430C mESCs, but not in WT cells, are in fact OPT domains, 
we would expect to see a large increase in the number of foci in the Y430C cells in response 
to replication stress. However, I found that incubating the cells with a low dose of aphidicolin 
(APH) actually had a larger effect on the WT cells than the Y430C cells. In WT cells the 
number of cells with >1, 5 or 10 foci increased significantly upon APH treatment. In Y430C 
cells, there was an increase in the number of foci but this was not statistically significant 
(Figure Ch5-8A). Furthermore, IF for OCT1 in the WT and Y430C mESCs showed that the 
persistent 53BP1 foci do not co-localise with OCT1 (Figure Ch5-8B). 
Together these data suggest that the persistent 53BP1 foci I see in the Y430C cells by IF are 









Figure Ch5-8. Response of WT and Y430C mESCs to replication stress. A) Graph 
shows percentage of cells that contain greater than 1, 5 or 10 53BP1 foci with or without 
APH treatment. Data is represented as mean +/- SEM from 3 biological replicates. P-
values calculated with t-test. B) Representative images of WT and Y430C mESCs upon 
DAPI staining and 53BP1 and OCT1 IF 16 hours post NCS treatment. Red arrows point 







   
 
5.3.2 Impaired DNA repair?  
The increase in foci number in the Y430C cells compared to WT is most significant at 16 
and 20 hours post NCS treatment (Figure Ch5-5B). This could indicate that there is a 
problem with DNA repair in the Brd4 mutant cells, causing 53BP1 to remain at the sites of 
damage for longer.  
5.3.2.1 Regulation of transcription of DNA repair genes  
BRD4 is directly involved in DNA repair through the transcriptional regulation of genes 
encoding DNA repair proteins (C. Sun et al., 2018; Li et al., 2018; Wilson et al., 2018). If the 
Y430C mutation were to affect the transcription of these genes, it could cause the increased 
53BP1 foci that I see in these cells. I therefore returned to my 4sU-seq and RNA-seq results 
to check for any differences in the transcription of DDR genes.   
Others have defined sets of genes that are mis-regulated when DNA damage repair pathways 
are perturbed; Peng et al., 2014 used genome-wide expression profiling to measure the cellular 
transcriptome reprogramming in HR-deficient (HRD) cells (deficient in BRCA1, RAD51 or 
MCPH1). Through microarray analysis of these cells they defined a HRD gene signature – a 
set of 230 genes whose expression differed by a factor of 2 or more. Li et al., 2018 found a 
set of NHEJ related genes to be differentially expressed after treatment of cells with JQ1.  
I compared the WT and Y430C profiles for these gene sets. Visualising the data on the UCSC 
genome browser, I did not observe any changes in transcription for both the 4sU-seq and 
RNA-seq datasets (Figure Ch5-9&10) (subset of genes shown). Plotting expression of exons 
in WT against Y430C also shows that these genes are expressed at a similar level in both cell 
lines (Figure Ch5-11). This suggests that transcriptional dysregulation of DNA repair genes 
is not the cause of the aberrant DDR signalling in the Y430C mESCs.
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Figure Ch5-11. Expression of DDR genes in WT vs Y430C mESCs. Log2 (FPKM) 
of WT exons against Y430C exons in A&C) 4sU data and B&D) RNA-seq data. HDR 
genes (A&B) and NHEJ genes (C&D) are highlighted in orange. Values are the average 
of 2 (4sU) or 3 (RNA) biological replicates. Grey dotted line = regression line 
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5.3.2.2 RAD51 binding at DSBs 
The absence of differences between DDR gene transcription in WT and Y430C cells does 
not rule out a problem with DNA repair itself; BRD4 may also regulate the chromatin 
environment around a DSB, altering accessibility to DDR proteins (Floyd et al., 2013; Pongas 
et al., 2017), and recruit and stabilise proteins of the DNA damage repair complex (Li et al., 
2018).  
RAD51 is a DDR protein that binds ssDNA after end-resection and is important for the 
regulation of HR at many steps (section 1.5.4.2)(Wright, Shah and Heyer, 2018b). To 
compare HR in the WT and Y430C mESCs, I induced damage with NCS and used IF to 
visualise RAD51 foci (Figure Ch5-12). Compared to WT, significantly more Y430C mESCs 
had RAD51 foci prior to NCS treatment and at 16 and 20 hours post treatment (Figure Ch5-
12&13). This corresponds with the results of the 53BP1 foci experiments (Figure Ch5-4&5) 
and supports the idea that Y430C cells have higher levels of endogenous breaks, and more 
persistent breaks, in response to induced damage. In contrast to 53BP1 focus formation 
however, considerably more WT cells had RAD51 foci than the Y430C cells at 1 hour post 
NCS treatment. This may indicate a slower rate of RAD51 recruitment to DSBs in the mutant 
cells, which could explain the increase in persistent foci after damage - if RAD51 is recruited 
more slowly, this could result in slower repair of the breaks. These results are consistent with 
the findings of Wilson et al., 2018, who found that BET protein inhibition caused a reduction 






















































































































































































Figure Ch5-13. Percentages of cells with RAD51 foci in WT and Y430C cells in 
response to DSB induction. Graphs show percentage of cells that contain A) >5 and 
B) >10 RAD51 foci after release from NCS treatment for given time points. NCS- = 
untreated cells. Data is represented as mean +/- SEM from 3 biological replicates. P-




   
 
5.3.3 eRNA transcription? 
It has been suggested that BRD4 inhibits bidirectional transcription from enhancers (section 
4.4) (Flynn et al., 2016). Such bidirectional transcription can result in convT – simultaneous 
transcription of a region on the sense and anti-sense strands -, particularly at SEs, where 
transcription start sites are highly clustered. This can lead to DNA damage through RNAPII 
collisions and activation-induced cytidine deamination (AID) (Meng et al., 2014). Therefore 
the loss of BRD4 from enhancers could result in increased damage mediated by convT.  
Through 4sU-seq, I have identified eRNAs at TEs and SEs. There are instances where these 
enhancers appear to be transcribed on both strands at the same time (Figure Ch4-24&25), 
suggesting convT. However, without carrying out single-cell analysis, there is no way of 
knowing whether this is occurring in one cell – ie. convT – or in different cells. Furthermore, 
whilst these eRNAs were present, I was unable to detect a difference in levels between WT 
and Y430C cells.  
To test whether transcription was contributing to the increased number of 53BP1 foci in 
Y430C mESCs, I treated WT and Y430C cells with 500 nM Triptolide (Trp) for 2 hours, and 
then carried out IF for 53BP1. Trp inhibits TFIIH to prevent transcription initiation (Chen 
et al., 2015). Trp treatment caused a significant decrease in the number of Y430C cells with 
>1 and >5 foci compared to the DMSO treated control cells (Figure Ch5-14). A slight 
decrease was observed in the WT cells after Trp treatment, but this was not significant. This 
suggests that transcription may be a cause of endogenous DNA damage in the Y430C 
mESCs.  
Trp is not specific to eRNAs however - it causes a global inhibition of transcription. 
Therefore, it is impossible to say from this data whether the decrease in 53BP1 foci in Y430C 
cells upon Trp treatment is caused by decreased eRNA transcription, or from decreased 
transcription in general. Furthermore, since Trp inhibits transcription initiation, it may not 
be the best inhibitor to use. An inhibitor of transcriptional elongation, such as DRB or 
flavopiridol (Bensaude, 2011), may be more appropriate, as it is during the elongation of 
eRNAs that RNAPII collisions would occur.  
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I have shown, through flow cytometry, that there is a difference between the cell cycles of 
WT and Y430C mESCs. The current gating suggests that a greater proportion of Y430C cells 
are in the G2/M phase of the cell cycle than in WT cells, which could be due to increased 
activation of the G2/M checkpoint. The categorisation of cells into cell cycle stages may 
need to be altered however, and it is possible that there are actually more Y430C cells in S 
phase than in WT cells, suggesting increased activation of the intra-S phase checkpoint. 
Either way, the flow cytometry results are supported by increased CHK1-P upon DNA 
damage in the Y430C cells compared to WT, and delay at either checkpoint would result in 
slower progression through the cell cycle. 
Cell cycle checkpoints are activated in response to replication stress and/or DNA damage 
(Bartek and Lukas, 2003). Induction of DSBs with NCS, and through replication fork stalling 
with HU, caused DDR signalling in WT and Y430C mESCs. After removal of the drugs the 
signalling decreased over time, but this decrease was less pronounced in the mutant cells. 
This shows that Y430C cells exhibit increased DDR signalling in response to ionising 
radiation and replication induced damage. Inhibition of BRD4 binding by JQ1 had a similar 
effect, increasing the number of foci in WT cells to greater than that seen in Y430C cells. 
Therefore, I conclude that the DDR phenotype in the Y430C mutant cells is a result of the 
decreased affinity of BRD4-Y430C to chromatin.  
Stalling of the cell cycle during S phase in the Y430C cells would suggest a problem with 
DNA replication. However, whilst APH treatment causes a significant increase in the 
number of WT cells with >5 53BP1 foci, there is little change in Y430C cells. Furthermore 
the 53BP1 foci in these cells do not co-localise with replication stress-induced OPT domains, 
and it has been reported that the loss of BRD4 binding (through BET inhibition by (+)-JQ1) 
Figure Ch5-14. Decreased number of 53BP1 foci after transcriptional inhibition in 
Y430C mESCs. A) Representative images of WT and Y430C mESCs upon 53BP1IF 
and DAPI staining, after treatment with DMSO control or 500 nM triptolide (Trp) for 2 
hours. B) Graph shows percentage of cells that contain >1, 5 or 10 53BP1 foci in WT 
and Y430C mESCs after treatment with DMSO control or 500 nM Trp for 2 hours. Data 
is represented as mean +/- SEM from 3 biological replicates. P-values were calculated 





   
 
causes decreased CHK1 phosphorylation and intra-S phase checkpoint signalling in cells 
undergoing replication stress (Zhang et al., 2018), which does not fit with the increased 
CHK1-P or the slower cell cycle that I have found in the Y430C cells.  Together these results 
suggest that the increased DDR signalling in Y430C cells is not caused by an increased 
sensitivity to replication stress. 
The Y430C mutation does not appear to affect the transcription of DDR proteins, despite it 
being shown by others that BRD4 regulates the expression of these genes (C. Sun et al., 2018; 
Li et al., 2018; Wilson et al., 2018). However, RAD51 IF showed a decrease in foci formation 
shortly after DSB induction, and an increase in persistent RAD51 foci at later time points, 
suggesting delayed RAD51 recruitment to DSBs in Y430C mESCs and impaired HR.  
Together these results lead me to hypothesise that the Y430C mutation reduces BRD4 
recruitment to DSBs (through reduced affinity for acetyl-lysine), and this affects the DDR in 
two ways: 1. Reduced inhibition of DDR protein spreading, leading to larger 53BP1 foci. 2. 
Delayed repair through HR. This slower rate of HR could be a result of a reduction in 
RAD51 recruitment by BRD4, or it could be that the loss of BRD4 affects HR upstream of 
RAD51, decreasing ssDNA for RAD51 to bind.   
BRD4 is thought to supress eRNA transcription to protect against convT and the subsequent 
DNA damage that this can cause (Flynn et al., 2016). I have found no difference in levels of 
eRNA between WT and Y430C mESCs, suggesting that the increased number and size of 
53BP1 foci in Y430C cells is not caused by an increase in convT at enhancers. However, 
inhibition of transcription with Trp did cause a significant decrease in endogenous 53BP1 
foci in Y430C cells. As eRNAs are seen in both WT and Y430C cells, it is possible that their 
transcription is a contributing factor to DSBs in both cell lines but that the increase in DDR 
signalling and reduced repair in Y430C cells renders these cells more sensitive to eRNA-
mediated damage. This would explain why the inhibition of transcription had a larger effect 
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6.1 Exploring 53BP1 occupancy by ChIP-
seq 
In Chapter 4, I showed that transcription occurs at enhancer elements (Figure Ch4-24&25), 
producing eRNAs, and that this is enriched at enhancers occupied by BRD4 (Figure Ch4-
26). BRD4 has been proposed to protect against DNA damage at these regions, by recruiting 
a complex of 7SK-BAF that inhibits excessive eRNA transcription (Flynn et al., 2016).  
In Chapter 5, I showed that Y430C mESCs have larger and more persistent 53BP1 foci in 
response to DNA damage, suggesting an increase in DNA damage signalling. If these foci 
are caused by convT at enhancers, I would expect to see 53BP1 localised at these regions of 
the genome. To determine the binding pattern of 53BP1 across the genome, I carried out 
ChIP-seq in the WT and Y430C mESCs using an antibody against 53BP1.  
This data is based on only one ChIP-seq replicate and so needs to be replicated and validated 
by ChIP-qPCR before any final conclusions can be drawn.  
6.1.1 Quality control  
The 53BP1 antibody that I used for IF (Novus; 100-304) in Chapter 5 has not been validated 
for ChIP-seq, and so I chose to use an alternative from the same manufacturer (Novus; 100-
904). Novus; 100-904 is a combination of Novus; 100-304 and another antibody (Novus; 
100-504) and has been previously used for ChIP by others.  
I performed 53BP1 ChIP using chromatin from WT and Y430C mESCs and made libraries 
for paired-end sequencing from the ChIP DNA, using their corresponding input samples as 
controls.  
FASTQC analysis showed that the sequencing results were suitable for further downstream 
applications. The per base sequence quality for this ChIP-seq was found to be acceptable for 
all samples (Figure Ch6-1), with scores generally above 28, suggesting a high accuracy of base 
calling. However, I did see a dip in the quality of the last base for all of the 53BP1 ChIP-seq 
samples. This is a common problem, attributable to the way the Illumina sequencing 
platform works. Illumina sequencing uses sequencing by synthesis. In this method all the 
sequences in a run are sequenced simultaneously in ensembles of identical molecules called 
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clusters. Sequencing is carried out by running a chemistry cycle, in which a tagged base is 
added to the end of each cluster, generating a single output sequence. The assumption is that 
every molecule is extended by one base. However, in reality, a small number of molecules 
will remain on the previous base, meaning that in the next cycle the signal coming from one 
cluster is actually a mix of signals from the current and previous base. The heterogeneity of 
the signal increases with each cycle, resulting in a decrease of per base sequence quality with 
increasing read length (Cliften, 2014).   
The samples showed no evidence of adaptor content or overrepresented sequences, and 
whilst there was low level sequence duplication, this was not enough to cause the samples to 
fail the QC.   
6.1.2 Mapping  
I mapped the sequenced DNA to the mm9 assembly of the mouse genome using Bowtie2 
(Langmead and Salzberg, 2012), and used Samtools (Li et al., 2009) flagstat to calculate the 
total number of reads, the number of reads correctly paired, and the number of reads 
successfully mapped (Table Ch6-1). This showed that all samples had over 60 million reads, 
100% of which had corresponding pairs for all samples. The percentage of mapped reads 
was high for all samples, ranging from 87.37-97.87%. 
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Figure Ch6-1. 53BP1 ChIP-seq per base sequence quality. Graphs show quality 




   
 
6.1.3 Visualisation 
I converted the mapped reads to bigwig format and visualised them on the UCSC genome 
browser. What was instantly apparent was the similarity in the 53BP1 binding pattern to that 
of BRD4 at enhancers; there are large peaks in the 53BP1 ChIP-seq at the SEs and TEs 
where I found BRD4 to be enriched (Figures Ch6-2 and Ch6-3A). This is interesting, as a 
role for 53BP1 at enhancers has not been well studied. 
The BRD4 ChIP-seq showed the number of reads across these BRD4 target regions to be 
higher in WT cells compared to Y430C cells (Figure Ch4-5). However, there is no obvious 
difference between WT and Y430C over the same regions for 53BP1 ChIP-seq (Figure Ch6-
2). Surprisingly there does appear to be more reads in the Y430C sample across the KLF4 
SE (Figure Ch6-2A), but this decrease is not apparent at the KLF4 promoter or consistent 
over other SEs (Figure Ch6-2B&C).  
There is very little evidence of 53BP1 binding at the Gsc promoter (Figure Ch6-3A) where 
BRD4 binding is also negligible (Figure Ch4-6). However, there are large, sharp, 53BP1 peaks 
at the TSS of many genes, such as Klf4 (Figure Ch6-2A), Nanog (Figure Ch6-2B), Sox2 (Ch6-
2C) and c-Myc (Figure Ch6-3B), which are not present in the BRD4 ChIP-seq. As with the 
53BP1 peaks at enhancers of these genes, the 53BP1 promoter peaks are of a similar size in 
WT and Y430C cells.  
BRD4 has been shown to recruit 53BP1 (Li et al., 2018), and so it is surprising that 53BP1 
occupancy doesn’t decrease in Y430C mESCs at regions where BRD4 binding is decreased. 
To compare occupancy at BRD4 target sites on a genome wide level, I generated heatmaps 
of the read coverage across all of the SEs, TEs and promoters in WT and Y430C mESCs 
 ChIP-seq mapping statistics 
 
Total reads % reads correctly paired  % reads aligned 
WT 53BP1 68,296,055 100 90.11 
Y430C 53BP1 82,185,592 100 87.38 
WT input 96,017,791 100 97.81 
Y430C input 66,892,195 100 97.87 
Table Ch6-1. Mapping statistics for WT and Y430C ChIP-seq FASTQ files. Files 




   
 
(Figure Ch6-4). These show an enrichment of reads over the centre of these regions versus 
the surrounding area, and a slight decrease in the number of reads at all three regions in 
Y430C cells compared to WT - although this decrease is not as strong as is seen in the BRD4 
ChIP. 
The enrichment of 53BP1 signal around the centre of promoters (Figure Ch6-4A) is much 
tighter than that of BRD4 (Figure Ch4-7A), and this is consistent with the sharp peaks seen 
at TSSs (Figure Ch6-2&3). The heatmaps of 53BP1 at TEs and SEs (Figure Ch6-4B&C) also 
show a different pattern to those of BRD4 (Figure Ch4-7A) – 53BP1 heat maps show a dip 






   
 
 
Figure Ch6-2. Genome browser view of 53BP1 binding. UCSC browser screenshot 
showing reads per 10 million (RP10M) over the extended A) Klf4 locus, B) Nanog locus 
and C) Sox2 locus for various datasets. Tracks 1 and 2 = 53BP1 ChIP-seq in WT and 
Y430C mESCs, tracks 3 and 4 = BRD4 ChIP-seq in WT and Y430C mESCs. Track 5 = 














Figure Ch6-3. Genome browser view of 53BP1 binding. UCSC browser screenshot 
showing RP10M over the extended A) Gsc locus and B) Myc locus for various datasets. 
Tracks 1 and 2 = 53BP1 ChIP-seq in WT and Y430C mESCs, tracks 3 and 4 = BRD4 
ChIP-seq in WT and Y430C mESCs. Track 5 = ATAC-seq from mESCs (provided by 























































































































































































   
 
6.1.4 Peak-calling 
I called significant peaks in the WT and Y430C datasets as before, using the MACS2 
software. Overall there were more peaks in the 53BP1 ChIP-seq in both WT and Y430C 
mESCs than in the BRD4 ChIP-seq, which may be attributable to the peaks of 53BP1 at 
TSSs. There were also more peaks in the WT 53BP1 ChIP-seq compared to Y430C 53BP1 
ChIP-seq (31205 and 29871 respectively) (Table Ch6-2). The decrease in 53BP1 peaks in the 
Y430C cells is less than the decrease seen in the BRD4 ChIP-seq (1.04 fold versus 1.76 fold), 
which fits with the smaller difference seen in the heatmaps.  
regioneR analysis showed 53BP1 to be most significantly enriched over promoters, TEs and 
SEs (Figure Ch6-5), and least enriched at heterochromatin, repressed regions and weakly 
transcribed regions. That 53BP1 shows similar genomic patterns of enrichment to BRD4 is 
in concordance with the idea that BRD4 might recruit 53BP1 to chromatin.  
6.1.4.1 Differential peak calling 
I next used MACS2 bdgdiff to call differential binding events between WT and Y430C 
53BP1 ChIP-seq (Table Ch6-2). 15,752 regions were found to have significantly more reads 
in WT than in Y430C, whilst no regions were significantly increased in Y430C. These results 
suggest that 53BP1 binds at a similar number of regions in both cell lines, but that less 53BP1 
binds at each region in the Y430C cells. Coupled with the heatmap data (Figure Ch6-4), 
which shows only a small difference in read coverage at CREs between the two cell lines, 
this indicates that the decreased 53BP1 occupancy may be occurring at regions other than 
those defined in the TE, SE and promoter files.  
I visualised the 53BP1 ChIP-seq across the regions where the peak size was found to be most 
different between WT and Y430C, confirming the difference (Figure Ch6-6). These genomic 
regions vary in their function, but include strong enhancers (defined by ChromHMM) 
(Figure Ch6-6A). regioneR analysis of these regions suggests that they are enriched in 
promoters, TEs and SEs (Figure Ch6-5). 
The BRD4 ChIP-seq data (Figure Ch6-6, tracks 3&4) shows that the regions where 53BP1 
binding is differential between WT and Y430C cells are also occupied by BRD4, with a 
decrease in BRD4 occupancy in the Y430C cells. These BRD4 peaks tend to be smaller and 
narrower than those present at the SEs (Figure Ch6-3&4). Whilst the decrease in BRD4 
occupancy in Y430C cells doesn’t appear to affect 53BP1 recruitment to SEs (Figure Ch6-
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3&4), it may be that at the non-SE regions, where it is already limited, a required threshold 















    
    
    
Peak calling results 
 Total peaks Specific peaks % specific peaks 
WT 31,205  15,752 8.2 
Y430C 29,871 0 0.8 x 10-5 
Table Ch6-2. Mapping statistics for WT and Y430C ChIP-seq FASTQ files. Files 



































































































































































































































































































   
 
 
Figure Ch6-6. Genome browser view of 53BP1 binding. UCSC browser screenshot 
showing RP10M over regions of differential WT and Y430C BRD4 binding. Tracks 1 and 
2 = 53BP1 ChIP-seq in WT and Y430C mESCs, tracks 3 and 4 = BRD4 ChIP-seq in WT 
and Y430C mESCs. Track 5 = ATAC-seq from mESCs (provided by Yatendra Kumar). 
Black bars = strong enhancers defined by ChromHMM. 
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6.2 Investigating a link between Y430C 
positive CdLS and classical CdLS.  
Heterozygous LOF mutations in NIPBL are responsible for most cases of CdLS (Ansari et 
al., 2014). Interestingly, NIPBL-deficient CdLS patient cells were found to have impaired 
early recruitment of 53BP1 to DSBs (Vrouwe et al., 2007; Enervald et al., 2013), highlighting 
a potential link between the mechanisms underlying CdLS caused by BRD4 and NIPBL 
mutations.  
6.2.1 Comparing NIPBL, BRD4 and 53BP1 occupancy in mESCs 
I took publicly available NIPBL ChIP-seq data from V6.5 (C57BL/6-129) mESCs 
(GSM560350) and mapped this to the mm9 genome, as for the BRD4 and 53BP1 ChIP-
seq datasets. I then uploaded this to the UCSC genome browser to allow a visual 
comparison of the binding of NIPBL, BRD4 and 53BP1 (Figure Ch6-7).  
The binding pattern of NIPBL was similar to that of BRD4, with large peaks of NIPBL 
at CREs. This is not surprising as both BRD4 and NIPBL are known to bind promoters, 
TEs and SEs of pluripotency related genes in mESCs (Kagey et al., 2010; Di Micco et al., 
2014). However, NIPBL also binds at promoters, in a pattern similar to that of 53BP1. 
The striking resemblance of the 53BP1 ChIP-seq peaks to the NIPBL peaks at promoters, 
and its co-localisation with both BRD4 and NIPBL at SEs, suggests that recruitment of 






   
 
 
Figure Ch6-7. Comparison on BRD4, 53BP1 and NIPBL binding at SEs. UCSC 
browser screenshot showing RP10M over A) Klf4, B) Nanog and C) Sox2 SEs. Tracks 1 
and 2 = BRD4 ChIP-seq in WT and Y430C mESCs, tracks 3 and 4 = 53BP1 ChIP-seq 




   
 
 
Figure Ch6-8. Comparison on BRD4, 53BP1 and NIPBL binding at promoters. 
UCSC browser screenshot showing RP10M over A) Setdb1, B) Tmem85 and 
2410042D21Rik and C) Fam38a promoters. Tracks 1 and 2 = BRD4 ChIP-seq in WT 
and Y430C mESCs, tracks 3 and 4 = 53BP1 ChIP-seq in WT and Y430C mESCs, track 
5 and 6 = NIPBL ChIP-seq from V6.5 (C57BL/6-129) mESCs (GSM560350) 
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6.2.2 Analysing endogenous DNA damage in NIPBL deficient LCLs 
The correlation between NIPBL binding, 53BP1 binding, and regions of differential BRD4 
binding in the mESCs, suggested that the NIPBL CdLS patient mutations could also perturb 
the DDR. So far, I have focussed on the mESCs carrying the Y430C mutation in BRD4 
identified in one patient with CdLS. However, to analyse the effects of NIPBL mutations on 
DNA damage signalling, I used two LCLs previously derived from CdLS patients with 
heterozygous mutations in NIPBL - I1206del (Tonkin et al., 2004) and R2298H (Gillis et al., 
2004).  
53BP1 IF after treatment with NCS, shows that these patient LCLs have an increased 
number of 53BP1 foci compared to the WT LCLs in the absence of any exogenous damaging 
agent (Figure Ch6-8A&B), suggesting that the NIBPL mutations in these patients may affect 
the DDR. 1 hour after NCS treatment, nearly all WT, R2298H and I1206del cells had >5 
53BP1 foci. At 16 and 20 hours post NCS treatment, these foci had begun to be resolved - 
although this was much less drastic than in the mESCs (Figure Ch4-5B), with ~70-80% of 
cells still containing >5 foci. In contrast to the mESCs, there was no significant difference 
in the number of cells containing >5 53BP1 foci at 16 or 20 hours post NCS treatment 
between WT and mutant LCLs. As all three LCLs still had high numbers of foci containing 
cells, it is possible that repair in these cells is slower than in mESCs and that a difference 
would become more apparent at a later time point. Before NCS treatment, the foci present 
in R2298H and I1206del LCLs are larger than in WT (Figure Ch6-8C), as well as more 
plentiful. This is consistent with the larger foci in the mESC mutant cells, and could mean 
that the spread of the DDR is greater upon mutation of BRD4 or NIPBL.  
6.2.3 Cell cycle analysis in NIBPL deficient LCLs 
As the NIPBL deficient LCLs showed an increased number of 53BP1 foci, I wondered if 
they might have an altered cell cycle; the BRD4 mutant ES cells showed slower cell cycle 
with an apparent arrest in the G2/M phase of the cell cycle. Cell cycle analysis by flow 
cytometry showed very similar profiles for all three LCLs (Figure Ch6-9) (Table Ch6-3). The 
lack of cell cycle changes observed with the NIPBL mutation may be due to the use of LCLs, 
which have different cell cycle timings to the mESCs in which the Brd4 mutation is modelled. 
Furthermore, LCLs are immortalised cell lines established by the transformation of B-cells 
with the Epstein-Barr Virus (Hui-Yuen et al., 2011)
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6.3 Conclusions  
My preliminary 53BP1 ChIP-seq results show that 53BP1 is enriched at enhancers, similarly 
to BRD4. This fits with the results of others, who have shown BRD4 to recruit 53BP1 to 
chromatin (Li et al., 2018). Unlike BRD4, 53BP1 is not decreased in the Y430C cells at SEs. 
However, there are a set of regions at which BRD4 occupancy is relatively low, where 53BP1 
occupancy is higher in the WT cells compared to the Y430C cells. I hypothesise that at these 
regions, the decrease in BRD4 affinity for acetyl-lysines means that there is too low a level 
of BRD4 binding in Y430C cells for the full recruitment of 53BP1. 
DNA-damage-induced histone H4 acetylation is thought to recruit BRD4 to chromatin (Li 
et al., 2018). If the Y430C mutation decreases BRD4 binding in response to damage, this 
result could suggest a subsequent decrease in 53BP1 recruitment to DSBs, as I saw for 
RAD51 (Figure Ch5-12&13), which may perturb DSB repair. I did not observe any 
difference between 53BP1 foci levels in WT and Y430C cells at 1 hour post NCS, however 
it may be that the large number of foci present in all cells at this time masks a more subtle 
difference.  
There is less 53BP1 binding in the Y430C cells compared to WT, as assayed by ChIP-seq. 
This is contradictory to my previous results, where I saw more 53BP1 foci by IF. However, 
this may be because the ChIP-seq peaks do not correspond to the foci that are present in IF 
after DSB induction. The 53BP1 peaks in ChIP-seq are unlikely to be DSBs as they are small, 
sharp peaks expanding <1 Kb (Figure Ch6-2,3,5&6), whereas the observed spreading of 
DDR factors around a DSB by ChIP is usually of several Mb (Iacovoni et al., 2010). The lack 
of 53BP1 peaks at DSBs in the ChIP-seq may be explained by the random manner of these 
breaks. If they are occurring in a different locus in each cell, this would not be picked up by 
ChIP, which combines the signals from millions of cells.  
53BP1 detection at enhancers by ChIP therefore implies that the binding of 53BP1 at these 
elements is consistent across the population of cells. This suggests a functional role for 
53BP1 at enhancers, which will be discussed further in section 7.3.  
53BP1 ChIP-seq also shows large, sharp peaks at promoters, which do not resemble those 
of my BRD4 ChIP-seq, but are strikingly similar to those seen in NIPBL ChIP-seq. NIPBL 
may be responsible for recruiting 53BP1 to promoters, and a loss of NIPBL (as in CdLS 
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patients with NIPBL mutations) could result in decreased 53BP1 recruitment. If this is the 
case, it would suggest that the loss of 53BP1 recruitment links the BRD4-Y430C mutation 
with the NIPBL mutations that cause CdLS.  Furthermore LCLs with mutations in NIBPL 
show signs of a perturbed DDR (Figure Ch6-8&9). Therefore a misregulation of the DDR 




























































   
 
7.1 Overview of results  
Recently David FitzPatrick’s lab identified de novo mutations in the BET protein BRD4 in 
three patients with CdLS-like syndromes, leading us to investigate how the disruption of 
BRD4’s normal function may result in CdLS. I focused on a Tyr to Cys point mutation 
located in BD2 of BRD4, termed Y430C, identified in a patient with a classical CdLS 
phenotype. In silico modelling of the mutation suggested that it would decrease the affinity of 
the BD to acetyl-lysines, and I confirmed this through experiments in a mESC line that I 
engineered to be homozygous for the Y430C mutation. I found that Y430C-BRD4 interacts 
less with acetylated H3K9 and H3K27 than WT-BRD4, and ChIP-seq showed that this 
decreased affinity impairs the binding of BRD4 to CREs, where it is usually enriched.  
BRD4 is involved in the regulation of transcription (Jang et al., 2005; Kanno et al., 2014), and 
in mESCs is known to bind the SEs of pluripotency associated genes and promote their 
transcription (Di Micco et al., 2014). However, I found the transcription of pluripotency 
related genes and global gene transcription to be similar between the WT and Y430C mESCs, 
indicating that the decreased occupancy of mutant BRD4 at CREs does not affect 
transcription in these cells.  
I observed a slower doubling rate of the Y430C mESCs compared to WT and propose that 
this is caused by increased G2/M cell cycle checkpoint activation. The G2/M checkpoint is 
activated by the DDR (Schmitt et al., 2007), suggesting that the Y430C mESCs may have a 
problem with DNA damage. I found that the mutant Brd4 cells exhibit increased DDR 
signalling in response to DSB induction, as evidenced by the increased size and number of 
53BP1 foci, and may have defective DSB repair through impaired HR.  
ChIP-seq of 53BP1 showed that it is enriched at CREs. At enhancers, 53BP1 binds in a 
pattern similar to that of BRD4. This is in agreement with recent studies that have found 
BRD4 to recruit 53BP1 to chromatin (Li et al., 2018), and suggests a functional role of 53BP1 
at enhancers that is yet to be elucidated. Furthermore, the decreased affinity of BRD4-Y430C 
for acetyl-lysines appears to affect the binding of 53BP1 at a subset of binding sites which 
could have further implications for DNA repair.  
At promoters, large, sharp 53BP1 ChIP-seq peaks correlate with those of NIPBL, suggesting 
NIPBL could be involved in recruitment or regulation of 53BP1 to these regions. 
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Furthermore, NIPBL co-localises with both BRD4 and 53BP1 at enhancers. Coupled with 
NIPBL’s known roles in DNA damage signalling and repair (Bot et al., 2017), and my finding 
that BRD4 interacts with NIPBL and cohesin ring components, this suggested that an 
impaired DDR could be a common mechanism of CdLS. My preliminary results in NIPBL-
deficient LCLs from CdLS patients corroborate this, with evidence of increased DNA 
damage signalling in the absence of exogenous damaging agents.  
 
7.2 Transcriptional dysregulation in CdLS  
Currently, dysregulated transcription is the preferred mechanism for how de novo mutations 
cause CdLS. Cohesin interacts with a number of transcriptional regulators (Kline et al., 2017) 
and many groups have reported altered gene expression profiles in CdLS patients (compared 
to healthy controls) (Liu et al., 2009; Mannini et al., 2015; Yuan et al., 2015; Boudaoud et al., 
2017; Mills et al., 2018). Furthermore, there is growing evidence for overlapping phenotypes 
between CdLS and developmental syndromes caused by mutations in transcriptional 
regulators – leading to the idea that CdLS may be best classified as a ‘transcriptomopathy’ 
(Kline et al., 2017).  
Given BRD4’s characterised function as a transcriptional regulator (Di Micco et al., 2014; 
Bhagwat et al., 2016; Hajmirza et al., 2018; Rahnamoun et al., 2018), I fully expected the 
BRD4-Y430C mutation to support the ‘transcriptome disruption model’ of CdLS – my 
hypothesis being that perturbation of BD2 would decrease BRD4 binding to acetyl-lysines 
at CREs and therefore inhibit transcriptional initiation and elongation of BRD4 target genes. 
This was not the case; I saw few significant changes in the transcriptomes of Y430C mESCs 
compared to WT, even at the pluripotency related genes – known targets of BRD4 in mESCs 
(Di Micco et al., 2014).  
Does this mean that I can discount transcriptional dysregulation as a contributing factor to 
CdLS in the patients with BRD4 mutations? No. I think it likely that the loss of BRD4 
binding observed in the Y430C cells causes changes in transcription that I am unable to 
detect. One explanation for this may be the use of ES cells.  
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ES cells display unique regulation of transcription. In contrast to differentiated cells, ES cell 
genomes are transcriptionally hyperactive - they express large regions at low levels and have 
elevated levels of chromatin remodelling proteins and transcription machinery. Global 
reduction of the active portion of the genome, coupled with increased activation of specific 
genes, promotes the differentiation of ES cells down specific lineages. Furthermore, 
chromatin proteins display hyperdynamic and looser binding to chromatin in ES cells than 
in undifferentiated cells (Efroni et al., 2008). It may be that decreased BRD4 binding would 
affect transcription in differentiated cells but this is compensated for by the high levels of 
transcriptional machinery in ES cells, or that transcription in ES cells does not require such 
‘tight’ BRD4 chromatin binding.  
It is also possible that the way that we culture ES cells – supplementing with the exogenous 
cytokine LIF to prevent spontaneous differentiation (Ohtsuka, Nakai-Futatsugi and Niwa, 
2015) – masks the effects of decreased BRD4 binding. This method would select against 
differentiating cells, whilst selecting for pluripotent and self-renewing cells. Since 
transcriptional dysregulation of ES cells might cause differentiation, cells that are resistant to 
this may be expected to outcompete the other cells – resulting in a population that shows 
few transcriptional differences.  
To investigate this further, I could repeat my experiments with differentiated cell lines, as 
discussed in section 7.8.4.  
 
7.3 A functional interaction between 
BRD4 and 53BP1 at enhancers? 
BRD4 has been shown to recruit a complex of the snRNA 7SK and the SWI/SNF chromatin 
remodelling complex BAF to TEs and SEs (Flynn et al., 2016). In mESCs, BAF maintains 
nucleosome depleted regions and promotes elevated nucleosome occupancy adjacent to 
these regions, suppressing ncRNA transcription (Hainer et al., 2015). At TEs and SEs, 7SK 
bridges interactions important for BAF’s activity. Loss of 7SK results in global reduction of 
BAF155 occupancy at enhancers and increased eRNA transcription. Unregulated eRNA 
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transcription can result in convT, and this can cause DNA damage through both RNAPII 
collisions and AID (Flynn et al., 2016).  
Through 4sU-seq I detected eRNA transcripts at TEs and SEs in WT mESCs, showing that 
some transcription is permitted at enhancers even in the presence of BRD4. This suggests 
that convT could be a feature of WT cells and may cause DSBs that require repair. 
My 53BP1 ChIP-seq showed that 53BP1 occupies TEs and SEs similarly to BRD4, however 
a role of 53BP1 at enhancers has not been reported. 53BP1 can be recruited by BRD4 (Li et 
al., 2018) and I found that decreased 53BP1 occupancy correlated with decreased BRD4 
occupancy at a subset of regions. I propose that 53BP1 could be recruited by BRD4 at TEs 
and SEs to aid the repair of DSBs that arise through convT (Figure Ch7-1). 53BP1 is 
extremely important for accurate DNA repair. It supresses the nucleolytic resection of DNA 
ends at breaks, inhibiting repair by HR and thus regulating the choice between HR and NHEJ 
(Noordermeer, Adam, Setiaputra, Barazas, Pettitt, Ling, Olivieri, Álvarez-Quilón, Moatti, 
Zimmermann, Annunziato, Krastev, Song, Brandsma, Frankum, Brough, Sherker, Landry, 
Szilard, Munro, McEwan, de Rugy, et al., 2018). In the absence of 53BP1, repair foci are slow 
to resolve and 53BP1 knockout mice exhibit growth retardation, radiation sensitivity and 
genomic instability (Fernandez-Capetillo et al., 2002). 
Figure Ch7-1. Model for the roles of BRD4 and 53BP1 at enhancer elements. BRD4 
binds to acetyl-lysines in TEs and SEs and recruits the 7SK-BAF complex and 53BP1. 
7SK-BAF surpresses pervasive eRNA transcription, whilst 53BP1 promotes the repair of 
DSBs that do occur.  
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7.4 BRD4 in the DDR  
7.4.1 Current literature   
BRD4 is overexpressed in a number of different cancers (Zhang et al., 2015; Pongas et al., 
2017; Dong et al., 2018) and this has recently been exploited through the design of small 
molecule inhibitors, such as JQ1, that decrease BRD4’s binding to chromatin and have 
shown efficacy in both solid tumours and hematologic malignancies (Ocaña, Nieto-Jiménez 
and Pandiella, 2017). The success of these therapies relies in part on the downregulation of 
BRD4 target proto-oncogenes such as MYC (Ba et al., 2018; Muhar et al., 2018), but also by 
sensitising cancer cells to DNA damaging agents (Zhang et al., 2018).  
This has led to a wealth of recent literature regarding the role of BRD4 in the DDR. BRD4 
localises to DSBs through recognition of H4 tail acetyl-lysine residues (Dhar et al., 2017; Li 
et al., 2018), where it is thought to promote DNA damage signalling through the regulation 
of DNA replication checkpoint signalling (Zhang et al., 2018), prevention of 
heterochromatin formation (Pongas et al., 2017), and recruitment of DDR proteins (Li et 
al., 2018). Previously however, BRD4 isoform b had been shown to inhibit  DDR 
signalling through the recruitment of the condensin II complex, which causes chromatin 
compaction and decreased accessibility of the DSB to DDR proteins (Floyd et al., 2013).  
Finally, the binding of BRD4 at enhancers is thought to inhibit DSB formation through 
the suppression of eRNA transcription (Flynn et al., 2016).  
7.4.2 How my results fit with the current literature  
The increase in the size and number of 53BP1 foci that I have shown in the Y430C 
mESCs, supports the idea that BRD4 acts to inhibit the spread of DNA damage signalling. 
Y430C-BRD4’s decreased affinity for acetyl-lysines may decrease the recruitment of 
BRD4 to DSBs, leading to a loss of inhibition of the DDR signal. Analysis of chromatin 
compaction in WT and Y430C mESCs by FISH, would help confirm whether this increase in 
signalling is in fact caused by enhanced accessibility to DDR proteins upon loss of BRD4 
binding – I could look specifically at loci where BRD4 is differentially bound between WT 
and Y430C cells, and/or at an induced DSB.  
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Through 4sU-seq I showed that eRNA transcript levels were similar in both WT and Y430C 
mESCs, indicating that the decrease in BRD4 binding at TEs and SEs does not affect the 
proposed role of BRD4 in supressing eRNA transcription. It may be that the diminished 
levels of BRD4 at these regions in Y430C cells is sufficient for inhibition of eRNA 
transcription. ChIP-seq or Chromatin Isolation by RNA Purification (ChIRP)-seq could be 
used to map the genome occupancy of BAF or 7SK respectively, in order to determine 
whether the decreased BRD4 levels affect 7SK-BAF binding at TEs and SEs. 
Furthermore, it would be interesting to map the location of DSBs in the Y430C mESCs, 
to see whether the additional 53BP1 foci observed in these cells are localised at enhancer 
elements. There are many methods available for this, which I will discuss in section 7.8.1.  
The persistent 53BP1 foci, delayed recruitment of RAD51 in response to DSBs, and 
decrease in 53BP1 binding at certain sites that I have identified in the Y430C mESCs, is 
in agreement with the proposed role of BRD4 in recruiting DNA repair proteins and 
promoting DSB repair. The multiple functions of BRD4, suggested by my own results 
and put forth by others, suggests that it plays a complex role in the DDR, and may fine -
tune the response to ensure the most appropriate outcome. 
 
7.5 How does increased DDR signalling 
and decreased repair cause CdLS? 
I have shown evidence for a defective DDR in the Y430C mESCs, suggesting that BRD4 
mutations could cause CdLS via this mechanism. Increased sensitivity of CdLS patient cells 
to DNA damage has been reported previously (Vrouwe et al., 2007; Enervald et al., 2013), 
indicating that this may also occur in CdLS caused by mutations in proteins other than BRD4 
– e.g. NIPBL. However, the question remains of how a dysregulated DDR might result in 
the CdLS phenotype.  
The most obvious outcome of an impaired DDR is an increased risk of cancer, and DDR 
gene alterations are prevalent in many human cancer types (Knijnenburg et al., 2018). These 
mutations may affect break repair, leading to increased genomic instability, and allow the 
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proliferation of cells harbouring deleterious mutations (Karanika et al., 2015). CdLS patients 
do not, however, have an increased incidence of cancer (OMIM 122470). 
The phosphorylation and activation of the checkpoint kinases, CHK1 and CHK2, is the end 
result of the DDR signalling cascade (Maréchal and Zou, 2013) and can lead to a delay in the 
cell cycle until DNA damage is repaired (Bartek and Lukas, 2003). The loss of BRD4’s 
inhibition of DDR signalling in the Y430C-BRD4 cells, resulted in increased CHK1 
phosphorylation and a slower cell cycle. This delay in the cell cycle, when occurring during 
development, could cause some aspects of the CdLS phenotype. The cell cycle is tightly 
regulated to ensure proper development and tissue homeostasis (Barnum and O’Connell, 
2014), and loss of certain cell cycle regulators have been associated with reduced body size 
(Rane et al., 1999; Sicinski et al., 1995; Ciemerych et al., 2002) neurological abnormalities 
(Sicinski et al., 1995; Ciemerych et al., 2002), craniofacial abnormalities (Humbert et al., 2000) 
and heart defects (Cloud et al., 2002) - all prominent features of CdLS. 
Recurrent infections have also been reported at a high frequency in CdLS patients and are a 
significant cause of mortality. The increased risk of infection in CdLS patients is thought to 
be a result of decreased percentages of T regulatory cells and T follicular helper cells 
(Jyonouchi et al., 2013). Cohesin binds sites flanking the enhancer and promoter of the T cell 
receptor alpha locus (Tcra) and is required for long-range promoter-enhancer interactions 
and H3K4 trimethylation that facilitates Tcra rearrangement. Tcra rearrangement drives the 
differentiation of thymocytes into T-cells, and thymocytes deficient in cohesin differentiate 
with reduced efficiency (Seitan et al., 2011). BRD4 is also critical for normal T-cell 
development – BRD4 regulates the differentiation of T-cells by promoting the transcription 
of certain genes (Kagoya et al., 2016; K. Cheung et al., 2017; Gegonne et al., 2018). 
Immunological defects are also present in patients with developmental disorders such as 
LiDS and RS-SCID, which show some overlap in phenotype with CdLS (Davis and Chen, 
2013a). In LiDS and RS-SCID the immune defects are the result of impaired NHEJ, which 
is essential for maturation of immune cells (Chaudhuri and Alt, 2004). The proposed 
impairment of DNA repair in the Y430C mESCs suggests that mutations in BRD4 could 
cause immunological defects in a similar way to those seen in patients with LiDS and RS-
SCID.  Whilst it is plausible that impaired BRD4 function could cause immune defects, these 
have not been reported in the patients with BRD4 mutations. 
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7.6 A model for the role of the Y430C-
BRD4 mutation in CdLS 
Combining the proposed roles of BRD4 (in the DDR and enhancer transcription) with my 
own results comparing WT and Y430C mESCs, I can begin to build a model for how the 
Y430C mutation might cause a CdLS phenotype (Figure Ch7-2). I propose: 
• The Y430C mutation causes decreased affinity of BRD4 to acetyl-lysines, affecting 
the binding of BRD4 to DSBs and to CREs.  
• At DSBs the reduced BRD4 occupancy allows an increase in the spread of DDR 
signalling - potentially through increased accessibility of other DDR proteins to 
DSBs via chromatin decompaction – and decreases the efficiency of repair, through 
a delay in the recruitment of the RAD51 and 53BP1.  
• In the absence of DSBs the effects of decreased BRD4 binding in the Y430C mESCs 
may be focussed at enhancers, where BRD4 is usually enriched. The loss of BRD4 
at enhancers decreases 53BP1 recruitment, perturbing its ‘protective’ role against 
breaks that may occur from convT of eRNAs.  
• The resulting increase in DDR signalling leads to increased cell cycle checkpoint 
activation and a slower cell cycle that, when occurring during development, could 
cause the CdLS phenotype.  
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7.7 A common mechanism for CdLS? 
CdLS is a heterogeneous syndrome. Cases caused by mutations in different genes share the 
main complement of symptoms, although the severity of the phenotype does vary (Boyle et 
al., 2015). This suggests that the underlying mutations all perturb the function of the same 
pathway. Originally, due to mutations in the cohesin components, SMC1, SMC3 and 
RAD21, and the cohesin regulators, NIPBL and HDAC8, CdLS was classified as a 
cohesinopathy – one of a group of disorders caused by mutations in the cohesin pathway 
(Skibbens et al., 2013). However, reports associating non-cohesin genes with CdLS (Ansari et 
al., 2014; Gallagher et al., 2015; Yuan et al., 2015) broadened the aetiology to more than that 
of a simple cohesinopathy. It is now thought that it is perturbation of cohesin’s role in a 
larger pathway – that of transcription – that underlies the phenotype.  
I have suggested that a Y430C mutation in BRD4 causes CdLS via mis-regulation of the 
DDR pathway. The patient with this mutation has a classical phenotype similar to those 
caused by NIPBL mutations, with a CdLS-like facial appearance, microcephaly, intellectual 
disability and cardiac malformation. Limb defects – which are usually associated with the 
more severe cases caused by NIPBL splice-site and nonsense mutations (Boyle et al., 2015) – 
are absent in the Y430C patient. However, it may be that a splice-site or nonsense BRD4 
mutation would result in a more severe phenotype, similarly to NIPBL mutations. Given the 
strong overlap in phenotypes caused by NIPBL and BRD4 mutations, I would expect the 
‘classical’ cohesin mutations of CdLS to also affect the DDR pathway. 
There is a lot of evidence that cohesin is involved in the DDR – it is recruited to DSBs and 
required for cell cycle checkpoint activation and DNA repair (Frattini et al., 2017; 
Countryman et al., 2018; Villa-Hernández and Bermejo, 2018) – and there have been reports 
of increased sensitivity to DNA damage in CdLS patients with NIPBL mutations (Vrouwe 
et al., 2007; Enervald et al., 2013), supporting the idea of misregulated DDR as a common 
mechanism. Furthermore, my own results in NIPBL deficient LCLs from CdLS patients 
suggest that there may be an increase in endogenous DDR signalling.  
Interestingly NIPBL has also been implicated in the suppression of intergenic or antisense 
intragenic transcription. Nipbl deficient cells showed an increase in ncRNA transcription, 
which was mainly bidirectional and occurred at poised promoters and active enhancers. 
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Therefore, the loss of NIPBL binding at enhancers could cause increased eRNA 
transcription and convT similarly to what I have proposed for BRD4 (Schwarzer et al., 2017).  
Recently, mutations in a number of transcriptional regulators were reported in patients with 
phenotypes overlapping those of CdLS (Ansari et al., 2014; Woods et al., 2014; Izumi et al., 
2015; Yuan et al., 2015), promoting the reclassification of CdLS as a transcriptomopathy. 
These genes do not appear to be involved in the DDR, indicating that these may represent a 
separate subgroup of CdLS to the BRD4 mutations. The absence of transcriptional 
dysregulation in the Y430C mESCs could suggest that, whilst the majority of CdLS cases 
(caused by mutations in NIPBL) feature both transcription and DDR misregulation, the less 
classical cases fall into two distinct categories – those caused by transcriptional mis-regulation 
and those caused by DDR defects. However, as discussed above, it is also possible that 
BRD4 mutations also cause transcriptional differences that I am unable to detect.  
 
7.8 Future directions 
The 53BP1 ChIP-seq presented in Chapter 6 is based on only 1 replicate and so must be 
repeated to ensure its reproducibility. The flow cytometry experiments also need to be 
repeated, to ensure assignation of the cells to their correct cell cycle stage. There are also 
many other experiments that I would like to have done, that could help substantiate my 
model or take it further.   
7.8.1 Mapping DSBs 
The model I have proposed for how the Y430C mutation causes CdLS posits that, in the 
absence of exogenous damaging agents, DSBs would be enriched at enhancer elements, 
particularly SEs. Mapping the location of DSBs in the WT and Y430C cells would therefore 
be a logical next step.  
Many protocols have been recently developed to map DSBs, each with its own limitations. 
Iacovoni et al., used ChIP-seq to map γH2AX at breaks by the AsiSI restriction enzyme, but 
it may not be sensitive enough to identify DSBs at non-sequence specific sites – where they 




   
 
Methods that map the DSB directly include Genome-wide, Unbiased Identification of 
DSBs Enabled by Sequencing (GUIDE-seq) (Wang et al., 2015) and integrase-defective 
lentiviral vector (IDLV)-mediated DNA break capture (Tsai et al., 2015), both of which are 
technically challenging and detect DSBs through the quantification of NHEJ products, 
meaning that they may overlook DSBs repaired through alternative pathways (Yan et al., 
2017).   
Methods such as direct in situ Breaks Labelling, Enrichment on Streptavidin and next-
generation Sequencing (BLESS) (Crosetto et al., 2013), and its derivatives END-seq (Canela 
et al., 2016), DSB capture (Lensing et al., 2016) and most recently Breaks Labeling In Situ and 
Sequencing (BLISS), map DSBs by ligation of sequencing adaptors to DNA ends. These 
methods are suitable for studying endogenous DSBs and, with each reiteration, are 
decreasing in required input and labour intensiveness, and increasing in sensitivity (Yan et al., 
2017).    
7.8.2 Analysing DSB repair  
I have also suggested that DSB repair is perturbed in Y430C mESCs. This was concluded 
from the reduced number of RAD51 foci 1 hour post DSB induction, and the greater 
number of 53BP1 and RAD51 foci at 16 and 20 hours post DSB induction, in Y430C mESCs 
compared to WT, but it would be interesting to investigate this more thoroughly.  
Cas9 could be used to introduce a site specific DSB, followed by targeted ChIP-seq to analyse 
the binding of repair proteins to this region (as in Iacovoni et al., 2010). ChIP-seq would 
allow the analysis of the spread and kinetics of protein binding. By carrying out ChIP-seq for 
multiple proteins involved in the different repair pathways, I could determine whether 
recruitment of proteins from a specific pathway is perturbed. 
Cas9 could also be utilised to measure the efficiency of HR versus NHEJ. If WT and Y430C 
cells are transfected with Cas9-gRNAs and a repair template, the frequencies of different 
outcomes can be used as a proxy for the efficiency of different repair pathways: incorporation 
of the repair template represents HR, the presence of small indels represents NHEJ and no 
change suggests no repair.  
7.8.3 BRD4 recruitment to breaks  
I have shown that Y430C-BRD4 has reduced affinity for acetyl-lysine residues and that this 
affects BRD4 occupancy at CREs. It has been shown by others that lysine residues in the 
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H4 tail are acetylated at sites of DNA damage and that this recruits BRD4 to DSBs (Li et al., 
2018). I have extrapolated this and suggested that the Y430C mutation decreases BRD4’s 
recruitment to DSBs, however it would be good to confirm this experimentally. The 
induction of a site-specific break by Cas9 followed by BRD4 ChIP-qPCR in the WT and 
Y430C mESCs could be used to test this.  
Additionally, ChIP for BAF components, DDR proteins such as 53BP1 and RAD51, and 
ChIRP for 7SK RNA, would be useful to determine if decreased BRD4 recruitment does 
affect the further recruitment of these proteins.  
7.8.4 Alternative cell lines 
My experiments were mainly carried out using mESCs. There is a wealth of datasets, both 
publicly available and produced within our lab, for the epigenetic profiles of these cells, and 
their enhancers are well defined (Rao, 2012). Furthermore, they are easy to grow, treat, and 
manipulate. However, as discussed above, their culture conditions and unique gene 
expression programme may mask transcriptional differences between the WT and Y430C 
cells. The use of a differentiated cell line may illuminate any differences. LCLs are often used 
for studies of patient mutations as they can be derived from patients themselves, rather than 
engineered to carry the mutation. However, the CdLS patient with the Y430C mutation did 
not agree to this.  
It would be interesting to use cell lines that could inform us about a specific phenotypic 
feature of CdLS, or a particular perturbation of the DDR. For instance, adipocytes may be 
used to focus on the low percentage of body fat seen in CdLS patients, or immune 
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